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ABSTRACT.
Low density lipoproteins (LDL) have been implicated as possible pro-thrombotic 
factors by enhancing platelet responsiveness. The aim of this study was to 
assess how the degree of oxidative modification of LDL altered their effects on 
platelet function. The effects of native and modified LDL on platelet 
responsiveness and platelet sensitivity to nitric oxide (NO) in vitro were 
assessed by conventional aggregometry and flow cytometry combined with 
immunolabelling.
Native LDL (nLDL) inhibited activation in platelet rich plasma (PRP) and 
aggregation of washed platelets (WP). Oxidised LDL (oxLDL) also inhibited 
platelet activation in PRP, but was found to inhibit aggregation in both PRP and 
WP, suggesting that inhibition was induced by a different mechanism to that of 
nLDL. In contrast, minimally modified LDL (mmLDL) potentiated ADP-induced 
fibrinogen binding and aggregation, possibly by enhanced release of platelet 
granules, and induced primary aggregation of WP independently of other 
agonists. The major physicochemical difference between native and minimally 
modified LDL was a relatively small increase in the level of lipid hydroperoxides 
(LPO), these low levels of LPO may account for the contrasting effects of nLDL 
and mmLDL with respect to platelet function. The data suggest that mmLDL may 
be potentially important pro-thrombotic factors.
The influence of peroxides on platelet aggregation and the sensitivity of 
platelets to NO were investigated using hydrogen peroxide, cumene 
hydroperoxide and 15 (S)-hydroperoxyeicosatetraenoic acid as models for LPO. 
Hydrogen peroxide, and cumene hydroperoxide both potentiated agonist-
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induced aggregation, but only when added post-agonist. These peroxides also 
attenuated the inhibition of platelet aggregation by NO when added post­
agonist. 15 (S)-hydroperoxyeicosatetraenoic acid alone did not affect 
aggregation, but potentiated aggregation when used as a complex with nLDL. 
15 (S)-hydroperoxyeicosatetraenoic acid antagonised the inhibitory actions of 
NO, but this only occurred when the peroxide was incubated with platelets 
before the addition of NO and thrombin.
In contrast, if hydrogen peroxide and NO were added to platelets before 
thrombin, aggregation was inhibited to a greater extent than by NO alone. The 
presence of hydrogen peroxide prolonged and enhanced the effects of NO when 
applied directly to WP. This was due in part to increased stimulation of 
guanylate cyclase activity, and could be reproduced with an NO-donor. 
Simultaneous addition of NO with cumene hydroperoxide or 15 (8)- 
hydroperoxyeicosatetraenoic acid did not produce the same effect. This 
suggested that hydrogen peroxide may have a physiological role in the 
enhancement of inhibition of platelets by NO.
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1.0 INTRODUCTION
1.1 Atherosclerosis.
Atherosclerosis is a benign multifactoral disease which leads to a narrowing of 
the arteries [Ross, 1986]. The disease is characterised by the presence of 
plaques beneath the luminal surface of the arteries. As the disease progresses 
the plaques enlarge such that they protrude into the lumen of the artery and if 
sufficiently large can compromise blood flow. Fissuring of atherosclerotic 
plaques are associated with the formation of thrombi [Falk, 1983; Davies and 
Thomas, 1985]. Thrombosis is an associated mutifactoral disease which can 
cause a reduction and blockage of the flow of blood leading to ischaemic events 
[Fuster etal., 1990]. Together these diseases of the cardiovascular system are 
the leading cause of mortality in industrialised nations.
Numerous risk factors contribute to the pathogenesis of these diseases, 
including smoking, hypertension, diabetes and elevated concentrations of low 
density lipoproteins (LDL). Atherosclerotic plaques contain lipid-laden 
macrophages, the major lipid present is cholesterol derived mostly from LDL 
[Hoff ef a/., 1979; Hoff and Gavbatz, 1981]. Evidence implicates the free radical- 
mediated oxidation of LDL as a key event in the pathogenesis of atherosclerosis 
[Steinberg etal., 1989]. Post-secretory oxidative modification of LDL renders the 
particles increasingly atherogenic, allowing their unregulated uptake by 
macrophages [Henriksen at a/., 1981]. Modified forms of LDL are thought to 
enhance the atherosclerotic process by inducing functional changes in local 
cells [Steinberg and|Witztum,1990]. Different cell types involved in this process 
include monocytes/macrophages, endothelial cells, smooth muscle cells (SMC), 
T-lymphocytes and platelets.
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Platelets were originally proposed to be involved in the initiation of 
atherosclerosis, as described in the 'response to injury hypothesis' [Ross and 
Marker, 1976] (see section 1.4.2). More recently, platelets have been relegated 
to a secondary role, whereby they contribute to the growth of the plaque, by 
being incorporated as a thrombus. Platelet activation and aggregation are 
intimately involved in the formation of thrombi [Heptinstall, 1980]. The formation 
of platelet aggregates at the plaque surface can have two outcomes depending 
on the extent of the fissure. If the fissure is small, then generally the subsequent 
aggregate would be modest and the thrombus incorporated into the plaque. If 
the plaque rupture is more extensive, then platelet aggregation is more 
substantial. If the coagulation cascade becomes activated, the subsequent 
thrombus is much larger and can lead to complete occlusion of the artery. 
Ultimately this leads to myocardial infarction and possibly death.
Therefore, both LDL and platelets are two of the key factors in the 
pathophysiology of arterial disease. In the following sections the properties and 
functions of lipoproteins and platelets will be discussed, followed by an outline 
of their known interactions under normal and pathological conditions.
1.2. Plasma lipoproteins.
Lipids are relatively insoluble in aqueous media, and as a result are transported 
in vivo as specialised particles termed lipoproteins. Plasma lipoproteins are 
complexes of lipid and protein structurally conserved by non-covalent bonds. 
Lipoproteins perform three major functions: 1) transport of dietary lipids from the 
intestinal mucosa, site of absorption, to other tissues. 2) transport of 
triglycerides (TG) from the liver to peripheral tissues where they are stored or
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utilised for energy, and 3) transport of cholesterol to and from the peripheral 
tissues.
Plasma lipoproteins are divided into five functionally distinct subclasses: 
chylomicrons, very low density lipoproteins (VLDL), intermediate density 
lipoproteins (IDL), low density lipoproteins (LDL) and high density lipoproteins 
(HDL). The distinction between different lipoprotein classes is determined by 
their individual flotation densities in saline media [Hatch and Lees, 1968], which 
can be used to separate them by ultracentrifugation. However, other parameters 
such as electrophoretic mobility and flotation rate have also been used to 
classify lipoproteins.
All lipoproteins possess a common structure. The particle core is hydrophobic 
in nature and is composed of variable amounts of cholesteryl esters (CE) and 
TG. This core is surrounded by a phospholipid (PL) monolayer (mainly 
phosphatidylcholine), and free cholesterol. Each class of lipoprotein possesses 
one or more specific proteins, termed apolipoproteins, which are embedded in 
the phospholipid monolayer /Tab/e 1.1]. Apolipoproteins remain associated with 
lipids by hydrophobic bonding between the fatty acyl chains of PLs and the non­
polar regions of the apolipoprotein and, by ionic interactions of the polar head 
groups of the PLs and oppositely charged amino acids of the apolipoprotein 
[Thompson, 1989]. Apolipoproteins have three major functions with respect to 
lipid metabolism: 1) they stabilise lipoprotein structure allowing functional 
viability, 2) they act as cofactors for enzymes involved in lipid metabolism and 
3) they function as specific ligands for the receptor-mediated uptake of 
lipoproteins [Mahley et al., 1984].
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property CM VLDL IDL LDL H D Li HDL3
major A -l B -100 B -100 B -100 A-l A -l
apoproteins B- 48 
C-l 
C-l l 
C- l l l
C-l
C-l l
c - l l l
E
E A-II 
C-l 
C-l l 
C-l l l
A-II 
C-l  
C-l l 
C-l l l
lipid:protein
ratio 98:2 91:9 
chemical compostion (% by wt.)
80:20 77:23 62:38 48:52
CE 5 12 25 39 26 20
0 2 7 9 9 5 3
TG 84 54 30 6 4 4
PL 7 18 16 23 27 21
protein 2 9 20 23 38 52
Table 1.1: The chemical composition of the five major classes of lipoproteins. 
Source: Handbook of hyperlipidaemia. Thompson, [1989].
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1.2.1. Low-density lipoproteins.
1.2.1.1 Structure.
LDL are spherical particles which have a plasma half-life of 2-3 days. They are 
the most abundant and major cholesterol carrying particle found in humans. The 
hydrophobic core contains a high proportion of CE (mainly cholesteryl oleate) 
with lower amounts of TG. The relative proportions of lipids found in LDL are 
summarised in Table 1.1. LDL show variation in composition and particle size 
and can be separated into two major subfractions, light and heavy, by 
ultracentrifugation [Krauss and Burke, 1982; Swinkels at al., 1987].
LDL contain only one apolipoprotein, termed apoB^ oo, which is synthesised in the 
liver and is secreted as part of VLDL. ApoB^oo possesses 4563 amino acids 
corresponding to a molecular weight of SIOkDa [Olofsson at a/., 1987]. The 
protein is highly glycosylated, containing 8-10% carbohydrate, which is mainly 
mannose [Mahley, 1984]. ApoBioo is fundamental to the function of LDL as it 
contains a specific amino acid sequence which is recognised by the cellular 
receptor, termed apoB/E receptor [Goldstein at a!., 1985] (see section 1.2.1.4). 
LDL also possesses various lipid soluble antioxidants: the most abundant of 
these is a-tocopherol, 6 molecules per LDL particle [Esterbauer at a/., 1990]. 
Other antioxidants include p-carotene, 1 molecule per 3 LDL particles, y- 
tocopherol, lycopene and ubiquinone [Esterbauer at a!., 1992] [Table 1.2]. The 
a-tocopherol content is positively correlated with the PUFA (linoleate and 
arachidonate) content of LDL [Esterbauer at al., 1990]. A diagrammatic 
representation of a LDL particle is shown in Figure 1.1.
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Figure 1 . 1 :  Schematic representation of the composition of Iona/ density 
lipoproteins.
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nmol/mg protein 
mean ± sd
n mol/mol LDL 
mean
Palmitic acid 1260 ±375 19 693
Palmitoleic acid 80 ±44 19 44
Stearic acid 260 ±118 19 143
Oleic acid 825 ± 298 19 454
Linoleic acid 2000 ± 541 31 1100
Arachidonic acid 278 ±100 31 153
Docosahexaenoic acid 53 ±31 15 29
tocopherol 11.6±3.3 87 6.37
•tocopherol 0.93 ±0.36 88 0.51
R-carotene 0.53 ± 0.47 122 0.29
carotene 0.22 ± 0.25 28 0.12
Lycopene 0.29 ± 0.23 136 0.16
Phytofluene 0.09 ± 0.05 10 0.05
Ubiquinol-10 0.18±0.18 7 0.1
Total PUFAs (mean) 2332 1283
Total antioxidants (mean) 13.8 7.6
Table 1.2: Polyunsaturated fatty acids and antioxidant composition in low 
density lipoproteins.
Source: The role of lipid peroxidation and antioxidants in the oxidative 
modification of LDL, Esterbauer et ai, [1992].
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1.2.1.2 Lipoprotein metaboiism (synthesis of iow density lipoproteins).
Lipoprotein metabolism can be divided into two pathways; endogenous and 
exogenous. LDL is formed by the endogenous pathway. Exogenous lipid 
transport begins with the incorporation of dietary fats into TG-rich chylomicrons 
in the intestine, which are subsequently secreted into the blood. Lipoprotein 
lipase (LPL), anchored to the luminal surface of the endothelium by 
glycosaminoglycans, is activated by apoC-ll present on chylomicrons. The 
activated LPL hydrolyses the chylomicron core leading to the release of free 
fatty acids, which are absorbed into the local tissues. The remaining CE-rich 
'chylomicron remnants' are taken out of circulation by the liver via specific apoE 
receptors present on its surface.
The endogenous pathway begins with the synthesis and secretion of TG-rich 
VLDL particles from the liver. VLDL is hydrolysed by LPL, via apoC-ll, and the 
TG removed to form IDL with the loss of apoA, C-l, C-ll and C-lll to the HDL 
pool. The resultant IDL has two possible fates; it is removed by the liver via the 
apoE receptor or it is converted to LDL by the action of hepatic triglyceride 
lipase and with the loss of apoE. It has been suggested that each LDL particle 
is synthesised from a single VLDL particle [Soutar et al., 1977]. LDL is 
subsequently removed from the circulation by a specific high affinity LDL 
receptor and undergoes cellular degradation (see section 1.2.1.3.).
Excess cellular cholesterol is removed from cells by HDL and is returned to the 
liver for excretion or recycling, by a process named reverse cholesterol transport 
[Oram, 1990]. The mechanism of this process remains unresolved, but may 
involve interactions between HDL and the cell surface. Free excess cholesterol
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is esterified by the plasma enzyme iecithln:choiestero! acyl transferase (LCAT). 
The neutral CE are attracted to the hydrophobic core of HDL allowing further 
estérification at the cell surface. ApoA-1 present on HDL is thought to activate 
LCAT. HDL are secreted by the liver as nascent HDL taking the form of disc like 
bilayers of PL with apoA-l and apoA-ll, while other components are acquired 
during circulation. HDL are divided into two subclasses, HDLg and HDL :^ it is 
HDL3 which are thought to accept cholesterol at the cell surface. HDLg formed 
by the accumulation of CE catalysed by the reaction of LCAT. HDLg transfer CE 
to VLDL in exchange for TG, a process which is facilitated by cholesterol ester 
transfer protein (CETP) [Barter ef a/., 1987]. Therefore, through a process driven 
by LCAT, HDL helps maintain cholesterol homeostasis.
1.2.1.3. Cellular uptake of low density lipoproteins.
The cellular uptake of LDL occurs by a process referred to as receptor mediated 
endocytosis. The LDL receptor, termed apoB/E receptor, are found clustered in 
clathrin coated pits at the cell surface. LDL binds to the receptor via a specific 
interaction with apoBioo> which facilitates the endocytosis of LDL as a vesicle. 
Once inside the cell, several LDL vesicles fuse to form an endosome, a 
subsequent drop in pH causes the receptor to dissociate from the LDL particles. 
Receptors are then recycled to the coated pits at the cell surface. Lysosomes 
bind to the LDL endosome stimulating the degradation of apoB.,00 to its 
constitutive amino acids and hydrolysis jof CE to cholesterol. The re-esterification 
of cholesterol is catalysed by the enzyme acylxholesterol acyltransferase 
(ACAT). The resultant increase in free cholesterol acts to regulate its own 
cellular concentration by:-
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[1] Down regulation of hydroxy methyl-glutaryl coenzyme A, which catalyses the 
rate limiting step in de novo cholesterol synthesis.
[2] Increased activity of ACAT.
[3] Down regulation of LDL receptor synthesis.
The process outlined above was The|Nobel prize winning work of Brown and 
Goldstein, [review, 1986] and was originally completed using human skin 
fibroblasts.
LDL function to deliver cholesterol to cells, used in both cell membrane 
structures and for steroidogenesis. However, the other components of the 
particles should not be disregarded. LDL provides a-tocopherol for protection 
against oxidative stress and phospholipids utilised during mitosis.
1.2.1.4. The ApoB/E receptor.
The apoB/E receptor is a single chain transmembrane acidic glycoprotein with 
a relative molecular mass of IGOkDa [Goldstein et al., 1985; Schneider, 1989]. 
Levels of expression of the receptor varies with the cell type, but is particularly 
high in the adrenals and gonads where cholesterol is used in steroidogenesis. 
The ligand binding domains are characterised by seven repetitive cysteine-rich 
negatively charged sequences which interact specifically with positively charged 
arginine and lysine residues on apoBioo- LDL with modified arginine and lysine 
residues do not undergo endocytosis [Goldstein eta!., 1979].
The mature LDL receptor is divided into five distinguishable domains:
[1] The first domain (ligand binding), which contains the NHg terminal and
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consists of 292 amino acids, houses the binding sites for the LDL particles. The 
domain consists of seven repeat sequences, which are extremely rich in 
cysteine residues. The cysteines form disulphide bonds and these are thought 
to confer stability to the binding sites. Housed in each of the repeating 
sequences is a cluster of negatively charged amino acids, which are thought to 
be complementary to positively charged sequences in both apoE and B, 
allowing lipoprotein particles to bind.
[2] The second domain consists of 400 amino acids and is homologous to a 
portion of the extracellular domain of the EGF precursor.
[3] The third domain is immediately external to the membrane spanning domain 
of the receptor. The region contains carbohydrate chains attached by an O- 
linkage. The function of these carbohydrate chains are unknown, but may keep 
the receptors extended from the membrane.
[4] The fourth domain is the membrane spanning region and consist of 22 
hydrophobic amino acids.
[5] The fifth domain is the cytoplasmic tail, which contains 50 amino acids. This 
domain may play an important role in the clustering of the receptor in coated 
pits, either through an interaction with clathrin or another clathrin associated 
protein.
1.2.1.5. Familial hypercholesterolaemia.
The elucidation of LDL catabolism led to better understanding of the inheritable 
disease, familial hypercholesterolaemia (FH). FH (heterozygous) is caused by 
inheritance of one mutant gene coding for the apoB/E receptor. Inheritance of 
two mutant genes results in homozygous FH. Based on behaviour of the mutant 
protein, five classes of mutations at the apoB/E (LDL) receptor have been
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elucidated [Goldstein et al., 1985]:-
[1] Class 1 mutations fail to produce any immunoprecipitable protein.
[2] Class 2 mutations encode proteins that do not fold properly after synthesis 
and are blocked, either partially or completely, in transport between the 
endoplasmic reticulum and the Golgi apparatus.
[3] Class 3 mutations encode proteins that are synthesised and transported to 
the cell surface, but have a reduced capacity to bind LDL.
[4] Class 4 mutations encode proteins that move to the cell surface and bind 
LDL normally, but are unable to cluster in clathrin-coated pits and thus do not 
internalize the lipoprotein.
[5] Class 5 mutations encode receptors which bind and internalize ligand in the 
coated pits, but fail to discharge the ligand in the endosome and fail to recycle 
to the cell surface.
A wide variety of mutations occurs within these five basic classes, all producing 
slightly different behaviours in the mutant proteins. Ultimately, these conditions 
result in a large increase in plasma LDL concentrations, leading to an 
accelerated development of atherosclerosis and reduced longevity of the 
individual.
1.3. The oxidative modification of low density lipoproteins.
Increased plasma LDL concentrations are associated with an increased risk of 
atherosclerosis [Steinberg eta!., 1989]. Recently, it has been proposed that LDL 
becomes oxidatively modified in vivo, which renders the particles more 
atherogenic [Steinberg and Witztum, 1990]. Goldstein at al., [1979] showed that
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LDL modified by acétylation resulted in a reduced rate of uptake by fibroblasts 
via apoB/E, but an increased uptake by the macrophage scavenger receptor. 
This led to massive cholesterol accumulation in the macrophages. It was 
proposed that the lipid laden foam cells found in atherosclerotic plaques were 
derived from blood-borne monocytes and macrophages [Gerrity, 1981]. 
However, chemical acétylation of LDL was unlikely to occur in vivo. The key 
finding linking the two observations was made by Henriksen et a!., [1981], who 
demonstrated that incubation of LDL with bovine aortic endothelial cells in the 
presence of trace amounts of transition metal ions, altered the LDL to a form 
recognised by the macrophage scavenger receptor. It was subsequently shown 
that activated macrophages [Cathcart at a/., 1985], smooth muscle cells (SMC) 
[Morel eta!., 1984] and more recently platelets [Aviram eta!., 1990] could induce 
the same modification of LDL. The study by Morel at a/., [1984] showed oxidised 
LDL (oxLDL) to have an increased relative electrophoretic mobility (REM) and 
was the first to suggest the modification of LDL involved a free radical 
mechanism. In contrast to endothelial cells and SMC, cultured fibroblasts failed 
to modify LDL under identical conditions [Henriksen at a!., 1981; Morel at al., 
1984]. Steinbrecher ef a/., [1984] suggested endothelial cells modification of LDL 
may involve lipid peroxidation of the PL, leading to the formation of lipid 
hydroperoxides.
An important observation was made by Heinecke at a/., [1984] who 
demonstrated that the incubation of LDL in media containing increased levels 
of transition metal ions enhanced the modifications induced by endothelial cells. 
This indicated that the concentrations of transition metal ions present played a 
key role in the oxidation of LDL, although there was an additional effect of
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cellular activity. It was subsequently demonstrated that Cu^  ^ ions could oxidise 
LDL independently of cells. This key finding allowed the oxidation kinetics of 
LDL to be studied in great detail. Esterbauer et al., [1987] modified LDL by 
exposure to oxygen-saturated buffer or CuClg confirmed the involvement of lipid 
peroxidation. This study showed that oxidation of LDL was associated initially 
with the loss of a-tocopherol and secondly the loss of PUFA content. The 
products of oxidation included lipid hydroperoxy and hydroxy derivatives of 
linoleate and arachidonate [Lenz at al., 1990] and various reactive aldehydes 
produced by the subsequent breakdown of the lipid hydroperoxides [Esterbauer 
at al., 1990]. In addition, oxidation of LDL led to an increase in cholesterol 
oxides, although the prominence of individual oxides was dependent on the 
method of oxidation (endothelial cells or Cu^ "") [Bhadra atal., 1991]. LDL is also 
thought to possess an intrinsic PLAg like activity due to the constant production 
lysolecithin during oxidation [Pathasarathy at al., 1985]. A role for lipoxygenase 
in LDL modification has also been proposed. Sparrow at al., [1988], 
demonstrated that co-incubation of soyabean lipoxygenase and PLAg with LDL 
mimicked cellular oxidation j without the requirement of transition metal ions. 
Lipoxygenase enzymes catalyse the oxidation of arachidonic acid to 
hydperoxyeicosatetraenoic acids (HpETEs). The kinetics and products of LDL 
oxidation in vitro has been reviewed extensively by Esterbauer atal., [1990].
The increase in REM associated with oxidation of LDL [Morel at al., 1984] 
indicated that structural changes of apoBioo had occurred in addition to 
modification of the lipid moiety. It has been proposed that the reactive aldehydes 
produced during oxidation, including malondialdehyde (MDA) and 4- 
hydroxynonenal (4-HNE), form adducts with apoB^ oo. leading to an increase in
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net negative charge [Steinbrecher, 1987; Steinbrecher et al., 1989]. The 
aldehydes form a Schiff s base with the e- amino group on lysine residues of the 
apoBioo- Fragmentation of apoB^ oo has also been shown to occur, arising from 
cleavage of the polypeptide chain by lipid peroxyl radicals. The structural 
changes of apoB^ oo observed with modification of LDL only occur after extensive 
oxidation; mild or short term oxidation of LDL did not increase REM [Zhang at 
a!., 1989]. Esterbauer ef a/., [1990] showed that a rapid rise in LPO during initial 
oxidation which was associated with a very small increase in TBARS. These 
studies suggested that oxidation of LDL may initially proceed without protein 
modification.
The oxidation of LDL in vivo is thought to occur in the subendothelial space 
immediately below the endothelium [Steinberg at ai., 1989], but the mechanism 
by which these changes occur still remains to be resolved. Evidence suggests 
the involvement of a free radical mechanism [Morel at ai., 1984; Steinbrecher at 
ai., 1984], although these studies also showed an absolute requirement for 
transition metal ions. The availability of free metal ions in vivo is limited, but may 
occur in areas of tissue damage [Halliwell and Gutteridge, 1989]. Subsequently, 
the production of free radicals in vivo was proposed to play a role in LDL 
modification. Superoxide anion (Og'") formed by endothelial cells, by activated 
macrophages during respiratory burst or SMC, was a proposed perpetrator. 
Heinecke at ai., [1986] and Steinbrecher, [1987] both showed that Og'" 
generated by cultured SMC and endothelial cells could be involved in oxidation 
of LDL. In contrast, VaniHinsbergh ef ai., [1986] showed that cell mediated 
oxidation of LDL did not involv«fe02*" or HgOg. Hydroxyl radicals have also been 
implicated in the initiation of LDL oxidation, but their production requires Fe^ "",
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as described by the Fenton reaction (reaction 1) which is unlikely to be available 
in vivo, at least under normal conditions.
Fe"+ + H2O2 -  OH' + OH- + Fe^ + (1)
However, both O2*" and OH' may be involved in the oxidation of LDL by another 
mechanism. Beckman et a!., [1990] have shown O2*" reacts rapidly with NO to 
form the peroxynitrite anion (ONOO ), which rapidly breaks down when 
protonated to form OH'. Since both O2*" and NO are produced by endothelial 
cells and macrophages in close proximity to LDL, they may form radicals which 
initiate oxidation of LDL in vivo. The effects and influence of oxLDL on the 
development and progression of atherosclerosis will be discussed in section
1.4.3.
1.3.1. Lipid peroxidation.
It is now accepted that oxidation of LDL probably occurs by a free radical chain 
reaction [Morel eta!., 1984; Steinbrecherefa/., 1984; Esterbauerefa/., 1987] 
[Figure 1.2]. This can be initiated by the abstraction of a H atom from the PUFA 
sidechains of the PL, to form a carbonyl radical (-CH-). The carbonyl radical 
spontaneously rearranges its structure to form a conjugated diene. In the 
presence of molecular oxygen, the conjugated dienes reacts to produce a lipid 
peroxyl radical (-C 00 '-) (reaction 1 ).
I -C 'H -  + O2 -  -HCOO'- (1)
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Lipid peroxyl radicals propagate the chain reaction by abstracting another H 
atom, forming a lipid hydroperoxide (CHOOH) and another carbonyl radical. This 
part of the chain reaction only ceases when H atoms and/or Og are no longer 
available. The lipid hydroperoxides break down to form alkoxyl radicals CO*, 
which eventually produce aldehydic derivatives.
Oxidation mediated by Cu^ "" has an absolute requirement for preformed lipid 
hydroperoxides [Thomas and Jackson, 1990]. Cu^ "" facilitates the breakdown of 
lipid hydroperoxides by fission of 0 -0  bond, to release alkoxyl radicals [Halliwell 
and Gutteridge, 1989] (reactions 2 and 3).
-H2COOH + Cu"+ -  -HgCOO* + Cu+ + H+ (2)
-H2COOH + Cu+ -  -H2C0 *+ Cu^ + + OH (3)
Antioxidant protection found within LDL, such as a-tocopherol, are consumed 
before the chain reaction commences [Esterbauer et al., 1987]. a-tocopherol 
protects against oxidation by scavenging lipid peroxyl radicals (chain breaking 
antioxidant) (reaction 4).
-H2COO* + a-toe -  -H2COOH + a-toe* (4)
a-tocopherol is thought to be replenished by electron transfer |to a-tocopherol from 
ascorbic acid, a plasma (water) soluble antioxidant (reaction 5).
a-toc* + asc -  a-toe + asc* (5)
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Figure 1.2: Schematic representation of mechanism of lipid peroxidation within 
an LDL particle.
Source: Free radicals, lipid peroxidation and atherosclerosis. Bruckdorfer, 1990.
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This model of lipid peroxidation was proposed by Halliwell and Gutteridge 
[1989].
1.3.2. Do oxidised iow density lipoproteins exist in vivo ?
If the oxidation of LDL occurs in vivo, it is unlikely to occur in the plasma, since 
this compartment contains high levels of antioxidants which would attenuate 
oxidative modification. In addition, the lipoproteins are unlikely to encounter high 
localised oxidative environments in the circulation as the blood flow would 
remove this very quickly. Modification requires LDL to be present in an 
environment where there is a sustained oxidative stress leading to the depletion 
of the antioxidant protection. The subendothelial space has been proposed to 
be such a compartment [Steinberg et a/., 1989]. LDL freely enters the sub­
endothelium, although they may be retained here by interactions between apoB 
and the proteoglycans associated with connective tissue of the intima [Hurt and 
Camejo, 1987]. Here, the lipoproteins may be subjected to free radical attack, 
the radicals being produced by cellular metabolism.
It has been demonstrated that oxLDL is present in atherosclerotic plaques. 
Haberland at al., [1988] demonstrated the presence of modified LDL using 
antibodies directed against MDA treated LDL. Using immunostaining it was 
found that these antibodies reacted with components of lesions in rabbit aortae, 
but not in other areas of the vessel. Material extracted from the aortic lesions of 
WHHL rabbits was found to react with antibodies against MDA-LDL, 4-HNE-LDL 
and oxLDL, suggesting the presence of these complexes in vivo [Palinski at a!., 
1989]. In both of these studies the antibodies failed to show reactivity towards 
autologous nLDL In addition Palinski at al., [1989] demonstrated the presence
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of autoantibodies to oxLDL in the plasma of WHHL rabbits,land these autoantibodies 
reacted with various forms of LDL in vivo. More importantly, Salonen et a!., 
[1992] showed that autoantibodies to oxLDL were present in human plasma. 
Finally, convincing evidence for the role of oxidative modification in lesion 
formation comes from studies demonstrating antioxidants such as BHT and 
probucol can inhibit lesion formation in WHHL rabbits and cholesterol fed rabbits 
respectively [Carewefa/., 1987; Kita eta!., 1987; Bjorkhem at ai, 1991].
The oxidation of LDL in the subendothelium is likely be a continuous process, 
with LDL at different stages of modification being present at any one time. While 
LDL are only mildly oxidised, with minimal protein modification, it is possible that 
they may escape into the plasma. Several reports have shown an LDL 
subtraction isolated from plasma which had a slightly increased negative charge 
[Avogaro at al., 1988, Cazzolato at al., 1991, Shimano at ai, 1991]. Several 
authors have investigated the actions of minimally modified LDL (mmLDL), 
defined as LDL with lipid, but no protein modification, as potentially important 
atherogenic factors. Their results show mmLDL to exert several cellular 
responses in vitro, which are similar to events proposed to occur in the early 
pathogenesis of the disease. These studies suggest that mmLDL are more 
biologically relevant than oxLDL and are discussed in greater detail in sections
1.4.3, 3.7.1 and 3.7.3.
1.4 BIOCHEMICAL PATHOGENESIS OF ATHEROSCLEROSIS.
Atherosclerosis is a multifactoral disease, which is characterised by the 
presence of lesions on the intima of the arterial wall. The pathogenesis and 
progession of atherosclerosis involves various cells, a large number of growth
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factors, cytokines and vasoregulatory molecules. The interactions between cells 
via different mediators is a highly complex process which has been reviewed 
extensively by Ross, [1993]. The following section provides a general overview 
of the biochemical pathogenesis of atherosclerosis and the theories proposed 
for disease development.
1.4.1. Atherosclerotic plaques.
The earliest lesions of atherosclerosis, the fatty streak, can be found in young 
children whereas the more advanced lesion, the fibromuscular plaque, generally 
appears in early adulthood and progresses with age.
1.4.1.1. Fatty streaks.
Macroscopically fatty streaks appear as a yellowish discolouration beneath the 
lining of the coronary arteries. Principally they consist of lipid-laden 
macrophages along with smaller numbers of lipid filled SMC [Stary, 1989]. Some 
evidence exists to suggest that fatty streaks were localised at anatomical sites 
which later developed into more advanced lesions, although this is not 
completely certain.
1.4.1.2. Fibromuscular plaques.
Fibrous plaques are white in appearance and are usually large enough to 
protrude into the artery, if sufficiently large they can compromise blood flow. The 
lesions consist of large numbers of lipid-laden macrophages, T-lymphoctes and 
proliferated SMC which are surrounded by large amounts of connective tissue 
(collagen, elastic fibres and proteoglycans). If the lesion has become unstable, 
it is prone to haemorrhage and thrombosis, if this has occurred the structure is
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referred to as a complicated lesion.
1.4.2. The 'Response to injury' hypothesis.
The 'response to injury' hypothesis was first proposed by Ross and Glomset, 
[1976] and was based on the similarity in appearance between early lesions of 
atherosclerosis and the response of arteries to experimentally induced injury, it 
was proposed that alterations to endothelial cells affects their function as a 
protective barrier. The insult to the endothelium can be induced mechanically, 
by the use of a balloon catheter to cause abrasion, or chemically by conditions 
such as hyperlipidaemia, homocysteineuria, diabetes or hypertension. For 
example, hypercholesterolaemic baboons were shown to have lost almost 10% 
of the endothelial lining of the thoracic and abdominal aorta [Ross and Marker, 
1976]. The loss of endothelial cells resulted in adhesion of platelets to 
underlying collagen fibrils. In vessels denuded of their endothelium platelets 
adhere to the subendothelium within seconds and continued for upto 48hours 
[Stemerman and Ross, 1972]. Adherent platelets degranulate thereby releasing 
various growth factors and active amines (see section 1.5.6). PDGF, which is 
stored in platelet alpha granules, induces the migration of SMC from the media 
to the intima and their subsequent proliferation. Proliferating SMC secrete large 
amounts of connective tissue, including collagen and proteoglycans [Opsahl et 
al., 1987]. At the same time, there is an accumulation of cellular lipid deposits 
into plaques, which also contributes to the bulk of the plaque. The lipid laden 
cells have been shown to be of monocytic origin [Aqel et a/., 1984].
The response to injury hypothesis implicates platelets as the key cell in the 
induction of atherosclerosis by their ability to induce themigration and proliferation 
of SMC.
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1.4.3. Lipid infiltration theory.
This hypothesis places more importance on LDL in the initiation and subsequent 
development of atherosclerosis. LDL can freely enter and leave the 
subendothelial space during its normal functioning and metabolism. Once 
present in the subendothelial space LDL may become trapped, possibly by 
binding to proteoglycans of the internal elastic lamina [Hurt and Camejo., 1987]. 
The retention of LDL in a microenviroment may lead to an exhaustion of 
antioxidant protection and therefore increases the potential for oxidation. 
Several lines of evidence point to the existence of oxLDL in vivo (see section 
1.3.2).
One of the earliest events in experimentally induced atherosclerosis is the 
adherence of monocytes to the endothelium [Gerrity et al., 1979]. MmLDL has 
been proposed to play a key role in this event. In cell culture studies mmLDL 
induced the release of MGP-1, a chemoattractant specific for monocytes, from 
endothelial cells [Cushing et a!., 1990], potentiated the release of MCSF and 
GSCF [Rajavashisth et a!., 1990] and induced the expression of glycoprotein 
adhesion molecules on the surface of endothelial cells [Berliner et al., 1990]. 
Monocytes enter the subendothelium where they undergo phenotypic 
transformation to macrophages. Activated macrophages may enhance monocyte 
entry, by releasing interleukin-1 which induced increased monocyte adhesion 
[Bevilacqua etal., 1985].
Fully oxidised LDL is thought to contribute heavily to the formation of the plaque. 
They decrease the effectiveness of nitric oxide (NO) disrupting vascular tone 
[Andrews et al., 1987, Jacobs et al., 1990, Tanner et al., 1991], increase Ca '^'
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entry of SMC allowing potential proliferation [Weisser et al., 1992], and exert 
cytotoxic effects on endothelial cells possibly leading to increased entry of LDL 
and monocytes [Quinn at al., 1987]. Macrophages accumulate oxLDL via the 
scavenger receptor, possibly as a protective mechanism against the cytotoxic 
effects of oxLDL, to form lipid-laden foam cells. The metabolic activity of 
macrophages is thought to contribute to oxidation of LDL leading to greater 
accumulation within the plaque. Foam cells along with proliferated SMC 
constitute the bulk of the plaque. Eventually the macrophages necrose, leaving 
a core of lipid and cell debris in the plaque which is surrounded by alternating 
layers of SMC and connective tissue.
1.4.4. Unification of theories.
The response to injury hypothesis suggests the key event is the initial damage 
to the endothelium and the subsequent activation of platelets. However, several 
studies have shown fatty streaks can develop under an intact endothelium 
[Faggiotto etal., 1984]. This points to an alteration in endothelial function rather 
than damage. The cytotoxic nature of oxLDL implicates it as a possible mediator 
of a dysfunctional endothelium. However, mmLDL have also been shown to 
increase adhesion molecule expression on cultured endothelial cells, without 
inducing cytotoxicity [Berliner et al., 1990]. The retention of LDL would allow 
intimate contact between LDL and endothelial cells which could lead to lipid 
exchange, leading to subtle alterations in the membrane and associated 
functions. Macrophages laden with oxLDL may also be involved with this 
process: in attempting to return to the plasma compartment they may cause 
physical pressures which lead to the loss over overlying endothelial cells. At this 
point the sequence of events proposed by the original response to injury
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Figure 1.3: Scheme showing the possible unification of the 'response to injury’ 
and 'lipid infiltration’ theories.
Source: Beyond cholesterol: modification of LDL that increase its 
atherogenicity. Steinberg etal., [1989].
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hypothesis would be applicable [Figure 1.3]. The role of platelets is of much 
more importance in the clinical sequelae of atherosclerosis, in particular 
thrombosis.
1.5 PLATELETS
Platelets are circulating anucleate discoid cells (2 - 4pm in diameter) which 
when activated form a haemostatic plug at sites of vascular injury thereby 
preventing excessive blood loss. Platelets are released as fully mature cells 
from bone marrow megakaryocytes,The cells have a plasma density of 2 - 4 x 
10® per ml and circulate in the blood for 7 - lOdays before removal by the 
spleen.
1.5.1 Platelet ultrastructure.
The platelet possesses a standard phospholipid bilayer membrane which has 
a highly glycosylated outer surface. This exterior coat or 'glycocalyx' is 
composed of several different glycoproteins which function as receptors for the 
platelet. The membrane serves to protect the interior of the cell, but when the 
cell is activated acts as a specific phospholipid surface for amplification of the 
coagulation cascade (see section 1.5.9). Immediately below the cytoplasmic 
surface of the membrane is a network of overlapping actin filaments which are 
thought to be important in pseudopodia formation. Beneath the filaments is a 
single microtubule coiled on itself several times. The microtubule is found along 
the greatest circumference of the equatorial plane of the cell and helps maintain 
the resting discoid shape [White, 1986].
Within the cytoplasmic zone are several structures and organelles, these
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include, mitochondria, peroxisomes, lysosomes, glycogen granules, molecular 
actin and two types of storage granules, a-granules and dense granules [Figure 
1.4]. In addition the platelet possesses two membrane systems, the open 
canalicular system (OCS) and the dense tubular system (DTS). The OCS is 
composed of numerous invaginations continuous with the plasma membrane 
and reaches into the furthest recesses of the cell. Ultimately this acts to greatly 
increase the surface area of the cell. Platelet DTS is randomly dispersed in the 
cell and is thought to originate from the rough endoplasmic reticulum of the 
parent megakaryocyte. The DTS selectively takes up Ca^ "" ions by a 
Ca^7Mg '^"ATPase system and is the major storage site for Ca^  ^ ions in the cell. 
The two membrane systems are not completely isolated and are found in close 
association with each other at several sites in most platelets [White, 1986] 
[Figure 1.4].
1.5.2 Physiology and biochemistry of the platelet.
Platelets circulate in the blood as quiescent cells. However, when confronted 
with a damaged endothelium they quickly adhere to the injured surface and form 
a haemostatic plug. The plug becomes re-enforced by the generation of 
thrombin at the platelet surface and the subsequent formation of fibrin. The 
functional response of platelets involves a series of marked morphological and 
biochemical changes which result in the accumulation of platelets at sites of 
vascular injury. The process involves the following principal events: a) 
activation, b) shape change, c) adhesion, d) aggregation, e) secretion, and f) 
metabolism of arachidonic acid (AA) and subsequent release of thromboxane 
Az (TXAz).
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Figure 1.4: Diagrammatic representation of the ultrastructure of the human blood 
platelet (equatorial plane).
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1.5.2.1 Platelet activation.
The physiological activation of platelets involves the binding of specific agonists 
to their individual receptors on the platelet surface. These agonists include 
adenosine diphosphate (ADR), adrenaline, collagen, platelet activating factor 
(RAF), serotonin, thrombin and TXAg. Agonist-receptor coupling leads to a 
cascade of biochemical events resulting in adhesion and aggregation 
[summarisedin Figure 1.5].
1.5.2.2 Guanosine triphosphate (G) -  binding proteins.
G-proteins are regulatory binding proteins which link receptor-agonist (or 
antagonist) interactions to secondary messenger production [Negata and 
Nozawa, 1990]. Each G-protein is composed of three subunits, a, 3 and y, with 
GDR tightly bound to the a subunit. Agonist receptor coupling causes the 
dissociation of GDR from the alpha-subunit and in the presence of Mg^ "" is 
replaced by GTR. Binding of GTR causes the dissociation of the a subunit 
(Ga.GTR) from the complex and allows it to interact with a membrane bound 
enzyme (eg, adenylate cyclase or phospholipase C). The Py components remain 
single functional unit and reassociates with the a subunit as the intrinsic 
GTRase activity of the a subunit hydrolyses GTR to GDR [Kroll and Schafer,
1989]. Several G-proteins have been described in platelets including, Gp, Gg, 
G|, and G* [Negata and Nozawa, 1990].
1.5.2.3 Phosphatidyiinositoi hydrolysis and secondary messengers.
RIatelet activation leads to the release of a phospholipid based secondary 
messenger system as described for other cells [Berridge and Irvine, 1984]. 
Agonist receptor occupancy leads to activation of Gp [Cockcroft, 1987; Kroll and
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Schafer, 1989] and subsequent activation of Iphosphatidylinositol specific 
phospholipase C (PLC). PLC hydrolyses membrane Iphosphatidylinositol 4,5 
bisphosphate (PIP2) to yield two secondary messengers, inositol 1,4,5 
trisphosphate (l(1,4,5)P3) and diacylglycerol (DAG).
I(1,4,5)P3 regulates agonist-induced increases in platelet cytosolic calcium 
[Berridge and Irvine, 1984]. Increases in [Ca^^, is fundamental to platelet 
activation {section 1.5.2.4). Intracellular l(1,4,5)P3 is thought to bind to specific 
receptors on the surface of the DTS and releases Ca^ '" from internal stores, 
presumably through a Ca^ "" channel [Daniel, 1989]. I(1,4,5)P3 is converted to 
I(1,3,4,5)P4 by the action of a l(1,4,5)P3 3-kinase [Irvine et a/., 1986]. 
I(1,3,4,5)P4 has been proposed to cause the influx of extracellular Ca^  ^across 
the plasma membrane associated with platelet activation [Irvine and Moor, 
1987]. I(1,3,4,5)P4 is subsequently converted to l(1,3,4)P3 by the action of a 5'- 
phosphomonoesterase, which is thought to be activated by protein kinase C 
(PKC) [Kroll and Schafer, 1989]; no function for 1(1,3,4)P3 has been elucidated. 
The same 5'-phosphomonoesterase converts l(1,3,4)P3 to IPg ending the Ca '^' 
elevating actions of l(1,4,5)P3.
The other secondary messenger, DAG, remains in the membrane matrix where 
it triggers the translocation of inactive PKC from the cytoplasm to the membrane. 
In the presence of Ca^  ^and phosphatidylserine, PKC becomes activated; DAG 
is thought to increase the affinity of PKC for Ca^  ^[Kroll and Schafer, 1989]. DAG 
is phosphorylated to phosphatidic acid and recycled back into 
phosphatidyiinositoi.
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1.5.2.4 Calcium and platelet activation.
plays a central role in platelet activation by triggering several important 
pathways. Resting platelets have a [Ca^ "'], of approximately 100nmol/l, which is 
almost three orders of magnitude lower than the plasma concentration. The 
platelets are able to maintain the low [Ca^ ]^, by the use of three distinct 
compartments for Ca '^’ storage:-
a) Dense granules: Ca^ '" is stored and released into the microenviroment during 
platelet secretion. This Ca '^' pool does not undergo exchange with the 
cytoplasmic pool.
b) DTS: This is the major storage site for Ca^ "" in the platelet, in which CaF"" is 
sequestered from the cytoplasm by a Ca^VMg '^" ATPase pump. Ca "^’ is released 
into the cytoplasm after binding of 1(1,4,5)P3 to its receptor on the DTS [Daniel,
1990].
c) Cytoplasm: The cytoplasmic pool (half life 17.5min) [Kroll and Schafer, 1989], 
which is regulated by a NaVCa '^" antiport and possibly by a Ca^VMg '^" ATPase 
pump in the plasma membrane.
All platelet activatory agonists with the exception of adrenaline have the capacity 
to induce increases in cytosolic [Ca^T [Rink and Sage, 1990]. The magnitude of 
these increases is dependent upon the individual agonist used [Ware et al., 
1986]. Ca^ "" increases are regulated by the action of 1(1,4,5)Pg on the DTS and 
by I(1,3,4,5)P4 possibly acting on a Ca '^' channel in the plasma membrane. The 
activation of a 5'-phosphomonoesterase to convert IP3 to IPg by PKC, has also 
been proposed to regulate [Ca^ ""], by feedback inhibition [Kroll and Schafer, 
1989]. The increase in [Ca^ '"], is important to platelet activation because several
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enzymes involved are regulated by cytoplasmic Ca^ "" ion concentrations. These 
enzymes include phospholipase Ag (PLAg), myosin light chain kinase (MLCK) 
and PKC. In addition Ca^  ^has been shown to trigger adhesion and aggregation 
of platelets independent of other agonists [Rink et al., 1982], although this 
probably involves the activation of the previously named enzymes.
1.5.2.5 Tyrosine kinases and platelet activation.
Stimulation of platelets with thrombin or collagen leads to increases in tyrosine 
phosphorylation of a common set of proteins [Nakamura and Yamamura, 1989]. 
With thrombin-activated platelets the phosphorylation of these proteins occurred 
in three distinct phases which were thought to correspond to activation, shape 
change and aggregation [Ferrel and Martin, 1988]. Two studies have also shown 
a relationship between increases in [Ca^ '"], and tyrosine phosphorylation 
[Takayama at a/., 1991; Vostal at a/., 1991]. The implication of tyrosine 
phosphorylation in platelet activation signalling was further advanced by 
experiments in which tyrosine kinase inhibitors (eg, tyrphostin), which inhibited 
thrombin induced aggregation and secretion [Rendu at a/., 1992]. The full 
characterisation of tyrosine kinase activity in platelet signal transduction is yet 
to be elucidated.
1.5.2.6 Metabolism of arachidonic acid.
AA is a PUFA (20:4, ü)-6) which is formed in the liver by the elongation and 
desaturation of the essential fatty acid, linoleic acid (18:4 o)-4). AA is esterified 
to membrane phospholipids, preferentially in the sn-2 position of the glycerol 
backbone. The metabolism of AA is important to vascular biology as it produces 
several vasoactive compounds. AA metabolism by the enzyme cyclo-oxygenase
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(prostaglandin Hg jsynthase) in platelets results in the production of [TXA2 
[Hamberg etal., 1975], while metabolism via the enzyme lipoxygenase leads to 
formation of leukotrienes [Samuelsson et ai, 1979].
Increases in [Ca^^j leads to the activation of | PLAg [Rittenhouse and Horne, 
1984]. PLA2 is the term given to a group of phospholipase enzymes, the platelet 
is thought to possess several isoforms of PLA2 [Loeb and Gross, 1986]. PLAg 
hydrolyse phospholipids to release AA from both the plasma membrane and the 
membrane of the DTS [Brass, 1991]. Cyclo-oxygenase catalyses the cyclization 
of carbons 8 to 10 by concomitant insertion of four oxygen atoms to produce 
prostaglandin G2 (PGG2) [Smith and Marnett, 1991]. PGG2 is the precursor of all 
AA derivatives mediated by cyclo-oxygenase, these include prostaglandins D2, 
E2, p2a, H , I2 and TXA2 [Figure 1.6]. TXA2 's a potent platelet agonist, SMC 
mitogen and vasoconstrictor [Kroll and Schafer, 1989]. Once formed TXA2 
diffuses out of activated platelets and acts to propagate aggregation by binding 
to a specific receptor on the platelet surface [Hanasaki and Arita, 1991]. The 
production of TXA2 and other eicosanoids can be blocked by the action of non­
steroidal anti-inflammatory drugs (NSAIDS) such as aspirin and indomethacin 
[Vane, 1971]. This has led to the use of aspirin for anti-platelet therapy in the 
prevention of thrombosis.
1.5.3 Platelet shape change.
The first morphological change observed during platelet activation is a shape 
change from a resting discoid to a spherical shape with extending pseudopodia 
or spiny spheres [Zucker and Borelli, 1954]. Shape change promotes 
aggregation by providing a greater surface area for platelet-platelet contact.
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Figure 1.6: The proposed pathways for arachidonic acid in vascular cells.
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During shape change the cytoplasmic granules are centralised by the 
contraction of the circumferential microtubule [White, 1986]. The contractile 
force for this process is the assembly of actin molecules into filaments and their 
interaction with the microtubule, probably through micotubule associated 
proteins [White, 1986]. Actin filaments also form parallel bundles at the 
periphery of the cell and their interactions may provide the cohesive strength to 
distort the membrane [White, 1986]. Inside the pseudopods are parallel 
associations of actin microfilaments, suggesting a role for actin in the support 
of pseudopodia structure [White, 1986]. Platelet shape change can be assessed 
by electron microscopy or nephelometry.
1.5.4 Platelet adhesion.
Platelets do not adhere to the endothelium under normal conditions, due to the 
physicochemical properties of endothelial cells, which provide an inert surface 
and secrete various substances to prevent this process [Vane et a/., 1990]. 
Platelets will rapidly adhere to exposed connective tissue (collagen) in injured 
vessels . The event is mediated by the interaction of subendothelial collagen 
and the glycoprotein (GP) la-lla complex at the platelet surface [Pischel etal., 
1987]. In addition, a vascular component, von WiIlebrandfactor (vWF), also 
mediates adhesion of platelets to the subendothelium [de Groot and Sixma,
1987]. It has been suggested that the initial reversible adhesion is mediated by 
vWF, while irreversible adhesion results from an interaction with collagen [Siess, 
1989]. vWF in synthesized by endothelial cells and is secreted partly into the 
circulation and partly into the subendothelial matrix, where it can exist as large 
multimers. It is present with other adhesive proteins, fibronectin and 
thrombospondin, which can also be involved with the adhesion event, but to a
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lesser extent. The binding of vWF to platelets is mediated by the GPIba,|3 - 
GPIX complex at the platelet surface [Roth, 1990]. vWF has also been shown 
to bind to GPIIb-llla complex in support of platelet aggregation. However, this 
is probably not physiologically relevant as FGN competes with vWF for binding 
and the plasma concentration of FGN exceeds that of vWF [Pietu et al., 1984]. 
Upon adhesion, platelets spread over the damaged surface. In vitro studies have 
shown that the body of the adhered platelets infiltrate the surface and the 
cytoplasm to spread filling the gaps between the pseudopods, eventually 
forming a thin film [White, 1986].
1.5.5 Platelet aggregation.
Platelet aggregation is a process whereby platelets adhere to each other to form 
a haemostatic plug, a process which requires both a platelet membrane 
component and a plasma component. During the early phase of activation a 
binding domain for fibrinogen (FGN) is exposed on the platelet GPIIb-llla 
complex, this allows FGN to bind and act as an interplatelet bridge, allowing 
platelet-platelet interaction (see section 1.5.8.1). The level of exposure of 
platelets to agonists is proportional to the exposure of fibrinogen binding sites 
and thus aggregation [Peerschke etal., 1980].
The introduction of the platelet aggregometer by Born, [1962] revolutionised the 
study of platelet function. Platelet aggregation in vitro is believed to mimic the 
formation of a haemostatic plug of platelet thrombus in vivo. Stirring in this 
system is essential to mimic the turbulent effects of blood circulation. The 
aggregometer allowed the characterisation of various agonists and antagonists 
on platelet function and providing valuable clues to the functioning of platelets
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in vivo (see section 2.6.5) The relationship between aggregation, TXAg release 
and secretion induced by different agonists is discussed in section 1.5.7.
1.5.6 Platelet secretion.
Adhesion and aggregation of platelets leads to the release of a plethora of 
vasoactive, pro-aggregatory and thrombotic factors. These are principally from 
the a and dense granules, but lysosomal granule release also occurs [Table 
1.3]. The mechanism of platelet secretion remains to be fully elucidated, 
although a working model has been proposed. The initial event is the 
centralization of secretory granules by the microtubule ring, which is thought to 
be induced by loose polymerisation of actin [White, 1986]. The second event is 
the increase in [Ca^ '"],, which activates two important enzymes, protein kinase C 
(PKC) and myosin light chain kinase (MLCK). Activated PKC phosphorylates a 
protein substrate, p47, this phosphoprotein is thought to allow the elongation of 
actin filaments [Kroll and Schafer, 1989]. In addition activation MLCK by Ca^ ""- 
calmodulin phosphorylates myosin light chain allowing activation of the myosin 
hexamer by actin. These two processes are thought to promote microtubule 
contraction, forcing the centralized secretory granule membranes to fuse with 
the OCS and thus release their contents into the surrounding microenviroment 
[White, 1986].
Platelet secretion can be quantified by measurement of ATP release using lumi- 
aggregometry [Feinman et a!., 1977] or by RIA of a particular granule 
component. However, the development of monoclonal antibody (MAB)
57
CONTENTS FUNCTION
a-granules
platelet factor 4
platelet derived growth factor (PDGF) 
transforming growth factor (TGF)
fibrinogen (FGN) 
von|Willebrand factor (vWF) 
thrombospondin 
fibronectin
p-thromboglobulin (p-TG)
factors V, VII and XI 
protein 8
plasminogen activator inhibitor 1 
(PAM)
Dense granules
serotonin (5-HT)
ADP, ATP
epinephrine
pyrophosphate
mitogen
mitogen
mitogen
physical support of aggregation 
physical support of adhesion 
reinforcement of FGN binding 
involved in platelet adhesion 
platelet specific anti-heparin protein
coagulation cascade proteins 
coagulation pathway protein 
inhibition of fibrin degradation
vasoconstrictor and platelet agonist 
vasodilators and platelet agonists 
vasoconstrictor and platelet agonist 
function unknown 
reinforcement of platelet activation
Glycogen granules
glycogen provision of metabolic energy
Lysosomal granules
acid hydrolases enzymatic digestion
Table 1.3: The various factors released from platelets and their intraplatelet 
sources. The granules are released during platelet aggregation and the contents 
help the cell fulfil its haemostatic function.
Source: The molecular basis of platelet function [Plow and Ginsberg, 1990]
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technology has led to the detection of specific protein markers which are derived 
from different secretory granules. These include the a granule membrane 
protein, P-selectin (GMP140, CD62P) [Stenberg etal., 1985] and CD63 (GP53) 
a lysosomal granule membrane protein [Nieuwenhuis at a!., 1987]. 
Quantification of these markers can be used as an index for platelet secretion.
1.5.7 The relationship between aggregation, thromboxane A2 release and 
secretion.
Although platelet aggregation is induced by a wide variety of agonists, it has 
become increasingly apparent that many of the agonists work via different 
pathways. Niewiarowski and Thomas, [1966], showed a synergistic effect on 
aggregation between thrombin and ADP which was greater than an additive 
effect and suggested the two agonists were working via different mechanisms. 
Later, cyclo-oxygenase inhibitors were shown to attenuate synergism between 
collagen and thrombin or ADP, but not between thrombin and ADP [Kinlough- 
Rathborne at a/., 1977]. These observations indicate that collagen-induced 
aggregation, but not thrombin- or ADP-induced aggregation is dependent on AA 
metabolism.
The work of Best and Holland, [1981] gave a much clearer indication of how 
different agonists work. Results from their study demonstrated:
a) Thrombin-induced aggregation and secretion was independent of TXAg 
biosynthesis.
b) Collagen-induced aggregation had a dual effect. At high concentrations 
(4pg/ml), aggregation was independent of TXAg production, but secretion had
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a partial dependency on TXAg,[synthesis. At lower doses of collagen (1 pg/ml) both 
aggregation and secretion were wholly dependent on TXAg. 
c) ADP-induced aggregation was independent of TXAg, but granule secretion 
was TXAg dependent.
Balduini et al., [1988] presented evidence to suggest that TXAg release in 
response to ADP was aggregation, but not FGN binding dependent. Inhibition 
of aggregation, but not FGN binding led to a decrease in TXAg release. This 
could have important implications for platelet analysis in non-stirred systems.
1.5.8 Platelet surface glycoproteins.
Platelets possess a family of cell surface adhesion molecule receptors, which 
mediate cell-cell interactions and involves use specific plasma proteins. These 
receptors are termed integrins, and all consist of non-covalently associated a 
and p subunits, with the p subunit common within the family [Phillips et a/.,
1988]. The integrins often exist as complexes of two or more glycoproteins 
subunits. Important integrin complexes which are involved in the aggregation 
and adhesion of platelets are the vWF receptor GPIa,P-GPIX, the collagen 
receptor GPIa-GPIIa and GPIIb-llla which binds FGN, vWF and fibronectin.
1.5.8.1 GPIIb-llla and fibrinogen binding.
GPIIb-llla is the most abundant integrin present on platelets with a density of 
approximately 50,000 per platelet [Phillips et a/., 1988]. The GPIIb-llla complex 
is a heterodimeric structure which requires Ca^ '" to maintain integrity of the 
complex. GPIIb consists of two polypeptide chains, one of 125kDa and a small 
cytoplasmic chain of 25kDa. The two chains are linked by one or more
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disulphide bridges [Phillips et al., 1988] [Figure 1.7]. GPIIIa is a single 
polypeptide chain of mol.wt., lOSKDa [Charo et a!., 1986]. The transmembrane 
regions of GPIIb-llla are connected to the cytoskeleton, possibly by the protein, 
talin [Painter ef a/., 1985]. Physiologically, the major function of GPIIb-llla is the 
binding of fibrinogen in support of platelet aggregation. In the resting platelet 
GPIIb-llla is thought to be relatively inert. Upon activation however, the complex 
becomes a receptor for several adhesive proteins, of which fibrinogen is the 
preferred substrate. The binding of fibrinogen acts to physically support platelet- 
platelet contact [Peerschke et a/., 1980].
FGN is a trimeric plasma glycoprotein (two Aa, two B(3 and two y chains) with 
a mol. wt. of 130kDa, the different chains being linked in antiparallel fashion. 
FGN is synthesised in the liver and secreted into the circulation and has plasma 
concentration of approximately 3g/l [Cook and Ubben, 1990]. Fibrinogen is also 
present in the a granules of platelets, this probably originated in the parent 
megakaryocyte [James et a/., 1977]. The binding of adhesive plasma proteins 
to GPIIb-llla is mediated by a specific amino acid, Arg-Gly-Asp (RGD), 
recognition sequence present on the particular plasma protein [Ruoslahti and 
Pierschbacher, 1987]. FGN possesses two RGD sequences both on the a chain 
and in addition contains a dodecapeptide sequence on the y chain which also 
binds to GPIIb-llla. [Phillips et a/., 1991 ].
The mechanism by which GPIIb-llla become activated still remains to be 
resolved, although two plausible mechanisms have been proposed. Shattil and 
Brass, [1987] suggested GPIIb-llla may be activated by direct interaction with
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Figure 1.7: Diagrammatic representation of the structure of the platelet GPIIb-llla 
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a G-protein, similar to a2-adrenergic receptors. Secondly, increases in 
intracellular cAMP levels and activation of PKC have both been shown to 
regulate exposure of FGN binding sites of GPIIb-llla [van Willigen and 
Akkerman, 1991]. The use of RGD containing peptides have provided evidence 
showing ligand binding to GPIIb-llla prior to platelet activation may trigger a 
conformational change in the receptor structure [Du etal., 1991].
1.5.9 Platelets and the coagulation cascade.
Activated platelets, in addition to forming primary haemostatic plugs, also 
participate in the coagulation cascade. Platelet activation leads to a loss of 
membrane phospholipid asymmetry, increasing the exposure of 
aminophospholipids, phosphatidylserine and phosphatidylethanolamine [Schroit 
and Zwaal, 1991]. Phosphatidylserine provides a catalytic surface for the 
interaction of coagulation factors [Schroit and Zwaal, 1991]. The most important 
reaction is the conversion of the prothrombin zymogen to the protease, thrombin. 
Factor Va, which is activated from factor V or secreted from platelet a granules, 
binds to the phosphatidylserine at the platelet surface. Factor Xa binds to factor 
Va to form a 1:1 stoichiometrical, Ca^ "" dependent complex [Tracy, 1988]. The 
membrane bound Va-Xa complex then interacts with prothrombin, which binds 
to phosphatidylserine. This assembled prothrombinase complex subsequently 
leads to the generation of thrombin. Thrombin in turn acts to aggregate platelets, 
cleave fibrinogen forming cross-linked fibrin meshworks and elicits the release 
various mitogens and vasoactive factors from the endothelium [Tracy, 1988].
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1.6 VASCULAR ENDOTHELIUM
1.6.1 Anatomy of the vessel wall.
The vessel wall consists of three layers of cells or 'tunica':
a) Tunica intima in man is a thin layer of endothelial cells which constitute the 
luminal surface of the vessel. The endothelial cells are supported physically by 
connective tissue, consisting mainly of collagen and basal elastic lamina. The 
intima is separated from the tunica media by this basal membrane.
b) Tunica media is a contractile layer found predominately in large arteries such 
as the aorta. It is composed of a large mesh of elastin molecules, with irregular 
shaped SMC and small amounts of collagen fibres. The SMC present control 
vascular tone in response to both neuronal and humoural stimuli.
c) Tunica adventia is the outermost layer of the artery and consists principally 
of skin fibroblasts and some SMC surrounded by a thin layer of connective 
tissue, predominantly collagen.
1.6.2 Endothelial cells
1.6.2.1 Structure and function.
The endothelium is composed of a continuous layer of cells, held together by 
junctional complexes [Simionescu and Simionescu, 1991]. The principal function 
of the endothelium is the provision of a non-thrombogenic permeable barrier 
between the circulation and underlying tissues. However, the endothelium is 
also a metabolically active tissue that subserves a wide range of functions 
relating to vascular haemostasis [Pearson, 1991]. The endothelium synthesises 
glycosoaminoglycans such as heparan sulphate, which when secreted remain
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on the luminal surface of the vessel wall as part of proteoglycans. Heparan 
sulphate is involved in the regulation of thrombin stimulation of the endothelium 
by catalysing the activation of anti-thrombin III [Rodgers, 1988] to reduce 
thrombin activity. Thrombin action is also controlled by the protein C pathway. 
The pathway is activated by the binding of thrombin to a endothelial surface 
receptor, thrombomodulin, causing the activation of protein C. Activated protein 
C inactivates factors Va and Villa which are intimately involved in thrombin 
generation at platelet surfaces [Rodgers, 1988].
More relevant to this study is the release of vasoactive factors from the 
endothelium which can influence platelet function. The endothelium synthesizes 
and releases two principal factors which have dual effects. Prostacyclin (PGIg) 
and nitric oxide (NO) are both vasodilators and platelet inhibitors and thus may 
be potentially important anti-thrombotic factors [Pearson, 1991]. The release of 
these substances is controlled by various blood borne mediators such as 
thrombin, acetylcholine (ACh), histamine, adenosine, ADP, ATP, and bradykinin 
(BK), all of which bind to specific receptors on the endothelial cells surface. In 
addition, metabolic activity within endothelial cells leads to the release of Oj*", 
which is converted to HgOz: these reactive oxygen species (ROS) can also 
influence platelet reactivity.
1.6.3 Prostacyclin.
PGIg is an AA metabolite which is synthesised via COX and prostacyclin 
synthase [Figure 1.6]. PGIg production is stimulated by either mechanical or 
chemical perturbation of the endothelial cell membrane. The binding of factors 
such as thrombin to cell surface receptors leads to phosphatidyiinositoi
65
hydrolysis and a subsequent increase in [Ca^'"]j(see section 1.5.2.3). Activated 
PLAg then liberates AA, which is metabolised to PGIg. Mechanical stimuli which 
induce PGIg production include pulsatile pressure [van Grondelle etal., 1984] 
and increased shear stress [Vane etal., 1990]. In addition, moderate damage 
to the endothelium by experimental methods have shown an acute burst of PGIg 
release [Weksler, 1984]. PGIg synthesis can be inhibited by glucocorticoids, 
which stimulate the formation of lipocortin, an endogenous inhibitor of PLAg 
[Vane etal., 1990] or by non steroidal anti-inflammatory drugs, such as aspirin 
or indomethacin, which inhibit COX [Vane, 1971]. In addition, high levels of lipid 
peroxides also inhibit PGIgproduction, by inhibiting PGIg synthase [Gryglewski, 
1976]. PGIg is unstable with a half life of approximately Sminutes before 
catabolism to 6-keto-PGFic [Moncada and Vane, 1978]. The measurement of 6- 
keto-PGFia in urine has been used to quantify iPGIg production in vivo and in 
vitro.
1.6.3.1 The vascular actions of prostacyclin.
PGIg is a potent inhibitor of platelet aggregation and vasodilator [Moncada et al., 
1976]. The biological effects of PGIg are induced by causing a transient increase 
in cytosolic cAMP concentrations by activation of adenylate cyclase [Tateson et 
al., 1977]. Due to its short biological half life PGIg, is a locally (paracrine) acting 
hormone rather than systemic hormone. When released into the vessell wall 
it acts to relax the underlying SMC, while its action luminally is to inhibit platelet 
activation. PGIg binds to specific receptor on the platelet surface which is 
thought to be linked to adenylate cyclase by the G-protein, Gg [Dutta-Roy et al., 
1987]. The subsequent rise in cAMP attenuates the phospholipid based 
secondary messenger system. cAMP inhibits the production of IP3 and DAG
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[Rittenhouse-Simmons, 1979], possibly by decreasing the activity of PLC. PGIg 
also increases the sequestration of cytosolic Ca^ '" into the DTS, preventing the 
activation of Ca '^' regulated enzymes [Tao et al., 1992] {section 1.4.2.4). The 
longevity of the cAMP signal is controlled by the action of specific 
phosphodiesterases. Additionally it has been proposed that the thrombin 
receptor is linked to Gj, which down regulates adenylate cyclase and favours 
platelet aggregation [Cooper and Rodbell, 1979].
1.6.3.2 Prostacyclin action in atherosclerosis.
The biological properties of PGIg may protect against atherosclerosis by 
suppressing the accumulation of cholesteryl esters by macrophages [Willis et 
a/., 1987] and increasing cholesteryl ester hydrolysis in vascular SMC [Hajjar et 
a!., 1982, Willis etal., 1987]. A reduction of PGIg activity, as seen in the area 
of atherosclerotic plaques [Sinzinger et al., 1977; De' Angelo, 1978], would 
favour thrombus formation. This is initiated by plaque rupture leading to 
activation of platelets and the coagulation cascade. Hence a reduction in PGIg 
synthesis may be detrimental to normal vascular homeostasis.
Platelets from patients with FH have been shown to have a diminished 
sensitivity to PGIg [Colli etal., 1983]. Inhibition of isolated platelet aggregation 
by PGIg was attenuated by the presence of LDL, this was associated in a 
reduced production of cAMP [Bruckdorfer et al., 1984]. In contrast to the effects 
on platelets, LDL increased PGIg release from cultured endothelial cells [Spector 
etal., 1985], with oxLDL having an even more potent effect [Thau etal., 1988]. 
These observations suggested a paradoxical role for LDL, increasing endothelial 
PGIg production while decreasing the sensitivity of its effects on platelets. In
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general it is accepted that there is diminished PGIg activity in plaque affected 
areas [Sinzinger ef a/ .,1977; De' Angelo, 1978].
1.6.4 Nitric oxide.
NO or a closely related species, has been implicated in a wide variety of 
biological events including regulation of vascular tone, inhibition of platelet 
adhesion and activation, neuronal signalling and macrophage cytotoxicity.
1.6.4.1 Discovery of endotheiium derived reiaxing factor (EDRF).
The endothelium plays an obligatory role in the relaxation of arterial SMC by 
acetylcholine (ACh) [Furchgott and Zawadzki, 1980]. In these now classic 
experiments aortic rings, precontracted with noradrenaline, were relaxed by the 
addition of ACh. The ACh induced relaxation was lost if the endothelium were 
removed. Relaxation in response to glyceryl trinitrate was unchanged. 
Furthermore, the magnitude of SMC relaxation in response to ACh was directly 
proportional to the amount of endothelium present. From these observations it 
was postulated that ACh acted on muscarinic receptors of the endothelium to 
release a factor (EDRF) which was not PGIg, but induced SMC relaxation 
[Furchgott and Zawadzki, 1980; Griffith etal., 1984]. ACh activated PLC-induced 
hydrolysis of AA, and it was postulated that EDRF was an AA metabolite, 
possibly a lipoxygenase product. Pulsatile flow through segments of canine 
femoral artery induced the release of a EDRF which was not PGIg, as evidenced 
by bioassay Rubanyi at a/., [1986].
It was proposed that EDRF was NO, since no significant differences in their 
actions were found on arterial relaxation [Ignarro at a/., 1987, Palmer at a/..
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1987]. Authentic NO solutions were compared directly to EDRF released from 
stimulated aortic endothelial cells cultured on microcarrier beads. No difference 
could be detected in biological half-life, the ability to relax contracted aortic 
strips, while the effects of both NO and EDRF were inhibited by the presence of 
Hb. Palmer etal., [1987] also showed that the O2*" produced by aortic strips was 
a major contributor to the decay of both NO and EDRF.
1.6.4.2 The biosynthesis of nitric oxide.
NO is synthesised in vivo from a biological substrate. Palmer at a/., [1988] 
demonstrated that NO derived from cultured endothelial cells was synthesised 
from the amino acid, L-arginine. Incubation of endothelial cells with L-arginine 
(L-arg), but not D-arg, significantly enhanced the production of NO in response 
to BK. Studies with L-arg demonstrated that L-citrulline was the other 
product produced in NO synthesis [lyenger at a/., 1987]. Inhibition of NO 
synthesis by N°-monomethyl L-arg (NMMA), strongly suggested that L-arg was 
the substrate and the guanidine N atoms were utilised in NO formation [Palmer 
ate!., 1988]. NO production in response to calcium ionophore A23187 indicated 
that the pathway may be initiated by an increase in intracellular Ca^ "^  [Palmer at 
a/., 1988].
Marietta at a!., [1988] proposed the existence of an enzyme, NO synthase, which 
catalyses the conversion of L-arg to NO in the presence of Ca^ '". The proposed 
synthesis of NO is outlined in Figura 1.8 and can be broken down into five steps:
a) Hydroxylation of a guanidino nitrogen atom to form N°-hydroxylarginine, with 
NAD PH acting as a co-factor.
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b) Two electron oxidation of the hydroxylamine moiety; an electron donor was 
not proposed.
c) Loss of a proton and subsequent production of an amino acid radical.
d) Fragmentation of the unstable radical, which produces NO and an amino acid 
derivative, carbodiimide.
e) Reaction of carbodiimide with HgO [Marietta, 1988], then produces L-citrulline.
It is of interest that NO is also released from macrophages, independently of 
Ca '^', when stimulated with lipopolysaccharide [Marietta, 1988]. This could be 
inhibited if cells were pre-incubated with N°MMA [Hibbs et a/., 1987], suggesting 
the presence of a NO/L-arginine pathway similar to that of the endothelium. SMC 
have also been shown to release an NO-like factor which inhibited platelet 
aggregation and was abrogated by the presence of oxyHb and N°MMA, but 
potentiated by SOD [Mollace at a/., 1991]. Importantly, the effects of LPS on 
macrophages could be abolished by pre-incubation with cyclohexJmide. This 
indicated that NO production by the endothelium and macrophages occurred by 
slightly different mechanisms, since the effects of cyclohextmide suggest protein 
(enzyme) synthesis was required [Mollace etal., 1991]. in addition the NOS of 
the endothelium was Ca^ "" dependent, while the macrophage and SMC NOS was 
Ca^  ^ independent and enzyme synthesis was required for NO production.
Several different NOS isoenzymes have now been characterised:
[1] Neuronal NOS (nNOS; type I) is the constitutive Ca '^' dependent enzyme 
found in neuronal tissue.
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Figure 1.8: The proposed mechanism for the formation of nitric oxide from L- 
arginine.
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[2] Inducible NOS (iNOS; type II) is the inducible independent enzyme 
found in macrophages.
[3] Endothelial NOS (eNOS; type III) is theconstitutiveCa^  ^dependent enzyme 
found in endothelial cells.
1.6.4.3 Nitric oxide: Biological effects and mode of action.
Vascular relaxation in response to ACh and BK is mediated by the release of NO 
[Furchgott and Zawadzki, 1980; Griffith etal., 1984]. The half-life of NO seems 
to be very short, ranging from 6 to 30s [Griffith at a!., 1984; Palmer at a!., 1987, 
Ignarro ef a/., 1987, Myers at a!., 1990]. NO, although an inorganic molecule, it 
is extremely lipophilic and once formed diffuses out of the cell into adjacent 
cells, which include endothelial cells, platelets or SMC, where it exerts its 
biological effect. In this respect NO is unique as it can be considered a primary 
intercellular messenger.
More relevant to this thesis, NO has been shown to be a potent inhibitor of 
platelet aggregation. Azuma at a/., [1986] first demonstrated that the effluent 
from a perfused rabbit aorta stimulated with ACh, both relaxed aortic strips and 
inhibited AA-induced platelet aggregation. Furlong at a/., [1987] showed 
endothelial cells produced EDRF inhibited both collagen- and TXAg-induced 
aggregation, this inhibition could be abolished by Hb and potentiated by SOD. 
NO also inhibited adhesion of radiolabelled thrombin-stimulated platelets to 
aortic strips stimulated with BK [Radomski at a/., 1987b]. In a more detailed 
study [Radomski at a!., 1987a], both endogenous and exogenous NO inhibited 
platelet adhesion, the inhibition was potentiated by SOD and inhibited by Fib.
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Furthermore PGIg and cAMP phosphodiesterase inhibitors had very little^ffect 
on adhesion, while specific cGMP phosphodiesterase inhibitors potentiated the 
inhibition of adhesion. These observations strongly implicated NO as the active 
agent in respect to platelet inhibition.
Nitrates, NO and *0H can stimulate guanylate cyclase to increase intracellular 
cGMP [Murad etal., 1978]. It was suggested that increases in cGMP induced by 
exogenous NO and NO donors inhibited platelet aggregation [Mellion at a/., 
1981]. Subsequently increases in platelet cGMP were shown to inhibit PI 
hydrolysis and p47 phosphorylation induced by thrombin [Takai at a!., 1981]. 
Furthermore endothelium dependent arterial relaxation was also associated with 
increased cytosolic cGMP [Rapoport and Murad, 1983]. The addition of 
exogenous NO to platelets led to a rapid increase in cGMP which occurred in 
the first 15s after addition [Salvemeni at a!., 1990, Nguyen at a!., 1991]. NO 
binds to the haem group of guanylate cyclase to form nitrosylhaem. This 
interaction pulls the Fe^ "" out of the plane of the planar porphyrin ring leading to 
enzyme activation [Ignarro, 1990]. Incubation of NO with gel filtered platelets 
prior to addition of thrombin, inhibited aggregation, serotonin secretion, p47 
phosphorylation and phosphatidic acid production, but enhanced [Ca^^,. The 
inhibition of NaF induced aggregation, which activates GTP binding proteins 
directly, and the decrease in phosphatidic acid production, indicated that NO 
inhibited G-protein activation of PLC and subsequent secondary messenger 
production rather than affecting receptor/G protein coupling [Nguyen at a/.,
1991]. Experimental evidence indicates that basal release of NO by endothelial 
cells may control platelet function and vascular tone. Adhesion of thrombin 
stimulated platelets to an unstimulated endothelial monolayer was inhibited by
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the presence of a specific cGMP phosphodiesterase inhibitor [Radomski et al., 
1987b]. The passage of platelets, once through rabbit coronary vascular bed, 
significantly increased platelet cytosolic cGMP without ACh stimulation of 
endothelial cells [Pohl and Busse, 1989]. However, addition of ACh to the 
perfusate did increase platelet cGMP compared to the effects of unstimulated 
endothelial cells. Platelets also possess an L-arginine/NO pathway which is 
activated during platelet aggregation and may represent a self-regulatory 
mechanism for platelet function [Radomski at a/., 1990a, b]. There appears to 
be basal release of NO from the endothelium which enters the platelet to 
increase cGMP [Radomski etal., 1987; Pohl and Busse, 1989]. These findings 
strongly suggest the biological actions of NO are mediated by increasing 
intracellular cGMP. The short half life of NO suggests it is a local, rather than a 
systemically acting messenger.
1.6.4.4. Reactions of nitric oxide.
(i) Nitric oxide and superoxide anion: formation of peroxynitrite.
Many studies involving NO observed that SOD increased the longevity of its 
biological effects [Rubanyi et ai, 1986; Palmer et ai, 1987; Radomski et ai, 
1987; Furlong et ai, 1987]. This suggested that 02*“ or a related species reacts 
with NO, resulting in the loss of its biological activity. Gryglewski et ai, [1986] 
implicated C)z*“ as the free radical species which nullifies NO, since SOD, but 
not catalase, protected arterial relaxations induced by BK stimulation of 
endothelial cells.
Beckman et ai, [1990] postulated that inhibition of NO activity by Og*' was due 
to a chemical interaction between the two free radicals. The product of the
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reaction is the peroxy nitrite anion (ONOO*"), which when protonated rapidly 
decomposed (half life approx. 1.9s) to produce NO'z and an oxidant with a 
similar reactivity to 'OH (reaction 1).
C)z"- + NO -  ONOO- + H+ # ONOOH -  'OH + NO'g -  NO3" + H+ (1)
If ONOO" is produced in vivo, it would be in close proximity to the luminal
surface of arteries and as a result may elicit endothelial damage, which in turn 
contribute to the development of atherosclerosis. The provision of a SOD on the 
luminal surface of the endothelium may protect against this process.
(ii) Nitric oxide and oxygen.
NO readily reacts with Og to produce NOg. NOg has two possible fates; firstly in 
the gaseous phase NOg could dimerise to form N2O4 while in solution NOg would 
yield nitrite and nitrate ions (reactions 1, 2 and 3).
2N0 + O2 -  2NO2 (1)
2NO2 ^ N2O4 (2)
2NO2 + H2O -* NO2" + NO3- + 2H+ (3)
Reactions 1 and 3 are the most biologically relevant and probably represent the 
actual inactivation pathway for NO during bioassay experimentation in vitro. In 
addition, reaction 1 indicates that the stability of NO is directly proportional to 
its initial concentration.
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(iii) Nitric oxide and Hemoglobin.
Hb possesses a very high binding affinity for NO; which binds to the Fe^  ^ ion of 
the haem group. The product of the reaction is nitrosyl-haem, a complex which 
is stable for several minutes [Keilin and Hartree, 1937]. Micromolar 
concentrations of Hb are present in the circulation and as such may influence 
the half-life of NO.
1.6.4.5. Does nitric oxide exist in vivo ?
It is accepted that the properties of EDRF can be mimicked by NO. However 
little evidence has been presented showing the existence of NO in vivo. Hence, 
it has been postulated that released NO may be complexed and stabilised by a 
carrier, in the plasma. Thiol groups (R-SH) can be nitrosylated in the presence 
of NO [Stamler et al., 1992], and it has been suggested that peptides and 
proteins containing free thiol groups may act as carriers for NO. Several S- 
nitrosothiols have been shown to inhibit platelet aggregation and increase cGMP 
[Mellion at s i, 1983]. More recently Myers at a/., [1990] showed 8- 
nitrosocysteine to induce vasorelaxation of porcine aortic rings, which was 80 
times more effective than authentic NO solutions. The effects of 8- 
nitrosocysteine were abolished by the presence of Hb, suggesting a mechanism 
involving the release of NO. In the same study, 8-nitrosoglutathione and 8- 
nitrosomercaptoethanol were found to induce relaxation, although to lesser 
extent than 8-nitrosocysteine. 8-nitrosocysteine also inhibited platelet activation 
and secretion, which was associated with an elevation in cGMP [Lieberman at 
a/., 1991]. A study by 8tamler at a/., [1992], showed that several plasma 
proteins could be nitrosylated and were found to be biologically active, as 
assessed by their abilities to relax aortic strips and inhibit platelet aggregation.
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Although the above studies do not provide evidence of the biological existence 
of S-nitrosothiols, they do demonstrate that they possess biological activity 
which may mediate the release of NO. It is reasonable to postulate that S- 
nitrosothiols constitute a mechanism by which NO can exert a systemic effect. 
The biological relevance of S-nitrosothiols requires more detailed investigation.
1.6.4.6. Nitric oxide and atherosclerosis.
The development of atherosclerosis is thought to associated with a loss of 
vascular tone in the affected areas. Strips taken from atherosclerotic human 
coronary arteries showed a decreased potential to relax when challenged with 
BK, compared with responses in normal arteries [Fostermann et al., 1987; 
Bossaller et al., 1987]. It was proposed that LDL played a key role in the 
mechanism of these effects. nLDL and oxLDL both inhibited relaxations induced 
by ACh; the effects of nLDL were reversible and dependent on the contracting 
agent [Andrews etal., 1987b]. In contrast, Tanner et al., [1991] showed oxLDL, 
but not nLDL, inhibited vascular relaxation. OxLDL only inhibited endothelium- 
dependent relaxation of blood vessels, since relaxation in response to Ca^  ^
ionophore, A12387, and SIN-1 (an NO donor) were unaffected. This indicated 
that the effects of oxLDL were at receptor level.
Activation of endothelial G-proteins by NaF induced the release of NO. this was 
only partially inhibited by pertussis toxin [Flavahan and Vanhoutte, 1990], 
suggesting the involvement of two distinct G-proteins, one of which was more 
sensitive to pertussis toxin (GJ. OxLDL at low concentrations (50mg/l) exerted 
its most potent effects against endothelial stimulators (thrombin and serotonin) 
of NO release which were G; dependent [Kugiyama et al., 1990]. At higher
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concentrations of oxLDL (100 - 300mg/l) the effects were more non-specific, 
inhibiting the actions of A12387 and BK (Gj independent) [Kugiyama et al., 1990, 
Tanner etal., 1991]. In the above studies, different incubation times were used 
which may account for some of the different results obtained, but in addition they 
may also give an indication to the mechanisms underlying the progression of 
atherosclerosis. The SMC of atherosclerotic coronary arteries respond normally 
to NO mimetics such as SIN-1, which would indicate that the effects of oxLDL 
are on the endothelial cells [Tanner et al., 1991; Shimokawa et al., 1991]. 
Endothelial dysfunction in the affected area is an early event in atherosclerosis 
[Hansson etal., 1987]. The endothelial dysfunction in atherosclerosis and that 
produced experimentally by oxLDL appear to be similar [Shimokawa et al.,
1989]. Evidence would suggest in early atherosclerosis or at low oxLDL 
concentrations, endothelial dysfunction is mediated by impaired G-protein 
function, in particular pertussis sensitive G-proteins [Shimokawa et ai, 1989; 
Shimokawa et ai, 1991]. In support of this concept Gj endothelial-dependent 
relaxations in hypercholesterolaemic animals have been shown to be reduced 
compared to Gj independent pathways [Shimokawa et ai, 1991]. As the disease 
progresses, equivalent to higher experimental concentrations of oxLDL and 
increased incubation times, the impairment of relaxation becomes less specific. 
Tanner et ai, [1991] suggested longer term exposure to oxLDL allowed the 
uptake of oxLDL by the endothelial cells scavenger receptor. Endocytosed 
oxLDL was proposed to interfere with the L-arginine/NO pathway, since 
pretreatment of aortic rings with L-arginine produced normal relaxation 
responses in the presence of oxLDL. The actions of oxLDL may be mediated by 
oxidation products, an example of which is lysolecithin.
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1.6.5. Reactive oxygen species and platelet function.
The endothelium continually produces superoxide anions (Og'l, which most 
probably originate from incomplete reduction of oxygen by the electron transfer 
chain in mitochondria [Ramasarma, 1982]. The respiratory burst of neutrophils 
is also a major source of Og'T Superoxide is generated by the addition of an 
unpaired electron to molecular oxygen (reaction 1):-
O2 + e" O2"- (1)
Superoxide radicals are normally removed in vivo by the action of (SOD), which 
catalyses the dismutation of superoxide anions to hydrogen peroxide (H2O2) 
[Babior and Peters, 1981] (reaction 2):-
2O2-  + 2H+ H2O2 + O2 (2)
Hydrogen peroxide is also thought to be cytotoxic and is subsequently converted 
to water and molecular oxygen in vivo by the action of the enzyme catalase 
(reaction 3):-
2H2O2 2H2O + O2 (3)
Although little has been published on the effects of superoxide on platelet 
function, H2O2 has been shown to influence the reactivity of platelets.
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Endogenous HgOg potentiated aggregation of platelets pre-exposed to ADP 
[Canoso et al., 1974]. This effect was shown to involve enhanced release of 
platelet granules [Rodvien at a!., 1976]. Exposure of washed platelets to HgOg 
(IpM) significantly increased [Ca^^j [Del Principe at a!., 1991]. These studies 
indicate that HgOg can influence aggregation. However, a recent study has 
demonstrated the endogenous production of HgOg by platelets [Maresca at a/.,
1992]. Del Principe at a!., [1985] showed that the addition of catalase inhibited 
collagen-induced platelet aggregation, consolidating that HgOg is involved in 
platelet aggregation. Subsequently, HgOg was shown to be produced by 
collagen- but not thrombin-stimulated platelets [Del Principe at a!., 1991], the 
authors suggested that HgOg was involved in the activation of cyclo-oxygenase.
1.7 LOW DENSITY LIPOPROTEINS AND PLATELET FUNCTION.
1.7.1. Platelets and hypercholesterolaemia.
The original observations suggesting that lipoproteins may influence platelet 
activity were made by Farbiszewski at a!., [1969], who demonstrated PRP had 
an increased susceptibility to aggregate when challenged with ADP if isolated 
LDL were added. LDL was also proposed to sensitise platelets in vivo, since 
platelets from type lia and Mb patients were more sensitive to agonist such as 
ADP and adrenaline. [Carvalho at ai., 1974]. These observations were confirmed 
by Joist at ai., [1979] and Zahavi at ai., [1981], who also showed increased 
release of platelet granules. These effects may have been due to increased 
plasma concentrations of catecholamines [Smith at ai., 1991], which are known 
to synergise with other platelet agonists. Hassell at ai., [1983a] showed a strong 
relationship between plasma LDL concentrations and platelet sensitivity to ADP 
and adrenaline. However, major differences were only observed between
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individuals of low and average LDL concentrations, no increase in sensitivity 
occurred with individuals of high LDL concentrations. Although these studies 
indicate lipoproteins do influence platelet function, the criteria for selection of 
controls must be addressed carefully as this would have a great bearing on the 
interpretation of the results.
The mechanism proposed for the effects observed in hyperlipidaemic subjects 
was that elevated plasma LDL concentrations led directly to an increased 
cholesterol content in platelet membranes and a subsequent reduction in 
membrane fluidity [Shattil and Cooper, 1977]. Incubation of platelets with 
cholesterol-rich liposomes, led to platelets which were more active than controls. 
Conversely, incubation with cholesterol-poor liposomes produced platelets of 
low reactivity. An increased membrane cholesterol content may alter the activity 
of membrane bound enzymes, such as adenylate cyclase and phospholipases. 
Other studies have failed to show a link between changes in membrane 
phospholipid/cholesterol ratio and platelet activity in, one, atherosclerosis 
[Moscat etal., 1986] and two, in patients with severe liver disease [Owen at a/., 
1981]. This indicates that increased membrane cholesterol may only be 
important in specific circumstances.
1.7.2. Direct effects of low density lipoproteins on platelets.
Since changes in P/C ratio did not fully explain the observations of increased 
platelet activity in hyperlipidaemics states, the concept that lipoproteins, 
particularly LDL, may have direct effects on platelets was proposed. Fujitani at 
a!., [1979] first showed aggregation of gel filtered platelets in vitro was increased 
by the presence of exogenously added LDL. These observations were
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subsequently confirmed by others [Aviram and Brook 1983; Hassall et al., 
1983b] in both PRP and washed platelet preparations. If LDL was added at 
pathophysiological concentrations (> 2.5g/l), secondary aggregation of isolated 
platelets was induced independently of other platelet agonists [Hassell at a!., 
1983b].
Other lipoproteins such as VLDL and HDL have also been shown to influence 
platelet function in vitro. Aviram and Brook, [1983] showed VLDL to enhance 
platelet activation while HDL was inhibitory. Hassell at ai., [1983b] found VLDL 
to have no effect with HDL again being inhibitory. Subsequently it was 
recognised that HDLg (apoE containing) invoked inhibitory effects while HDLg 
had little effect [Desai at ai., 1989; Higashihara at ai., 1991].
Since platelets are enucleate their cholesterol requirements must be fulfilled by 
the megakaryocyte or provided by LDL. If platelet cholesterol is derived from 
LDL then this would require a receptor for LDL binding and subsequent 
endocytosis. Mazurov at ai., [1982] first showed the binding of fluorescently 
labelled LDL to gel filtered platelets. Labelled LDL was displaced by a twofold 
excess of unlabelled LDL, but required a twenty-fold excess of HDL to have the 
same effect. A subsequent study showed that LDL binding to washed platelets, 
was temperature dependent, saturable and displaced by excess LDL and HDL, 
divalent cation independent and independent of platelet activation state [Curtiss 
and Plow, 1984]. Homozygous FH subjects were also found to bind LDL, 
suggesting that the apoB/E receptor was not involved [Shmulewitz at ai., 1984]. 
Koller, [1986] found LDL, HDLg and HDi^ all bound to isolated platelet 
membranes, binding was Ca^ "" independent and not mediated by arg or lys
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residues of apoB. In a more detailed study, two major lipoprotein binding 
membrane glycoproteins were isolated and identified as the GPIIb-llla complex. 
LDL and HDL bound to the isolated complex and to the individual subunits. 
Competition for binding sites on GPIIIa was observed between FGN, LDL and 
HDL, while FGN also inhibited binding of LDL and HDL to GPIIb without binding 
itself [Koller etal., 1989]. The proposed binding site for lipoproteins on GPIIb-llla 
was further reinforced by Kowalski etal., [1990], who inhibited binding of VLDL 
and LDL to the platelet surface by the presence of RGD-containing peptides and 
Mabs to the GPIIb-llla complex. Hassell et ai, [1990], demonstrated that LDL 
binding to platelets was biphasic and saturable binding was to a receptor with 
a different molecular weight to that of the apoB/E receptor. In all these studies, 
saturable binding was achieved over time periods ranging from 15min to 3h, 
methodological differences probably account for these and other differences in 
results, but the evidence strongly suggested that LDL-receptor coupling occurs 
at the platelet surface.
1.7.3. Influence of low density lipoproteins on post-receptor events.
LDL induced activation of platelets has been shown to influence post receptor 
events. Several groups have shown LDL to increase platelet [Ca "^”], [Andrews et 
al., 1987a, Dunn etal., 1988, Knorr efa/., 1988, Block ef a/., 1988, Katzman et 
al., 1991], although to varying degrees. The mobilization of Ca '^' is crucial to 
platelet activation, activating several important enzymes (see section 1.5.2.4). 
The increase in Ca "^’ was associated with phosphorylation of p47 and PKC 
activity [Andrews etal., 1987a], increased PI turnover [Block etal., 1988] and 
increased TXAgformation [Knorr etal., 1988]. It is likely that all the latter effects 
are associated with the effects on Ca^ *. In addition, LDL was shown to inhibit the
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activity of adenylate cyclase and the resultant increase in cAMP [Bruckdorfer et 
al., 1984].
1.7.4. Oxidative modification of low density lipoproteins and platelet 
function.
LDL is thought to become oxidatively modified during the progression of 
atherosclerosis (see section 1.3). Aviram, [1989] showed oxLDL to inhibit 
collagen-induced platelet aggregation, while acetylated LDL, PLC treated LDL 
and hepatic lipase treated LDL had no effect. In another study by Ardlie etal., 
[1989] nLDL enhanced ADP stimulated aggregation, while oxLDL induced 
aggregation, although preparations of oxLDL had TBARs concentrations much 
lower than those quoted in other studies. Similarly Meraji etal., [1991] showed 
that oxLDL, with relatively low concentrations of oxidation products, potentiated 
and induce aggregation of isolated platelets. Two products of lipid oxidation, 
lysophosphatidylcholine and 4-HNE are known to inhibit platelet aggregation 
[Besterman and Gillette, 1971; Selley et al., 1988]. Other oxidised lipids have 
also been shown to influence platelet function; 13-hydroxydienoic acid inhibited 
platelet activity [Simon et al., 1990], while 15-HETE potentiated thrombin- 
induced platelet activation [Setty etal., 1992].
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1.8 AIMS.
There were four major aims of the present study:
[1] To investigate how the extent of oxidative modification of LDL influenced the 
effects of the lipoproteins on platelet function.
[2] To identify which components of LDL or modified LDL were responsible for 
the activation of platelets.
[3] To investigate whether LDL/modified LDL affected the sensitivity of platelets 
to NO.
[4] To study the influence of peroxides, including hydrogen peroxide, on 
platelets as target cells for NO.
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2.0 MATERIALS AND METHODS.
2.1 REAGENTS LIST.
Acetylsalicylic acid 
Adenosine diphosphate 
1, 1,3, 3-ethoxypropane 
Human thrombin 
Hydrogen peroxide 
Isomethylbutyl xanthine (IBMX)
Manganese oxide 
Prostaglandin Ig
The above chemicals were all purchased from Sigma Chemicals Co., U.K.
c a r b o x y - p h e n y l - 4 , 4 , 5 , 5 - t e t r a m e t h y l i m i d a z o l o i n e - 1 - o x y l - 3  
oxide,(Calbiochem, U.K.)
Collagen (equine) (Hormon Chemie, France)
CHOD-iodide (Merck, U.K.)
Cyclic guanosine monophosphate RIA kit (Life Sciences Ltd, U.K.)
15 (S)-Hydroperoxyeicosatetraenoic acid (Cookson chemicals, U.K.)
Nitric oxide gas (Lyndi gas, U.K.)
Nitrogen gas (British Oxygen Company, U.K.)
S-nitrosoglutathione (Tocris Cookson, U.K.)
Rabbit anti-human anti-fibrinogen antibody (Dako Ltd, Denmark) 
IOP62-FITC (The Binding Site, U.K.)
RFAC-4 (Dr. A H. Goodall, Royal Free Hospital School of Medicine, U.K.)
86
All other chemicals were obtained from BDH unless otherwise stated in the text, 
and were of Analar grade or above.
2.2 EQUIPMENT LIST.
Platelet aggregometer (Centratronic Sales Ltd, U.K)
Platelet aggregation cuvettes (Pollution and Process Monitoring., U.K.)
Micro magnetic stir bars (Pollution and Process Monitoring., U.K.)
Flow cytometer ( EPICS PROFILE II; Coulter, U.K.)
Ultracentrifuge (XL70; Beckman Ltd, U.K.)
Ultracentrifuge rotor (70Ti; Beckman Ltd, U.K.)
Polycarbonate ultracentrifuge tubes (Beckman Ltd, U.K.)
Centrifuge (Centra-7R refrigerated centrifuge; I.E C., U.K.)
Thrombocounter (Coulter Elelectronics Ltd, U.K.)
Spectrophotometer (DU70; Beckman Ltd, U.K.)
Scintillation counter (Beckman 5000LS)
Gas sampling tubes (University College London glassblower, U.K.) 
Polypropylene sterile syringes (Becton Dickinson Ltd, U.K.)
Butterfly needles (sterile, 19 or 21 gauge; Venesytems, U.K.)
Needles (sterile, 21 gauge; Venesytems, U.K.)
Rubber septa (Phase separators, U.K.)
Monovette tubes (Starstedt Ltd., U.K.)
Centrifuge tubes (Corning Ltd, U.K.)
Plastic universal collection tubes (B.D.H.)
Gas-tight syringes (Hamilton, U.S.A.)
Agarose gel electrophoresis kit (Universal Gel/8; Ciba Corning Ltd, U.K.)
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2.3 BUFFERS AND SOLUTIONS.
2.3.1 Low density lipoprotein preparation.
[1] Acid-citrate-dextrose (pH 6.4): 72.6mM NaCI, 113.8mM glucose, 29.9mM tri­
sodium citrate and 2.8mM citric acid.
[2] Density solution (1.063g/ml) (pH 7.4): j 68mM NaBr, 0.3mM EDTA, 5mM 
NaOH and 1 pM DTPA.
[3] Density solution (1.151g/ml) (pH 7.4):260mM NaBr, 0.3mM EDTA , 5mM 
NaOH and 1pM DTPA.
[4] Tris buffer (for dialysis; pH 7.4): 140mM NaCI, 12mMTris, 1pM DTPA 
Both density solutions were prepared with in deoxygenated water
2.3.2 Platelet preparation.
[4] Modified Tyrode's HEPES buffer (pH 7.4): 150mM NaCI, 0.5mM HEPES Na, 
0.55mM NaH2P04.2H20, 7mM NaHCOg, 2.7mM KCI, O.SmM MgCl2 and 5.6mM 
glucose.
[5] HEPES buffered saline (pH 7.4): 150mM NaCI, 5mM KCI, 1mM MgS04.7H20 
and 10mM HEPES Na.
[6] Formyl saline (0.2%v/v): 5ml formaldehyde (stock solution 40%) in 995ml 
saline (0.9%w/v).
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[7] EDTA-wash buffer (pH 6.5): 36mM citric acid, 10mM EDTA, 5mM KCI, 90mM 
NaCI and 5mM glucose.
[8] Tyrode's phosphate buffer (pH 7.4): 136.9mM NaCI, 11.9mM NaHCOg, 
4.2mM NaHP04.2H20, 2.7mM KCI.
2.3.3 Electrophoresis.
[9] Barbitone buffer (pH 8.4): lOOmM NaCI, 2.3mM barbitone, 14.2mM sodium 
barbitone, 1 pM EDTA,
2.4 COLLECTION OF BLOOD SAMPLES.
All blood samples were obtained from healthy volunteers, who denied taking any 
medication in the previous 14 days. Blood was taken by antecubital 
venepuncture, with minimal stasis, using a 19 or 21 gauge butterfly needle into 
sterile plastic syringes. The blood was transferred to sterile universal pots 
containing acid-citrate-dextrose (ACD, ratio 1:4) as an anticoagulant, and gently 
inverted. All blood samples obtained were handled in this way and centrifuged 
within 5min of collection, unless otherwise stated.
2.5 LOW-DENSITY LIPOPROTEIN RELATED METHODS.
2.5.1 Isolation of low density lipoproteins.
LDL were isolated from human plasma by discontinuous density 
ultracentrifugation using a fixed angle rotor, based on the method of Chung et 
al., [1980]. Freshly citrated whole blood was centrifuged at 2000g for 20min at 
4°C to yield plasma. The plasma density was adjusted to 1.3g/ml by addition of 
solid sodium bromide (NaBr; 31 g per 70ml plasma), which was essentially
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transition metal ion free; NaBr was dissolved in the plasma by slow stirring. 10ml 
of density adjusted plasma was underlayed beneath 0.9% sodium chloride 
(NaCI) solution in 36.5ml non-disposable polycarbonate centrifuge tubes. These 
were centrifuged at 200000g for 2.5h at 4°C, to yield a bright yellow band of LDL 
in the middle of the tube [Figure 2.1]. The LDL were removed using a syringe 
and a 19G needle, disregarding the chylomicrons and VLDL at the top of the 
tube, and subjected to a second centrifugation to remove possible impurities 
such as HDL and albumin. Here 10ml of LDL was overlayed on 6.5ml of 
1.151g/ml density solution (see section 2.3.1) and the remainder of the tube 
topped up with 1.063g/ml density solution (see section 2.3.1). The tubes were 
spun at 200000g for 16h at 4°C, after which LDL floated at the top of the tube.
LDL were concentrated in disposable concentrators (Amicom Centriprep 100), 
which removed 95% of the salts present. This was followed by dialysis against 
5L. of de-oxygenated Tris buffer (pH 7.4;see section 2.3.2) for 8h at 4°C, with 
four complete changes of buffer. Dialysis was performed in an air-tight container 
to prevent re-oxygenation of the buffer and in the dark to eliminate any 
possibility of photo-oxidation. Dialysis tubing was boiled in EDTA solution prior 
to use, to remove any transition metal ions which may have been present. Once 
prepared, all LDL samples, except aliquots to be oxidised, were supplemented 
with diethylenetriaminepentaacetic acid (DTPA, 1 pM) to prevent any oxidation. 
In addition all solutions used in the isolation and preparation of LDL were 
supplemented with DTPA (IpM).
2.5.2 Estimation ofiow density iipoprotein concentration.
LDL concentration was expressed as protein concentration and determined by
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a modification of the Lowry method [Markwell et al., 1978]. Bovine serum albumin 
(stock 200|jg/ml) was used to produce a standard curve and the concentration of the 
stock solution checked spectrophotometrically immediately prior to each assay.
Absorbance was read at 660nm in a DU-70 spectrophotometer and the concentration
of LDL protein calculated from the standard curve using straight line regression
constants.
2.5.3 Oxidation of isoiated iow density iipoproteins.
In this study two different methods of oxidation were used to modify LDL.
[1] Fully oxidised LDL (oxLDL).
LDL were exposed CugSO^ .SHgO (6.4pM/mg protein/ml) under sterile conditions 
at 37°C for 24h. Oxidation was halted by the addition of excess DTPA (13pM/ mg 
protein), to chelate the Cu^ "" ions. OxLDL was then dialysed in 51 deoxygenated 
Tris buffer for 4h at 4°C, with two complete changes in buffer, to remove the 
chelated Cu^  ^ions. After dialysis the oxLDL was supplemented with DTPA (1 pM) 
to prevent further oxidation.
[2] Minimally modified LDL (mmLDL).
LDL were exposed to air under sterile conditions at 37°C for 18 - 24h. The 
sample was placed in a sterile glass vial and sealed with a rubber septum; this 
was then pierced with a ISgauge needle attached to a 0.22pm disposable filter 
to allow gaseous exchange. On completion, the mmLDL was removed and 
supplemented with DTPA (1 pM) to prevent further oxidation.
All LDL preparations were characterised by determination of their content of lipid
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Figure 2.1 : Isolation of low density lipoproteins from density adjusted plasma by 
ultracentrifugation.
LDL were isolated from human plasma by discontinuous density 
ultracentrifugation of plasma, based on the method of Chung et al., [1980]. 
Briefly, density adjusted plasma was underlayed beneath NaCI (0.9%) centrifuged 
to leave LDL in the middle of the tube, as in (1). The LDL is removed and 
overlayed on 1.151g/ml density solution, while the remainder of the tube is 
topped up with 1.063g/ml density solution (2). After Centrifugation the LDL flots 
at the top of the tube, as shown in (3).
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hydroperoxides (LPO) (see section 2.5.6) and the formation of thiobarbituric acid 
reactive substances (TBARS) (see section 2.5.7). Samples were stored in air­
tight vials at 4°C and used within one week of preparation. At no point during this 
study were individual LDL preparations pooled.
2.5.4 Preparation of 15(S) Hydroperoxyelcosatetraenoic acid (HpETE) and 
15(S) Hydroperoxyelcosatetraenoic acid (HpETE)-LDL.
15(S)-HpETE was supplied in ethanol, therefore its effect on platelets could not 
be tested directly, because of the inhibitory effect of alcohols on platelet activity. 
Consequently, the lipid hydroperoxide was dissolved in physiological buffer 
before addition to platelets, as follows. The ethanolic 15 (S)-HpETE was placed 
in a darkened glass vial and the ethanol evaporated under nitrogen. The 
subsequent residue was dissolved in 0.01 M NaOH and then diluted to the 
appropriate concentration in deoxygenated phosphate buffered saline. The 
whole procedure was performed in a chamber continually flushed with nitrogen. 
Once prepared all 15 (S)-HpETE solutions were kept on ice until added to the 
platelets. Within each experiment testing the effects of 15(S)-HpETE on platelet 
aggregation an internal control (blank) was used to account for the effects of any 
residual ethanol. An equal volume of ethanol to that which the 15 (S)-HpETE 
was resuspended from, was subjected to the same procedure as that of 
authentic 15 (S)- HpETE. This 15 (S)-HpETE blank was added directly to the 
platelets, and any effects on aggregation noted.
In some experiments nLDL were used as carrier particles for the fatty acid 
hydroperoxide. Here, ethanolic 15(S)-HpETE was placed in a 1ml plastic 
microfuge tube (Eppendorf) and the ethanol was evaporated to dryness under
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nitrogen. 0.5ml of nLDL (5 mg protein/ml) was added to the tube and incubated 
for 60min at 4°C to allow for uptake of the fatty acid hydroperoxide by LDL. After 
incubation, the 15(S)-HpETE-LDL was dialysed against deoxygenated Tris 
buffer for 30min at 4°C to remove any residual ethanol. The total amount of LPO 
was measured spectrophotometrically (see section 2.5.6).
2.5.5 Identification of oxidised low density lipoproteins by agarose gel 
electrophoresis.
During the oxidation of LDL, the relative negative charge of the particles 
increase due to modification of apoB^oo [Morel at a/., 1984]. Agarose gel 
electrophoresis, based on the method of Blix, [1941], was used to identify 
different forms of apoB^oo according to their relative net charge.
Agarose gels were peeled away from backing plate and the wells filled with 
approximately Ipl of sample or control. The gel was then loaded into the 
electrophoresis cassette and placed in a tank containing barbitone buffer (pH 
8.6). The electrophoresis was run for 35min at 100V and 4mA. Under these 
conditions proteins migrated towards the anode. On completion the gel was 
oven dried at 55°C for 15 to 20min, cooled to room temperature and stained for 
Imin with Fat Red 7B. The gel was destained in methanol/water solution (ratio 
2:1) and oven dried for 15 to 20min.
2.5.6 Assay for Lipid hydroperoxides (LPO) content of low density 
lipoproteins.
The method used for measurement of total lipid hydroperoxides in LDL was 
based on an assay developed by El-Saadani at a!., [1989]. The assay utilises
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the colour reagent of a commercially available test kit for cholesterol 
measurement (CHOD-iodide). The test proceeds by the oxidation of iodide (I ), 
in the form of potassium iodide, to iodine (Ig) by lipid hydroperoxides. This can 
be measured spectrophotometrically at 365nm. The colour reagent contained 
detergents, these provided suitable conditions for its interaction with lipid 
hydroperoxides, which remain associated with the lipid phase of the LDL. Values 
were calculated from the absorbance values at 365nm by the Beer-Lambert law 
(see below), using the molar extinction coefficient (e = 2.46 x 10"* M’’' cm'^) and 
expressed as nmol/mg apoB^ oo-
A = G x L
Where A is absorbance, G is the extinction coefficient for peroxides, L is the
path length and C is the concentration. Results were expressed as nmol LPO 
/mg protein .
2.5.7 Assay for Thiobarbituric acid reactive substances (TBARs) following 
LDL oxidation.
The TBARs assay provided an index of reactive aldehydes produced from the 
breakdown of lipid hydroperoxides. The assay is widely cited, but limited to 
measurement of malondialdehyde (MDA). MDA is a breakdown product of 
arachidonic acid and is produced in relatively constant proportions to the 
peroxidation process [Esterbauer et a/., 1990]. It is highly hydrophilic, which 
results in its release from the lipid phase of the LDL particle. In contrast, the 
other aldehydes produced are highly lipophilic and thus remain associated with
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the LDL [Esterbauer etal., 1990]. As MDA is formed only from arachidonic acid 
and therefore the molar concentrations found in various forms of LDL are less 
than those for LPO.
Trichloroacetic acid was used to precipitate the LDL leaving the soluble MDA in 
the aqueous phase to react with the thiobarbituric acid, producing a pink 
colouration measured at 532nm. Values were calculated from a standard curve 
of MDA, freshly prepared by the acid hydrolysis of 1, 1, 3, 3 - 
tetraethoxypropane [Beuge and Aust, 1978]. Results were expressed as nmol 
MDA equivalents/mg apoBioo-
2.6 METHODS FOR THE STUDY OF PLATELETS.
2.6.1 Preparation of platelet rich plasma.
Whole blood, taken into ACD, was centrifuged (Centra-7R refrigerated
centrifuge, lEC) at 120g for IBmin at 20“C to produce platelet rich plasma (PRP).
PRP was removed by sterile Pasteur pipettes, leaving at least 0.5cm of PRP
near to the buffy coat to limit any erythrocyte and neutrophil contamination,
before being transferred to sterile plastic centrifuge tubes. Autologous platelet
poor plasma was prepared by recentrifuging the PRP BOOg for 10 min.
The pH of the PRP was adjusted with Tyrodes HEPES buffer prior to experimentation. 
All experiments were completed within 2h of isolation.
2.6.2 Preparation of washed platelets.
Platelets isolated from freshly taken whole citrated blood, was based on the 
method of Vargas eta!., [19B3]. For preparation of washed platelets (WP), PGIg 
(final concentration 50nM; Ipl of 1 mg/ml stock per 5ml PRP) was added directly 
to the PRP and the tube immediately inverted. The PRP was recentrifuged at
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800g for 10min at 25°C, to leave a platelet pellet. The supernatant, platelet poor
plasma (PPP), was discarded and the inside of the tubes wiped clean with tissue
to remove any traces of plasma. Platelets were then carefully resuspended in
Tyrodes HEPES buffer (see section 2.3.2). WP were counted using a
thrombocounter, and diluted with Tyrodes HEPES buffer (see section 2.3.2) to
give a final concentration of 3 x 10® platelets/ml (approximate plasma density).
Upon resuspension of the WP they were checked for the characteristic 'swirling',
which indicated the platelets had been resuspended successfully. Platelets were
left for 1h to recover their sensitivity to agonists and used within 3h of
venepuncture. The WP preparations were supplemented with CaClg (ImM) and 
fibrinogen (0.3mg/ml) prior to experimentation.
PGIg transiently increased the concentration of cAMP and was used to inhibit 
platelet activation during the isolation procedure. Isolated platelets were left for 
1h to recover their responsiveness, as the cAMP is broken down, by 
endogenous phosphodiesterases. This method of platelet preparation has been 
shown to maintain platelet functional viability to a greater extent than methods 
using changes in platelet pH [Brackwell etal., 1982].
2.6.3 Alternative methods for platelet preparations.
For some experiments alternative platelet preparations were used:-
[1] The Tyrode's HEPES buffer was substituted by a modified Tyrode's 
phosphate buffer (see section 2.3.2).
[2] After resuspension the platelets were incubated with HgOg (lOpM) for 5min 
before being subjected to a second centrifugation at 800g for 5min at 25°C. The
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platelets were then resuspended in Tyrode's HEPES buffer (see section 2.3.2).
[3] A second washed platelet preparation was used, based on the method of 
Lagarde at a/., [1980]. Whole blood was taken into universal tubes containing 
3.8% tri-sodium citrate (ratio 1:9), inverted and centrifuged at 130g for 15min at 
20°C to produce PRP. The pH of PRP was then adjusted to 6.4 by the addition 
of 0.3M citric acid and the platelets recentrifuged at 750g for lOmin at 20°C. The 
supernatant was discarded and the platelet pellet resuspended in EDTA-wash 
buffer (see section 2.3.2). The platelets were then centrifuged again under the 
same conditions and the new supernatant was discarded, the platelet pellet 
resuspended in Tyrode's HEPES buffer (see section 2.3.2). For aggregation 
studies, WP were supplemented with CaClg (ImM) and used immediately.
[4] For flow cytometric studies, blood was taken via a 21 gauge butterfly needle 
into Monovette tubes containing 3.8% tri-sodium citrate and centrifuged at 120g 
for 18min at 20°C to produce PRP.
2.6.4 Acetyfsalicylic acid treated platelets.
In some experiments thromboxane Ag (TX/^ ) formation was inhibited by 
acetylsalicylic acid (ASA), which acetylated and therefore inhibited the active 
site of cyclo-oxygenase enzyme.! WP were incubated with ASA solution (lOOpM 
final concentration) for 30min at 37°C before use.
2.6.5 Platelet aggregation In vitro.
Platelet aggregation was assessed turbidometrically using a dual channel 
aggregation module, fitted with a dual pen chart recorder, based on the method
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of Born, [1969]. The technique measures increases in light transmission of a 
stirred platelet suspension. Suspension of platelets have high light scattering 
properties. As platelet aggregates of increasing size are formed (induced by the 
addition of physiological agonists), the amount of light transmitted by the 
suspension increases and is detected by a photocell. Upon stimulation by 
agonists a slight decrease in light transmission occurs, resulting from a 
reversible shape change (see section 1.5.3). This may or may not be followed by 
aggregation depending on the strength of the stimulus. Aggregation may be one 
of two types: 'primary aggregation’, which is reversible and does not involve 
release of granule contents [Figure 2.2a], and secondary aggregation’ which is 
irreversible and is accompanied by granular secretion [Figure 2.2c/. A transitory 
phase between primary and secondary aggregation also exists. This is usually 
the minimum dose of agonist required to induced secondary aggregation and is 
termed the threshold 6ose[Figure 2.2b].
Aggregation was measured as percentage increase in light transmission through 
a stimulated platelet preparation, relative to the light transmission through a 
resting platelet preparation. The platelet aggregometer was calibrated with an 
WP suspension or PRP to give the baseline reading or 0% light transmission 
(aggregation). While Tyrode's-HEPES buffer or autologous PPP were used to 
calibrate for the maximum reading or 100% light transmittance (aggregation), as 
these would represent an aggregated sample. Aggregation tests were performed 
in duplicate, using lOOpI of WP or PRP in flat bottomed glass cuvettes kept at 
37°C with continual stirring (SOOrpm) byimicro magnets. The cuvettes and micro 
magnets had previously been soaked in dimethyldichlorosilane (BDH) and dried 
to create an inert surface. Platelets were stirred for 1 min prior to addition of the
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Figure 2.2: piagrmm^tic representation of the different types of aggregation traces.
(a) Primary of reversible aggregation.
(b) Threshold response.
(c) Secondary of irreversible aggregation.
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agonist to allow for temperature equilibration and to observe any spontaneous 
aggregation.
The agonists used in this study were (final concentrations);-
[1]ADP0.1 -10|jM
[2] thrombin 0.005 - 0.1U/ml
[3] collagen 0.1 - 1.0pg/ml
Agonists were added from stock solutions in volumes no greater than 5pl and 
the aggregation observed for 3min after the last addition.
2.6.6 Flow cytometry.
2.6.6.1 Principles.
Flow cytometry is a technique which allows analysis of single cells. In 
combination with immunolabelling of antigenic epitopes by monoclonal 
antibodies (mabs) the method provides a specific, highly sensitive diagnostic 
tool [Tschope etal., 1992].
Target cells, once introduced to the system, are hydrodynamically focused into 
single cell flow by a surrounding sheath fluid. Cells challenged by the laser 
beam produce a forward light scatter, the extent of which is determined by cell 
size and a right-angle light scatter which is determined by cell granularity. These 
two parameters may be used to characterise different cell populations, by means 
of a two-dimensional plot (bitmap). If fluorescently labelled Mabs to a particular 
epitope are added to the system, bound Mabs after excitation by the laser beam 
will emit light of a defined wavelength. This is recorded in a logarithmic intensity
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scale to give both intensity and distribution of fluorescence and thus |to i quantify 
the expression of the epitope.
2.6.6.2 Application and method.
Flow cytometry combined with immunolabelling of antigenic epitopes by mabs 
allows the elucidation of changes in platelet surface characteristics [Abrams and 
Shattil, 1991]. The exposure of binding domains of GPIIb-llia on the platelet 
surface is known to be a post-activatory event. Consequently, the extent of 
fibrinogen binding to the platelet surface can be used as a relative index of 
platelet activation. The addition of fluorescein isothiocyanateflTC) conjugated 
rabbit anti-human fibrinogen antibody (Rafgn-FITC) to PRP allows the binding 
of fibrinogen to be quantified [Warkentin etal., 1990]. In the current study this 
allowed comparison of the effect of LDL on early platelet activation (fibrinogen 
binding) and the full functional response of aggregation. The same principle can 
be applied to platelet degranulation. This process results in the expression of 
extrusion markers of post-degranulated platelet surface. Fluorescently labelled 
Mabs to P-selectin, IOP62-FITC, (The Binding Site) and CD63, RFAC-4, [Cox 
and Goodall, 1991] bind to granule specific glycoproteins. This allowed a 
specific and detailed quantification of platelet granule release. The technique 
provides a finite value for the level of degranulation within set platelet 
population, in this case 5000 cells.
PRP (5pl) was incubated with Rafgn-FITC (5pl: diluted 1:1 with HEPES buffer), 
HEPES buffer (45pl), ADP(5pl) and in the presence or absence of LDL (5pl) for 
20min. ADP was always added last as the starting point of the experiment. Each 
tube was mixed gently by hand and incubated for 20min before being fixed with
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10-fold excess of 0.2% formyl saline (500|jl) [Warkentin et al., 1990]. The flow 
cytometer (Coulter EPICS PROFILE II) analysed 5000 platelets from each tube 
and produced two quantitative results, % fluorescence bound to each platelet 
and mean fluorescence intensity.
2.6.6.3 Methodological considerations of flow cytometric analysis.
Incubation of WP with Rafgn-FITC in the absence of agonists indicated the 
platelets were activated slightly during preparation. The specificity of the 
technique showed that approximately 20% of WP had fibrinogen bound to their 
surface. This increase in fibrinogen binding occurred during the second 
centrifugation of the isolation procedure and subsequent manipulation, since 
incubation of PRP with Rafgn-FITC produced only 4% of platelets with bound 
fibrinogen. Consequently, it was decided that the use of WP would not give a 
true representation of any effects of LDL on platelet fibrinogen binding and 
experiments using WP were not pursued.
In addition, the flow cytometric experiments are performed in a non stirred 
system, which is an important difference between this technique and 
nephelometry. The lack of turbulence allows the study of individual epitopes on 
the platelet surface without inducing the full functional response.
2.7 PREPARATION, USE AND MEASUREMENT OF NITRIC OXIDE 
SOLUTIONS.
2.7.1 Nitric Oxide (NO) preparation.
NO was prepared as a solution from NO gas in double distilled water (ddw) 
according to the method of Palmer at a/., [1987]. Ddw was boiled for lOmin and
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allowed to cool to 60°C, before being pulled under vacuum into a specially 
adapted 100ml glass sampling tube (prepared by a glassblower at University 
College, London). One end of the tube was sealed with a teflon-rubber septum 
and ddw was subsequently de-oxygenated by bubbling with Ng gas for 45min. 
The open end of the tube was then carefully sealed with a septum to prevent 
reoxygenation. The appropriate amount of NO gas was then injected through 
the septum using a gas-tight syringe. At high concentrations of NO, if the water 
had not been fully de-oxygenated, the solution had a slight brownish tinge due 
to formation of NOg. However, this was undiscernible with low concentrations of 
NO solutions, the bio-activity of which could not be assessed until tested with 
platelets. All glassware used in the preparation of NO solutions had been 
washed in nitric acid, thoroughly rinsed in ddw and dried prior to their use. NO 
solutions were kept on ice throughout the experiments. Concentrations of NO 
solutions were calculated on the basis of Avogadro's law: one mole of any gas 
at S.T.P. occupies approximately 22400cmf. In some cases the concentrations 
of NO solutions were tested using and NO electrode or the Griess reaction (see 
section 2.7.2 and appendix 1).
#
2.7.2 Griess reaction: measurement of nitrite concentrations.
The Griess reaction allows the estimation of the nitrite content of a given 
solution, unfortunately the resolution of the assay is only IpM. The reaction 
mixture consists of the sample, MCI and sulphanilic acid, to which a nitrite 
specific dye was added (l-(naphthyl) ethylenediamine), producing a purple 
colouration measured at 548nM. Values were calculated from a standard curve 
prepared from NaNOg.
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2.7.3 Preparation of s-nitosoglutathlone solutions.
S-NOG solutions were prepared in deoxygenated water, with fresh stock 
solutions used in each individual experiment.
2.7.4 Hydrogen peroxide solutions.
H2O2 (stock solution 8.82M) solutions were diluted in deoxygenated water, to 
prolong the half life, and stored in air tight vials for the duration of the 
experiments. Inactive H2O2 solutions were prepared by leaving the solutions 
stirring overnight while exposed to air, or by heat treatment at 100'C for 30min.
2.7.5 Premixing of Nitric Oxide and Hydrogen peroxide.
NO or NO and H2O2 added simultaneously (10pl respectively), were delivered 
as a bolus into a platelet aggregation cuvette containing stirred Tyrode's HEPES 
buffer (37°C, 800rpm). The cuvettes were left stirring for the required period of 
time before an aliquot was removed, no more than 5pl, and delivered into a 
separate cuvette containing stirred WP (100pl). The concentrations of the pre­
mixed NO and H2O2 stock solutions were 20-fold greater to allow for the extra 
dilution.
2.8 PREPARATION OF PEROXYNITRITE.
Peroxynitrite is a potent oxidant highly unstable at physiological pH, formed in 
vivo through a reaction between NO and C)2' [Beckman et al., 1990]. 
Experimentally this can be achieved by a reaction involving acidified nitrite and 
hydrogen peroxide (reaction 1 and 2).
3HNO2 ^ HNO3 + 2N0 +H2O (1)
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HNOz + H2O2 -* HOONO + H2O (2)
NaN02 (10ml) was placed in a glass syringe, while another was filled with HNO3 
(1M, 6.3ml), H2O2 (8.8M, 0.85ml) and H2.O (3.15ml). The syringes were 
connected via sterile plastic tubing and a Y-junction. From the bottom of the Y- 
junction more tubing was positioned directly over a beaker of NaOH (1.2M, 
10ml). The tubing in close proximity to each syringe was clamped to prevent 
any premature mixing of the reactants [Figure 2.3]. At the appropriate time both 
clamps were released and even pressure applied to each syringe plunger. The 
reactants then mixed in the tubing and were passed directly into the NaOH 
(1.2M). By passing the mixture into immediately into a highly alkaline 
environment the peroxynitrite could be preserved in its anionic form (ONOO ). 
Excess H2O2 was removed by passing the peroxynitrite through a small column 
of manganese oxide, until all effervescence had ceased. The concentration of 
peroxynitrite was calculated from its absorbance value at 302nm [Figure 2.4] and 
molar extinction coefficient (e =1.67 *10f M-1 cm-1) according to the Beer- 
Lambert law (see section 2.5.6). All reactants and the glass syringes were kept 
on ice for 30min prior to use.
Peroxynitrite controls were prepared by following the identical procedure except 
the mixture was passed into H2O rather than NaOH, leading to spontaneous 
decomposition (reaction 1 ). NaOH was added to the solution later to give the 
correct pH.
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Figure 2.4: Scan of freshly prepared peroxynitrite solution.
Authentic peroxynitrite was prepared from NaNOg, HNO3, and 4 O as 
described in section 2.8. A known volume of the solution was added to 1ml of 
NaOH and the mixture scanned from 250 - 400nm. The spectrophotometer was 
blanked on decomposed peroxynitrite.
108
2.8.1 Effects of peroxynitrite on the buffering capacity of Tyrode's HEPES 
buffer.
After dilution of peroxynitrite in water the solution was still highly alkaline in 
nature, therefore, the buffering capacity of Tyrodes HEPES buffer (see section
2.3.2) against peroxynitrite was tested. The peroxynitrite was diluted 
immediately before use and aliquots of known concentrations added to the 
stirred buffer while the pH was monitored.
2.9 RADiOiMMUNOASSAY OF 3', S' CYCLiC GUANOSiNE 
MONOPHOSPHATE.
cGMP levels of WP were measured by a commercially available 
radioimmunoassay kit (Amersham, UK). The assay was based on competition 
between unlabelled cGMP and a fixed quantity of cGMP for a limited number 
of binding sites on a cGMP specific antibody. This is reacted with a second 
antibody, which is attached to magnétisable particles, and the samples 
centrifuged. Supernatants were discarded to remove any unbound cGMP and 
the radioactivity of the pellets read in a scintillation counter. Using fixed 
quantities of antibody and ^^^cGMP, the amount of^^^l cGMP bound to the 
antibody was inversely proportional to the concentration of unlabelled cGMP.
IBMX (100pM final conc.), a phosphodiesterase inhibitor, was added to the 
platelets 30min before the experiment. NO, H2O2 or NO/H2O2 were added to the 
WP in the platelet aggregometer and left for 1 min at 37°C with continual stirring. 
This was halted by the addition of cold perchloric acid (100pl, 0.5M), after which 
the WP were vortexed and stored at -70°C. On the day of the assay samples 
were thawed and the acid neutralised by addition of K2HPO4 (200pl; 1M).
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Samples were vortexed and a slight precipitation of potassium perchlorate was 
allowed to settle before 20pL aliquots were removed and used in the assay. The 
results indicate the rate of formation of cGMP in the platelets.
Statistical analysis.
Data; were expressed as mean ± S.E.M. and analysed by Student's t test, while 
the number of each experiment performed is shown on each figure legend..
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CHAPTER THREE: THE INFLUENCE OF LOW DENSITY LIPOPROTEIN 
OXIDATION ON PLATELET FUNCTION.
3.1 INTRODUCTION.
The influence of LDL on platelet responsiveness is now well documented, 
although the mechanism by which this influence is exerted remains unresolved. 
Farbiszewski et al., [1969] first showed PRP to have an increased potential to 
aggregate when stimulated with ADP in the presence of isolated LDL. This 
finding was complemented by Carvalho at a!., [1974], who demonstrated that 
PRP from type lia hyperlipidaemic patients (increased plasma LDL and VLDL 
concentrations) possessed an increased susceptibility to aggregate when 
challenged with ADP or adrenalin, in comparison to PRP from non- 
hyperlipidaemic patients. These observations were confirmed Joist at a/., [1979] 
and Zahavi at a!., [1981], but not by Corash at a!., [1981]. Indirect evidence for 
increased platelet activity was also provided by Tremoli at a!., [1984] who found 
that patients with type lia hyperlipidaemia possessed increased circulating 
concentrations of MDA and TXBg markers for lipid peroxidation and platelet 
activation respectively.
It is possible that in earlier studies the LDL used may have been partially 
oxidised, since the potential importance of oxidised LDL were not fully 
appreciated. In the work described by Ardlie at a!., [1989], where oxidised LDL 
activated platelets, the LDL were only moderately oxidised, which indicated that 
the level of oxidation may be an important factor in how LDL influence platelet 
activity. Therefore it was important to define the oxidation state of LDL which 
activated platelet most effectively. A detailed study of the extent to which 
oxidative modification of LDL influenced their effects on platelet responsiveness
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was undertaken. LDL were prepared with great care to prevent any oxidation 
throughout the isolation procedure. The effects of nLDL on platelet function were 
then compared directly to those of mmLDL and oxLDL. mmLDL probably most 
closely represent^' a physiologically relevant modified LDL in plasma and for the 
most part in atherosclerotic plaques.
Two different platelet models were used in this study, WP allowed the 
assessment of direct interactions between LDL and platelets, while PRP, 
represented a model closer to the whole blood milieu where LDL-platelet 
interactions could be studied in the presence of other plasma factors normally 
present in vivo, and which both LDL and platelets would encounter under 
physiological conditions. Platelet function was assessed by three parameters.
[1] Aggregation, as assessed by nephelometry.
[2] Early activation, assessed by the binding of fluorescently labelled fibrinogen.
[3] Late activation (degranulation), as measured by the expression of P-selectin 
and CD63.
These three parameters allowed a more detailed and complete investigation of 
platelet function compared to previous studies. Nephelometry allowed 
assessment of the influence of LDL on platelets normal haemostatic function, 
while FGN binding was used to assess the activation process. The 
measurement of platelet granule extrusion markers, rather than measurement 
of granule contents, provided a more accurate method for quantifying
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degranulation.
3.1.1 Summary of aims.
[1] To investigate how the extent of LDL modification affected their influence on 
platelet function.
[2] To identify the form of LDL which was most effective when activating 
platelets.
[3] If possible to identify the component(s) of the particles which may be 
responsible for their activatory effects.
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3.2 RESULTS.
3.2.1 The identification of the extent of LDL oxidation by measurement of 
oxidation products.
Isolated nLDL possessed low concentrations of both LPO and TBARs [Table 
3.1], despite the presence of metal ion chelators throughout the isolation 
procedure. When LDL were subjected to the oxidation conditions, a range of 
concentration of oxidation products were produced, despite identical oxidation 
times. This highlighted the heterogenous composition of the particles and 
demonstrated a variation in the rates of oxidation of individual samples. mmLDL 
possesses a two-fold increase in LPO, a more modest increase in TBARs 
relative to nLDL [Table 3.1] and in addition retained their yellow coloration. A 
small number mmLDL samples were prepared by short exposure to Cu^ "" with 
similar concentrations of LPO and TBARs obtained. However, the use of Cu^  ^
was not ideal. In the presence of Cu^ "", the differences in rates of oxidation 
became more pronounced, and many samples became over oxidised. Longer 
term exposure of LDL to Cu "^‘ produced oxLDL, these lipoproteins possessed 
much greater concentrations of LPO and TBARs [Table 3.1J. The range of LPO 
concentrations with oxLDL was very large, emphasizing variations in oxidation 
kinetics of the individual samples. The formation of LPO during the oxidation of 
LDL is biphasic, increasing to a maximum before declining rapidly [Esterbauer 
et a/., 1990]. Higher LPO values represented LDL with a slower oxidation rate 
and I vice versa. Since higher LPO concentrations are indicative of oxidation 
halted near the peak of LPO production, while the lower values are found when 
LPO are converted to TBARs. OxLDL lost the yellow coloration of P-carotene, 
becoming white in colour and appeared to be extensively aggregated. The 
concentrations of oxidation products found in the different LDL preparations are
114
lipid peroxides TBARs
LDL preparations n nmol/mg apoB nmol/mg apoB
nLDL 11 10.2-25.0 0.2-0.9
(13.7 ±1.3) (0.5 ±0.1)
mmLDL 23 18.9- 56.7 0.7-2.7
(39.2 ±2.1) (1.3±0.1)
oxLDL 7 100-369 3.7-16.3
(243 ±33) (11.4 ±1.7)
Table 3.1: Measurement of lipoprotein oxidation in the different preparation of 
low density lipoproteins.
Native low density lipoproteins were oxidised by either exposure to air (mmLDL) 
or Cu^  ^(oxLDL). The extent of oxidation in all the lipoprotein preparations was 
characterised by the concentrations of lipid peroxides (LPO) and thiobarbituric 
acid substances (TBARs). The results are expressed as nmol/mg LDL protein 
and represent the range of values obtained. Figures in brackets are the mean 
± SEM and n = the number of independent experiments on individual LDL 
preparations.
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summarised in Table 3.1.
3.2.2. Agarose get electrophoresis (AGE).
A clear distinction between oxLDL and nLDL could be observed using AGE 
[Figure 3.1]. OxLDL showed an increased migration towards the anode, by 
comparison mmLDL showed an identical electrophoretic mobility to nLDL. This 
apparent increased negativity of the oxLDL particles suggested modification of 
the positive amino acid residues of apoBioo, and also indicated that with mmLDL 
lipid peroxidation had occurred without significant modification of apoBioo [Figure 
3.1J.
3.2.3. Concentrations of endogenous LDL and HDL present in piateiet rich 
plasma.
Experiments performed with PRP contained endogenous lipoproteins, and 
therefore it was important to measure their initial concentrations. The LDL and 
HDL cholesterol levels of all donors were within the normal ranges [Table 3.2]. 
Only in experiments where nLDL was added to PRP was the total concentration 
of LDL calculated, as mmLDL and oxLDL must be considered as separate 
species.
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nLDL mmLDL oxLDL
Figure 3.1: Agarose gel electrophoresis of low density lipoproteins following 
oxidation.
Native low density lipoproteins were isolated from fresh human plasma (see 
section 2.5.1) and were oxidised by exposure to air under sterile conditions for 
18 - 24h (mmLDL) or by exposure to Cu^ "' for 24h (oxLDL). The samples (Ipl) 
were then applied to an agarose gel and electrophoresed at pH 8.6 in barbitone 
buffer for 35 min (100V and 4mA) and the gels stained with Fat Red B and 
destained in methanol/water solution (ratio2:1) and oven dried for 15 - 20min. 
The gel is typical of those in 4 independent experiments
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Experiment n LDL HDL 
( mmol cholesterol/l.)
nLDL - aggregation 3 2.0 ±0.7 1.6 ± 0.6
mmLDL - aggregation 6 2.1 ±0.7 1.7 ±0.2
mmLDL - flow cytometry 6 2.5 ±0.5 1.7 ±0.2
oxLDL - aggregation 3 2.4 ±0.7 1.7±0.1
oxLDL - flow cytometry 3 2.8 ± 0.1 1.4±0.1
Table 3.2: Concentrations of LDL and HDL cholesterol in the donors used to 
prepare platelet rich plasma.
Samples of platelet poor plasma were taken for analysis of LDL and HDL by 
convential methods using the Friedewald formula to determine the concentration 
of LDL indirectly
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3.3. NATIVE LOW DENSITY LIPOPROTEINS AND PLATELET FUNCTION.
3.3.1 The effects of native low density lipoproteins on the aggregation of 
washed platelets.
The action of nLDL on platelet aggregation was assessed by investigating four 
possible outcomes:
[1] Aggregation in the absence of known platelet agonists.
[2] Potentiation of aggregation stimulated by sub-maximal concentrations of 
platelet agonists.
[3] Inhibition of agonist-induced platelet aggregation.
[4] No activation or inhibition.
nLDL (0 -1 mg protein/ml) added directly to WP and incubated for 3min did not 
induce platelet aggregation. nLDL incubated with WP for 1min prior to the
addition of sub-maximal doses of ADP (1 - 2pM) did not enhance aggregation, but caused 
a slight reduction of the normal response. Similar results were obtained when
sub-maximal thrombin (0.005U/ml) was used to stimulate WP.
Stimulation of WP with ADP (10pM) or thrombin (0.1U/ml) induced normal 
secondary aggregation, indicating that the platelets had retained their functional 
viability after isolation [Figure 3.2a, b]. If WP were incubated with nLDL prior to 
addition of ADP (10pM), a significant reduction in the normal ADP-induced 
aggregation response was observed [Figure 3.2a]. The effect was concentration-
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Figure 3.2: Typical aggregation traces demonstrating the effects native and oxidised 
low density lipoproteins on platelet aggregation.
(a) WP were activated by the addition of ADR (10pM) in the presence or absence olj 
nLDL or oxLDL (1 mg/ml)., The lipoproteins were incubated with WP for 1 min prior 
to the addition of ADP, and aggregation measured 3min later.
(b) as for a, except thrombin was used to stimulate the WP.
LDL ADP
oxLDL
nLDL
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LDL Thrombin
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nLDL
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dependent for nLDL, with all concentrations of nLDL causing inhibition. Maximal 
inhibition of platelet activity, 43.6 ±|5.7%(p< 0.01), was induced by Img 
protein/ml, but the effect was also significant at 0.75mg protein/ml (41.0 ± 9.2%, 
p< 0.05) [Figure 3.3]. Repetition of the experiments using thrombin (0.1 U/ml) to 
stimulate the platelets, also resulted in a concentration-dependent inhibition of 
the normal agonist-induced response in the presence of nLDL [Figure 3.2bJ. The 
magnitude of the maximal effect induced by Img protein/ml (36.6 ± 10.7%) was 
less than that observed with ADP-stimulated aggregation [Figure 3.3]. However, 
all concentrations of the native lipoproteins produced significant inhibition of 
platelet aggregation (p< 0.05). Inhibition by nLDL showed a reduction in both 
total aggregation and aggregate size, the aggregation traces took the 
appearance of reduced secondary responses [Figure 3.2a, b].
3.3.2. The influence of native low density lipoproteins on platelet 
aggregation in piatelet rich plasma.
nLDL (0-1 mg/ml) was incubated with PRP for 3min, without any change in light 
transmittance detected. When incubated for Imin prior to the addition of ADP 
(lOpM), nLDL failed to inhibit aggregation compared to control responses of 
ADP only.
To investigate whether the interaction was time dependent, PRP was incubated 
with nLDL for 30min at 37°C without stirring, prior to addition of ADP. When 
challenged with ADP (0.1 - lOpM) there was a substantial inhibition of 
aggregation, as compared to PRP incubated with Tyrodes HEPES buffer (see 
section 2.3.2) [Figure 3.4]. nLDL inducedj an inhibition of platelet aggregationi 
at all concentrations of ADP used. With submaximal concentrations of ADP (0.1
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Figure 3.3: The effects of nLDL on agonist induced-aggregation of washed 
platelets.
Native low density lipoproteins were prepared by ultracentrifugation of fresh 
human plasma and incubated with WP for 1min prior to the addition of ADP 
(10pM; shaded bars) or thrombin (0.1 U/ml; open bars). The results are 
presented as % inhibition of aggregation and are expressed as mean ± SEM 
(n=4) compared to aggregation induced by the agonist alone. * p< 0.05, **p< 
0.01 (Student's t test of paired samples were calculated from the % 
aggregation).
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Figure 3.4: The effects of nLDL on agonist-induced aggregation of platelet rich 
plasma.
Native low density lipoproteins were incubated with PRP for 30min at room 
temperature without stirring. The lipoproteins and platelets were then transferred 
to an aggregation cuvette and left to temperaturejequilibrate for Imin before 
being stimulated with ADP (lOpM). The results are presented as % inhibition of 
aggregation after 3min and are expressed as mean ± SEM (n=3) compared to 
aggregation induced by the agonist alone.
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and 1|jM) nLDL (1mg protein/ml) caused almost complete inhibition of 
aggregation (p< 0.05 and p< 0.001, for the two concentrations of ADP 
respectively). The effects were less pronounced at maximal ADP (lOpM) with 
nLDL (Img protein/ml) inducing 28.3 ±| 5.1%(p< 0.01) inhibition [Figure 3.4]. 
The contrasting effects found between WP and PRP suggested that a plasma 
factor may influence any rapid interactions between the native lipoproteins and 
platelets.
As indicated earlier the total concentration of LDL present in the PRP 
experiments was greater than with WP. In the present set of experiments the 
mean concentration of LDL was 2mmol cholesterol which equates to 
approximately 0.4mg protein /ml. Therefore, the maximum augmentation of LDL 
concentrations above those found physiologically was approximately 3-fold at 
1.4mg protein /ml. Interestingly, the maximum inhibition induced was 28.3 ± 
5.1%, which was lower than the effects observed with Img protein/ml with WP. 
This demonstrates that increasing the concentration of LDL above physiological 
levels do not increase their anti-aggregatory effects.
3.3.3. Native low density lipoproteins and platelet activation (fibrinogen 
binding).
Platelets in PRP were identified by their size and side scatter characterististics, 
which are digitized to produce a bitmap [Figure 3.5a]. This was confirmed by the 
fluorescent detection of bound anti-GPIB Mabs (RFGP37-FITC) on the platelet 
surface [Figure 3.5b]. The influence of nLDL on the binding of fluorescently 
labelled fibrinogen to the platelet surface |was tested using flow cytometric 
analysis. Stimulation of platelets in PRP with ADP (0.1 - lOpM) produced a
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Figure 3.5; Flow cytometric analysis of platelets.
a) Platelet in PRP were identified by their size (LFS) and side scatter (LSS) 
charateristics.
b) Fluorescence profile of platelet incubated with FITC-conjugated anti-GPIb 
Mab which binds to 100% of platelets.
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concentration-dependent increase in FGN binding [Figure 3.6a]. The presence
of nLDL (0 - 1mg protein/ml) inhibited ADP (1 and 10pM)-induced fibrinogen
[binding in a concentration-dependent manner (data not shown). Using highest ADP 
concentration (10pM), nLDL (0.5 and 1mg protein/ml) significantly inhibited FGN binding by
29.1 ± 5.7% and 37.7 ± 8.4% (p< 0.05) respectively, compared to controls of 
ADP only [Figure 3.6b]. The magnitude of the lipoprotein induced effects 
increased with increasing concentration of ADP. This is not unexpected, as 
greater stimulation of platelets would expose more binding sites for FGN and 
thus allow a greater opportunity for nLDL to exert their effect on the interaction 
of FGN and GPIIb/llla.
The maximum inhibitory effect was induced by Img protein /ml which when 
added to the endogenous concentrations LDL translated to a 3-fold increase 
over physiological concentrations.
Two internal controls were used in the experiment:
[1] nLDL were incubated with PRP in the absence of ADP, and no increase in 
fluorescence was observed in comparison to PRP only. This suggested that nLDL 
had no activatory effects.
[2] nLDL was incubated with RFAC-4 alone to observe for non specific binding 
of the antibody; no fluorescence was detected.
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Figure 3.6a: The influence of native low density lipoproteins on binding of 
fluorescently labelled fibrinogen to the platelet surface.
Flourescence profiles of platelets incubated with RaFgn-FITC in the absence 
of exogenous agonists (resting sample; top panel), with ADP (1pM: middle 
panel) and with ADP (1pM) and nLDL (0.5mg protein/mi; bottom panel).
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Figure 3.6b: The influence of native low density lipoproteins on binding of 
fluorescently labelled fibrinogen to the platelet surface.
PRP (5pl) were added to HEPES buffer (50pL) containing native low density 
lipoproteins (0 -1mg protein/ml) and RaFgn-FITC. The experiment was started 
by the addition of ADP (0.1, 1, 10pM) and then incubated at room temperature 
for 20min. Three concentrations of nLDL were tested 0.25mg/ml (#), 0.5mg/ml 
(■) and 1 mg/ml (O)and the effects were compared to FGN binding induced by 
ADP alone (□). The platelets were then fixed with formyl saline (500pl) and 
analysed by flow cytometry. Platelets were identified by their size and side 
scatter charateristics and the results expressed as the percentage of cells 
positive for bound fluorescence. The data represents mean ± SEM of 3 
independent experiments. For statistical significance refer to text {section 3.3.3).
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3.3.4. The influence of native iow density lipoproteins on plateiet 
degranulation.
During platelet degranulation protein markers, specific to the different type of 
granule, are exposed at the platelet surface. These can be measured by the use 
of Mabs and thus quantify the extent of the degranulation process. In the present 
study P-selectin and CD63, markers for the a- and lysosomal granules 
respectively, were measured. P-selectin also acts as a platelet receptor for 
adhering leukocytes.
nLDL (0 - 1mg protein/ml) incubated with PRP in the absence of ADP did not 
induce expression of P-selectin or CD63. Stimulation of PRP with i 
ADP(10pM) induced an increase in expression of P-selectin and CD63 [Table 
3.3]. ADP-stimulated expression of P-selectin and CD63 was not affected by the 
presence of nLDL.
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P-selectin CD63 antigen
unstimulated PRP 2.5 ± 0.9 6.5 ± 3.6
ADP(10ijM) 16.8 ±2.1 14.2 ±3.6
ADP(10|jM) +
nLDL 17.0 ±2.5 13.9 ±0.8
mmLDL 23.2 ± 3.5*** 25.4 ± 3.8'
oxLDL 15.1 ±3.2 12.6 ±0.9
Table 3.3; The influence of LDL on ADP-induced expression of platelet granule 
markers.
Platelet rich plasma (5pl) were added to HEPES buffer (50pL) containing low 
density lipoproteins (I.Omg protein/ml) and FITC-conjugated CD62P and CD63 
Mabs. The experiment was started by the addition of ADP (lOpM) and then 
incubated at room temperature for 20min. The platelets were then fixed with 
formyl saline (500pl) and analysed by flow cytometry. Platelets were identified 
by their size and side scatter charateristics and the results expressed as the 
percentage of cells positive for bound fluorescence at one concentration of ADP. 
The data represents mean ± SEM of 4 independent experiments. * p< 0.05, 
***p< 0.005 (Student's t test of paired samples).
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3.4. THE INFLUENCE OF MINIMALLY MODIFIED LOW DENSITY 
LIPOPROTEINS ON PLATELET FUNCTION.
nLDL did not show any pro-activatory properties, but the data suggest they may 
play an inhibitory role. Modified forms of LDL have been shown to exert different 
effects from nLDL on various cell types. The following section investigated how 
mmLDL, LDL which has undergone lipid oxidation only, affected platelet 
function.
3.4.1. Influence of minimally modified low density lipoprotein on platelet 
aggregation.
The work by Ardlie et al., [1989] suggested modified LDL could enhance
aggregation of platelets exposed to low concentrations of agonists more
effectively than native lipoproteins. In the present study, WP were stimulated
with sub-maximal ADP (1 -2pM) to induce primary aggregation. Incubation of
mmLDL (0 - Img protein/ml) with WP for Imin prior to the addition of ADP,
caused significant enhancement of aggregation [Table 3.4]. The effect was not
concentration-dependent for mmLDL within the physiological range, the greatest
change was observed with 0.25mg protein/ml 22 ±2 % total aggregation; p<
0.001), compared to ADP alone. However, all concentrations of LDL, except Img /mldid 
enhance total aggregation (p< 0.05) [Table 3.4]. In these experiments ADP
induced primary aggregation responses, which were enhanced to secondary 
responses by the presence of mmLDL, demonstrating the ability of these 
lipoproteins to sensitize platelets to ADP. However, if ADP induced a secondary 
response the effects of mmLDL were not detected.
The short incubation of mmLDL with WP alone in the previous experiments
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caused a slight aggregatory effect (increase in light transmission), which was not 
observed in control experiments using Tyrode’s HEPES buffer (see section
2.3.2). Consequently, mmLDL (0-1 mg protein/ml) were left to incubate with WP 
for 3min and the aggregation measured. mmLDL induced primary aggregation 
of WP, which peaked at approximately 2min after addition of mmLDL, before the 
aggregate disassociated [Figure 3.7]. The effect was concentration-dependent, 
with 0.5 and Img protein/ml mmLDL inducing 4.7 ±|2.7%and 16.5 ±|s.9% (p< 
0.05) aggregation respectively [Table 3.4], compared to controls (addition of 
equal volume of Tyrodes HEPES buffer). No additional increase in aggregation 
were observed with concentrations of mmLDL above 1 mg protein/ml.
The data indicated that mmLDL acted as a weak platelet agonist, an effect which 
was concentration-dependent and saturable.
3.4.2. Platelet aggregation in PRP: influence of minimally modified iow 
density lipoproteins.
mmLDL incubated with PRP for Imin prior to addition of ADP (0.2 - I.OpM), 
enhanced total aggregation compared to ADP alone [Table 3.4]. The 
potentiation was less effective than with WP and no concentration-dependent 
effect was evident. Maximal potentiation of platelet aggregation was induced by 
0.25mg/ml mmLDL, 18.6 ± 2.9 (p< 0.05) [Table 3.4]. In contrast to experiments 
with WP, mmLDL in the absence of ADP failed to induce aggregation, 
demonstrating that the plasma enviroment inhibited the direct effects of mmLDL 
on platelets.
A-
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mmLDL 
(mg protein/ml)
percentage aggregation 
no agonist ADP (1pM)
|WP
(n=6)
PRP
(n=3)
|WP
(n=5)
PRP
(n=6)
0 0 0 9.3 ±1 9.6 ±0.8
0.25 0 0 22 ±2*** 18.6 ±2.9*
0.50 4.7 ±2.7 0 21.6±3.1*** 18.3 ±2.4**
0.75 nd nd 14.6 ±2* 16 ±2.6*
1 16.4 ±3.9 0 11.8±3.7 11.7 ±2.4
Table 3.4: The influence of minimally modified low density lipoproteins on 
platelet aggregation.
The effects of mmLDL were tested inlVpand PRP either alone or 1 min before the 
addition of ADP (1pM) and aggregation measured Smin after the final addition. 
The results represent the percent maximum aggregation and are expressed as 
mean ± SEM, where n= the number of individual experiments.
*< pO.05; **p< 0.01; *** p< 0.005. nd= not done.
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Figure 3.7: Typical trace of platelet aggregation induced by mmLDL (1 mg/ml)
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3.4.3. The influence of minimally modified iow density lipoproteins on 
platelet fibrinogen binding.
In the previous sections {3.4.1 and 3.4.2.) mmLDL were shown to both induce 
and potentiate aggregation of platelets. These effects can only occur by an 
increase in platelet-FGN interactions and in this present section the influence 
of mmLDL on FGN binding was assessed. MmLDL preparations were incubated 
with PRP, and the platelets activated with ADP (0.1 - lOpM). The level of 
fibrinogen binding induced by ADP was significantly (p< 0.05) enhanced in the
presence of mmLDL (0 - 1mg protein/ml) [Figure 3.8a]. Potentiation, although 
modest, occurred with all concentrations of mmLDL tested. In addition, 
potentiation of the agonist responses also occurred at the highest concentration 
of ADP (10pM), a phenomenon not detected using nephelometry [Figure 3.8bJ. 
The specificity of the present technique probably allowed these responses to be 
recorded.
In subsequent experiments, incubation of mmLDL with PRP in the absence of 
agonists, showed increase in FGN binding, compared to PRP alone. The effects 
were significant at all concentrations of mmLDL tested, but no concentration- 
dependent pattern emerged. The largest increase in FGN binding was invoked 
by O.Smg protein/ml, 11.4 ± 2.0 (p< 0.05), although the effects were more 
significant at 0.75 and I.Omg protein/ml mmLDL (p< 0.01) [Figure 3.9J. Maximal 
effects were reached at 0.5mg protein/ml, no significant increases in activation 
were observed with higher concentrations of mmLDL. Incubation of mmLDL with 
the antibody alone (RFAC-4) produced no fluorescence, indicating there was 
little or no non-specific binding of the antibody.
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Figure 3.8a: The enhancement of ADP-induced fibrinogen binding by minimally 
modified low density lipoproteins.
Flourescence profiles of platelets incubated with RaFgn-FITC in the absence 
of exogenous agonists (resting sample; top panel), with ADP (1pM: middle 
panel) and with ADP (1pM) and mmLDL (O.Smg protein/ml; bottom panel).
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Figure 3.8b: The enhancement of ADP-induced fibrinogen binding by minimally 
modified low density lipoproteins.
PRP (5pl) were added to HEPES buffer (50pL) containing minimally modified low 
density lipoproteins (0.5 mg protein/ml) (O) and RaFgn-FITC. The experiment 
was started by the addition of ADP (0.1, 1 or lOpM) and then incubated at room 
temperature for 20min. The platelets were then fixed with formyl saline (SOOpI) 
and analysed by flow cytometry. The effects of mmLDL were| compared to to ADP 
alone (•) .Platelets were identified by their size and side scatter charateristics 
and the results expressed as the percentage of cells positive for bound 
fluorescence. The data represents mean ± SEM of 4 independent experiments. 
For statistical significance refer to text {section 3.4.3).
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Figure 3.9: Flow cytometric analysis of fibrinogen binding induced by minimally 
modified low density lipoproteins in the absence of physiological agonists.
PRP (5pl) were added to HEPES buffer (50pL) containing minimally modified low 
density lipoproteins (0 -I.Omg protein/ml) and RaFgn-FITC and incubated, 
without the addition of agonist, for 20min at room temperature. The platelets 
were then fixed with formyl saline (500pl) and analysed by flow cytometry. 
Platelets were identified by their size and side scatter charateristics and the 
results expressed as the percentage of cells positive for bound fluorescence. 
The data represents mean ± SEM of 6 independent experiments. For statistical 
significance refer to text (section 3.4.3).
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The results suggest that mmLDL, in contrast to nLDL, induced and potentiated 
the binding of FGN to the platelet surface, which indicates the increased 
activation of platelets in the presence of ADP and possibly other agonists.
3.4.4. Is piatelet degranulation influenced by minimally modified low 
density lipoproteins ?
The actions of mmLDL on platelet degranulation were tested, as the release of 
these vasoactive factors has an important propagating effect on platelet 
aggregation.
3.4.4.1. The effect of minimally modifed low density lipoprotein on P- 
selectin expression.
mmLDL (1mg protein/ml) incubated with PRP alone did not induce expression 
of P-selectin. The presence of mmLDL enhanced ADP-induced expression of 
P-selectin (p< 0.005) [Table 3.3].
3.4.4.2. The effect of minimaily modified lipoproteins on CD63 expression.
mmLDL (1 mg/ml) alone did not induce expression of CD63. However, 
expression of CD63 stimulated by ADP (10pM) was significantly enhanced in the 
presence of mmLDL. CD63 expression increasing from 14.2 ± 3.6% to 25.4 ± 3.8% 
( p< 0.05) [Table 3.3J.
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3.5. THE INFLUENCE OF OXIDISED LOW DENSITY LIPOPROTEINS ON 
PLA TELET FUNCTION.
Fully oxLDL|are mostly found in the foam cells of the atherosclerotic plaque and 
I is therefore unlikely to interact with platelets directly even under pathological 
conditions, unless there is fissure of the plaque. In this respect the relevance of 
experimentation on the actions of oxLDL may not be as important as those for 
nLDL and mmLDL. Nevertheless, the effects of oxLDL were investigated for 
comparison.
3.5.1. The effects of oxidised low density lipoproteins on aggregation of 
washed platelets.
OxLDL did not induce aggregation of WP after 3min incubation and inhibited 
sub-maximal ADP (1 - 2pM) (not shown). Incubation of oxLDL (1mg protein/ ml) 
with WP for 1min prior to addition of ADP (10pM), induced a concentration- 
dependent inhibition of agonist-stimulated aggregation [Figure 3.2a]. Maximal 
inhibition was induced by 1 mg/ml oxLDL, 54.3 ± 4.4% (p< 0.01 ), but the effects 
were also significant at 0.5mg/ml (35.0 ±4- 5'%, p< 0.05) [Figure 3.10]. Using 
Img protein/ml the inhibitory effects oxLDL on ADP-induced aggregation were 
greater than those of nLDL. In one experiment oxLDL was tested against 
thrombin-induced aggregation. OxLDL inhibited the aggregation response by 
32% [Figure 3.2b].
3.5.2. Platelet aggregation in PRP: influence of oxidised low density 
lipoproteins.
The previous experiments were repeated using PRP with similar results 
obtained. oxLDL did not induce aggregation and was inhibitory to both sub-
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maximal and maximal ADP. The experiments with oxLDL alone and with sub­
maximal ADP (0.2 - 1.0pM) were not pursued. Inhibition of ADP (10pM)- 
induced aggregation by oxLDL was concentration-dependent and maximal 
inhibition was induced by 1mg protein/ml, 50.6 ± 8.2% (p< 0.05). These results 
are in contrast to those found previously with nLDL (section 3.3.2), where 
inhibition of ADP-induced aggregation of PRP was only observed after a 30min 
incubation. This indicated that inhibition by nLDL and oxLDL may proceed via 
different mechanisms.
3.5.3. The effects of oxidised iow density apoproteins on piateiet 
fibrinogen binding.
OxLDL incubated with PRP alone, did not to induce fibrinogen binding. PRP 
stimulated with ADP (1pM) showed a slight inhibition in the presence of oxLDL. 
However, stimulation of FGN bnding in PRP with ADP (10pM), was inhibited by 
oxLDL in concentration-dependent manner [Figure 3.11]. The inhibition was to 
a greater extent than that observed with nLDL and was significant at all 
concentrations of oxLDL used. Maximal inhibition, 64.1 ± 5.2%, was induced by 
Img protein/ml (p< 0.01). Incubation of oxLDL with RFAC-4 alone, showed no 
increase in fluorescence.
3.5.4. Do oxidised iow density apoproteins infiuence piateiet 
degranuiation?
oxLDL had no significant effect on P-selectin or CD63 expression, either alone 
or in combination with ADP [Table 3.3J.
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Figure 3.10: The effects of oxidised low density lipoproteins on agonist induced 
platelet aggregation.
Oxidised low density lipoproteins were prepared by exposure to Cu^ "" for 24h at 
37°C (see section 2.5.3) land incubated with WP (hatched) or PRP for 1 min prior 
to the addition of ADP (lOpM). The results are represent as % inhibition of 
aggregation and are expressed as mean ± SEM (n=3) compared to aggregation 
induced by the agonist alone. For statistical significance refer to text (sections
3.5.1 and 3.5.2).
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Figure 3.11: The influence of oxidised low density lipoproteins on ADP-induced 
fibrinogen binding.
PRP (5pl) were added to HEPES buffer (50pL) containing oxidised low density 
lipoproteins (0 -I.Omg protein/ml) and RaFgn-FITC. The experiment was started 
by the addition of ADP (0.1, 1, lOpM) and then incubated at room temperature 
for 20min. Three concentrations of oxLDL were tested 0.25mg/ml (#), 0.5mg/ml 
(■) and 1 mg/ml (O)and the effects were compared to FGN binding induced by 
ADP alone (□). The platelets were then fixed with formyl saline (500pl) and 
analysed by flow cytometry. Platelets were identified by their size and side 
scatter charateristics and the results expressed as the percentage of cells 
positive for bound fluorescence. The data represents mean ± SEM of 3 
independent experiments.For statistical significance refer to text (section 3.5.3).
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3.6. THE INFLUENCE OF COPPER IONS AND DTP A ON PLATELET 
AGGREGATION.
Copper ions (Cu^ "") and DTPA were used in the isolation and oxidation of LDL. 
Theoretically neither of these substances should be present after dialysis of 
LDL, however their direct effects on platelet aggregation were assessed, to 
allow for any possible trace levels left in the LDL preparations. Cu '^’ (0 - 5pM) 
added directly to both WP and PRP, did not induce aggregation..
The presence of Cu^ "" with platelets stimulated with ADP (10pM) or thrombin 
(0.1 U/ml) did not inhibit agonist induced aggregation. DTPA (0 -1 pM) failed to 
induce aggregation when added directly to platelets and also failed to alter ADP 
or thrombin induced responses. Cu "^’ (1 pM) and DTPA (1 pM) were then added 
in combination and again failed to aggregate or inhibit agonist induced 
aggregation of platelets.
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3.7 DISCUSSION.
Current evidence suggests important roles for both oxidised LDL and platelets 
in the pathogenesis of atherosclerosis and thrombosis. LDL have previously 
been shown to sensitise platelets to other agonists (see section 1.7.2) and 
hence may be important pro-thrombotic factors. Here, the effect of oxidation of 
LDL on platelet function was studied in detail.
3.7.1 Low density lipoprotein oxidation.
Isolated nLDL possessed a range of concentrations of both LPO and TBARs, 
which highlighted the heterogeneous nature of the particles and also suggested 
that slight oxidation of LDL may occur in vivo. All solutions used in the isolation 
procedure were supplemented with DTPA, which has been shown to completely 
inhibit the oxidation of LDL [Heinecke at a/., 1984], indicating that the products 
may have been preformed. There are several possibilities as to where these 
lipid peroxides may have originated. It is feasible that LDL may become partially 
oxidised in the circulation, despite the presence of antioxidants. Alternatively, 
the LPO originate from the oxidation of HDL and subsequently transferred 
through simple lipid exchange. Bowry at a/., [1992] demonstrated that HDL may 
be the major source of lipid peroxides in vivo: this concept is supported by the 
fact that HDL has less antioxidant protection than LDL. A third possibility is that 
the peroxides originate from a dietary source. In terms of disease development, 
these preformed lipid peroxides found in native LDL may an important factor in 
their subsequent development into plaque associated oxLDL. LDL with 
preformed lipid peroxides may be primed and more susceptible to oxidation by 
cellular free radical attack, if they become trapped in the sub-endothelium. 
However, it must be also accepted that the peroxides may have been formed
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during the isolation procedure.
One of the aims of this study was to produce LDL at different stages of oxidation, 
corresponding to LDL with purely lipid oxidation (mmLDL), formed by slight 
oxidation of the fatty acid side chains present on the phospholipid monolayer of 
the particles, and also a more extensively oxidised LDL with both lipid and 
protein modification (oxLDL). In the present study oxidation of LDL was achieved 
by one of two methods, exposure to Cu^ "" or air. These methods were used 
because they were logistically easier to perform, and produced more consistent 
oxidation kinetics than cell-induced oxidation. Oxidation induced by copper has 
been extensively studied and after correction for the different concentrations of 
ions used, direct comparisons can be made.
LDL can be modified by several methods in vitro to produce oxLDL (see section 
1.3). The oxidative modification, regardless of the method, probably proceeds 
by a free radical chain reaction leading to the peroxidation of the PUFA 
associated with the phospholipid surface monolayer of LDL (see section 1.3.1). 
Oxidation of LDL can be followed and quantified by the measurement of lipid 
peroxidation products. The most consistently used method is the TBA assay 
[Beuge and Aust, 1978],This measures MDA as a lipid oxidation product which 
is produced in fairly constant proportion to the peroxidation process [Esterbauer 
et ai, 1990]. When LDL are prepared at different stages of modification, the use 
of the assay as a sole index of oxidation is flawed because it is limited to the 
measurement of MDA. LDL has been shown to contain two major PUFA, 
linoleate and arachidonate, the relative proportions of these PUFA in LDL are 
9:1 [Esterbauer et al., 1990]. The problem may be circumvented by
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measurement of the total amount of fatty acid oxidation products. In the present 
study, the measurement of total PUFA peroxidation was performed using a 
spectrophotometric assay for total LPO measurement (see section 2.5.6). Thus, 
oxidatively modified LDL could be quantified by both total PUFA and 
arachidonate oxidation products, giving a clearer indication of the extent of 
modification.
Oxidation of LDL is a dynamic process, whereby the concentrations of LPO and 
TBARs are constantly changing. Profiles of Cu '^"-induced oxidation show an 
initial lag phase, associated with the loss of vitamin E [Esterbauer et a/., 1989], 
followed by a sharp increase in the concentrations of LPO resulting from the loss 
of linoleate and arachidonate. LDL oxidation by Cu '^' is totally reliant on the 
presence of preformed LPO [Thomas and Jackson, 1990], since the removal of 
peroxides before exposure to Cu^  ^ prevented increases in the REM. This 
indicates that Cu^ '" does not initiate lipid peroxidation. The extent of preformed 
LPO in LDL is positively correlated to an increased susceptibility to Cu^ '" induced 
oxidation [Frei and Gaziano, 1993]. Since nLDL were shown to possess low 
levels of LPO Cu^  ^was used to initiate the oxidation. All LDL preparations were 
exposed to Cu^ "" for 24h, yet the concentrations of oxidation products varied 
greatly. This highlighted the heterogeneous nature of LDL particles with respect 
to individual oxidation kinetics. The levels of LPO and TBARs corresponds well 
with previous studies using similar concentrations of Cu^  ^ [Esterbauer et al., 
1987; Esterbauerefa/., 1989; Thomas and Jackson, 1990; Lodge eta!., 1995]. 
OxLDL produced by the present method has been shown to undergo extensive 
macrophage uptake in vitro [D. Mayer. PhD thesis, London University 1994]. The 
oxidation was halted by the addition of excess DTPA (see section 2.5.3).
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During the early stages of LDL oxidation lipid peroxidation occurs without protein 
modification [Zhang ef a/., 1989]. This group demonstrated that slight oxidation 
of LDL, associated with small increases in LPO, did not increase the REM 
compared to non-oxidised LDL. In the present study, nLDL were oxidised by 
exposure to air to produce mmLDL. This was for two reasons, one, the method 
was less severe than Cu '^"-induced oxidation which helped to avoid protein 
modification, and two, under normal physiological conditions LDL is unlikely to 
encounter high levels of transition metal ions [Halliwell and Chirico, 1993]. 
Oxidation by air proceeded at a slower rate compared to Cu '^"-induced oxidation. 
After 18 - 24hrs incubation, a 2-fold in LPO and TBARs were found in these LDL 
preparations, compared to the native lipoproteins. In addition, the mmLDL were 
distinctly yellow in appearance and were almost indistinguishable from 
autologous nLDL. mmLDL prepared by long-term storage of nLDL at 4°C or by 
exposure to Fe^ [Berliner ef a/., 1989; Rajavashisth etal., 1990; Watson et ai, 
1995], possessed approximately 11 nmols TBARs/mg LDL, compared to 
approximately 7.5nmols TBARs/mg LDL in this study. This indicated Ithat the 
method used presently, reliably produced mmLDL in a 'relatively short period of 
time without exposing the lipoproteins to unphysiological levels of transition 
metal ions. These levels of peroxides are close to those which have been 
observed within the pathophysiological range in human plasma [Stringer at ai,
1989].
When the different forms of LDL were analysed using agarose gel 
electrophoresis, oxLDL showed an increased REM in comparison to nLDL, while 
mmLDL was indistinguishable from nLDL. These results validate the methods 
chosen to modify LDL, as they confirm mmLDL preparations were devoid of
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significant protein modification, while the physicochemical changes of oxLDL 
were much more extensive.
3.7.2 Influence of native low density lipoproteins on platelet function.
In previous studies, LDL had been shown to sensitise platelets to physiological 
agonists and in some cases activated platelets independently of agonists 
[Fujitani et ai, 1979; Hassell et ai, 1983; Aviram et ai, 1983]. In the present 
study stringent isolation procedures were used for the preparation of LDL, and 
using preparations, nLDL induced a concentration-dependent inhibition of 
agonist-induced aggregation. nLDL inhibited aggregation of WP after an 
incubation of only Imin, which suggested a rapid surface-mediated event. In 
contrast, experiments with PRP required a 30min incubation for nLDL to induce 
a comparable effect, indicating that the presence plasma proteins or another 
plasma factor prevented the rapid effects seen with WP. In relation to these 
experiments, Surya et ai, [1992] demonstrated that a 30-60min incubation of 
platelets with LDL led to the transfer of arachidonate from platelets to LDL, thus 
decreasing potential platelet aggregation. It is possible that a similar 
phenomenon occurred here. Interestingly, the presence of endogenous nLDL 
in PRP did not seem to increase the inhibitory effect of LDL, suggesting that any 
inhibitory effect may already have been maximal.
nLDL inhibited the binding of FGN to the GPIIb-llla complex at the platelet 
surface. These observations, taken with the aggregation data, would suggest 
that nLDL probably inhibit platelet aggregation by attenuating the early stages 
of activation (FGN binding) and thus blocking interplatelet bridging. Several 
studies have shown LDL to be capable of binding to the platelet surface
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[Mazurov ef a/., 1982; Curtiss and Plow, 1984; Koller, 1986; Hassell et al., 1990; 
Katzman et al., 1991; Pedreno et a!., 1994]. The phenomenon also occurs with 
platelets from FH patients, indicating that the apoB/E receptor is probably not 
involved. Koller et al., [1989] demonstrated that both LDL and HDL bound to 
isolated GPIIb and Ilia, the binding was saturable and in the case| of GPU la was 
competitively inhibited by excess FGN. FGN did not affect lipoprotein 
interactions with GPIIb. However, this is not surprising as no binding site on 
GPIIb for FGN has been reported and the observation may represent non­
specific binding. The data suggests that lipoproteins may compete with FGN for 
a single binding site on GPIIIa. This may also explain the apparent inhibitory 
effects of HDLg on platelet function [Desai et al., 1989; Higashihara et al., 1991 ]. 
However, caution must be exercised in the interpretation of these results, as the 
isolation of the GPIIb-llla complex could alter its normal binding characteristics.
In support of the supposition, Kowalski etal., [1990] inhibited lipoprotein binding 
to platelets by the inclusion of GPIIb-llla Mabs or RGD containing peptides, the 
latter suggesting lipoproteins may interact via the RGD recognition sites or 
regions in close proximity. Recently, an amino acid sequence on GPIIIa has 
been discovered which possesses a high similarity to the LDL binding regions 
on the apoB/E receptor [C. Ettelaie, personal communication], with 23% identity 
and 78% similarity [Figure 3.12]. This may represent a binding site for 
lipoproteins on platelets, but requires further investigation for the full 
implications to be established. Competition for binding between FGN and LDL 
may explain the differences in results between the WP and PRP aggregations 
experiments. PRP would contain much higher concentrations of FGN and hence 
may prevent nLDL having a rapid effect.
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Figure 3.12. Space filling models of amino acid sequences from both apoB/E 
receptor and glycoprotein Ilia.
The diagram shows a sequence on GPIIIa which has a high similaritywith a sequeri^ 
found in the binding region of the apoB/E receptor, and may represent a possi 
binding site for LDL on platelets.
a) ApoB/E receptor residues 283 - 291. :
b) Platelet GPIIIa, residues 39 - 47.
Space filling models of the two sequences were constructed using the Alchemy I 
program (Tripos Associates Inc, St. Louis, USA), and was a gift from Dr. C. Ettelaie 
Royal Free Flospital School of Medicine.
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The influence of TXAg on platelet activity may be important to the interpretation 
of the results from both the aggregation and flow cytometric experiments. 
Platelet aggregation in vitro (Born aggregometry; see section 2.6.5) is thought 
to mimic thrombus formation as the stirring recreates the turbulent effects of 
blood flow. With ADR-stimulated platelets, TXAg formation is dependent on 
aggregation, not FGN binding [Balduini etal., 1988], and thus in the aggregation 
system platelet derived TXAg would enhance aggregation. This means in the 
aggregation experiments nLDL is opposing the actions of both ADP and TXAg. 
In a non-stirred system, TXAg release would be limited, hence the actions of 
nLDL would be an effect purely on ADP-induced FGN binding and could not be 
compared directly to aggregation. Thus flow cytometric analysis allows the study 
of the early stages of platelet activation (FGN binding), and not the full functional 
response, which involves granule secretion and TXAg formation. Therefore, 
caution must be exercised when comparing observations in stirred and non­
stirred systems.
The results showing nLDL to inhibit platelet activity are in contrast to other 
studies, where LDL were reported to activate platelets. A recent study by Van 
Willigen et a/., [1994] demonstrated nLDL significantly increased the FGN 
binding to platelet stimulated with ADP. However, the nLDL samples were 
prepared in the presence of thimerosal, an antibacterial agent, which has been 
shown to activate platelets and remain associated with LDL [Schacter et a!.,
1990]. nLDL has also been shown to enhance aggregation of whole blood by a 
new method of filtragometry, although the level of LDL oxidation was not 
reported [Brôijersén etal., 1993].
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The significance of the inhibitory effects of nLDL on platelet activity is unclear. 
However most importantly, nLDL prepared by the present methods does not 
activate platelets. This is not entirely surprising, as in evolutionary terms it would 
be unfavourable for a normal plasma component to activate cells in which they 
are in intimate contact throughout the circulation. If nLDL did increase platelet 
aggregation, this would be detrimental to normal haemostasis possibly leading 
to increased thrombotic complications. nLDL may fulfil a mild inhibitory role with 
respect to platelet function, although their full contribution to regulation of 
platelet function is yet to be elucidated. If LDL does reduce aggregation by 
binding to GPIIb-llla, the effects on FGN binding may proceed by two 
mechanisms. Firstly, the size of LDL, once bound, could sterically block access 
of the receptor to FGN, reducing interplatelet bridging. Alternatively, binding of 
the lipoproteins to GPIIb-llla may alter the binding characteristics of the receptor 
and thus down regulate FGN-receptor coupling. A reduction in FGN binding to 
GPIIb-llla may lead to a down regulation of FGN binding associated tyrosine 
phosphorylation [Ferrell and Martin, 1989], again leading to a reduction in 
aggregation. Therefore, the inhibitory effects of nLDL may be two-fold, a 
physical attenuation of FGN-binding, leading to a possible reduction in tyrosine 
phosphorylation, secondary messenger levels and ultimately aggregation. It is 
interesting to note that increasing the experimental concentrations of LDL above 
the physiological concentration (0.5mg/ml), did not increase their inhibitory 
actions, indicating that if plasma nLDL concentrations reach pathophysiological 
levels their possible anti-aggregatory effects are not increased. Furthermore, 
their beneficial effects maybe masked by the pro-aggregatory actions when 
oxidised (discussed later).
153
3.7.3 Modified low density lipoproteins and platelet function.
In contrast to the effects of nLDL, mmLDL activated platelets. They induced FGN 
binding and aggregation of platelets independently of agonists and also 
enhanced ADP-induced activation and aggregation. Previous studies have 
shown LDL to induce secondary aggregation of WP using pathophysiological 
concentrations of LDL (> 2mg protein/ml) [Hassell et al., 1983]. In the present 
study, mmLDL only induced primary aggregation. |With concentrations in excess, of 
1 mg protein/ml, a significant increase in aggregation was not observed. 
However, mmLDL did potentiate sub-threshold concentrations of ADP to induce 
secondary aggregation. One possible explanation for these results is the effects 
of mmLDL on platelet secretion: mmLDL alone failed to induce expression of P- 
selectin and CD63 which is consistent with the inability to induce secondary 
aggregation. However, in the presence of ADP, mmLDL did enhance platelet 
secretion. The release of vasoactive factors from platelet granules may help to 
sustain and increase the aggregation response. Partial degranulation measured 
by P-selectin and CD63 expression is associated with granule content release, 
as evidenced by the levels of p-thromboglobulin [Janes etal., 1994]. The data 
complement previous work showing LDL to increase dense granule secretion. 
Surya et al., [1992] has demonstrated that short term exposure of washed 
platelets to LDL leads to an increase in dense granule secretion by TXAg. 
dependent and independent mechanisms, after initial stimulation by a-thrombin. 
However, the degree of LDL oxidation was not measured in this study. LDL were 
also shown to enhance platelet activation stimulated by sub-maximal serotonin 
in PRP [Fetkovska, 1992]. In a morphological study, Zhao etal., [1993] showed 
LDL, prepared without protection from potential oxidants, to induce platelet 
shape change.
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The mmLDL preparations in this study were very mildly oxidised, and it is 
conceivable that with earlier studies, where the full implications of LDL oxidation 
had not been appreciated, that slight oxidation of the lipoproteins may have 
occurred. Resulting in a form of LDL very similar to that described here as 
mmLDL. The only recognisable physicochemical difference between nLDL and 
mmLDL was a 1.5/2-fold increase in LPO/TBARs. However, their effects on 
platelets were very different. Agarose gel electrophoresis demonstrated that the 
apoB of both nLDL and mmLDL were unmodified, indicating that LPO are of 
fundamental importance to the actions of mmLDL. It is plausible that mmLDL 
could bind to platelets in a similar fashion to that proposed for nLDL, but the 
presence of LPO could create an oxidative microenviroment leading to a change 
in the cell surface characteristics, for example, increased permeability to Ca^ "" 
or an altered functioning of membrane bound enzymes. LDL have been shown 
in numerous studies to increase [Ca^ ,^ concentrations in both platelets [Andrews 
etal., 1987a, Dunn etal., 1988, Knorref a/., 1988, Blockef a/., 1988, Katzman 
et al., 1991, Bochkov et al., 1991, Katzman ef al., 1994] and other cell types 
[Galle etal., 1991]. An increase in [Ca^ ""], may explain how LDL increased other 
secondary messenger markers of platelet activation, since this increased [Ca "^’], 
may activate PLAg (see section 1.6.3). Zhao et al., [1993], suggest that the 
increased [Ca^ ""], requires Ca^ "" from the extracellular compartment, as the 
presence of EDTA inhibited the LDL-induced increase in [Ca^ "'],. Wiedtmann et
al., [1995], have recently presented work which is very similar to the present
/
study. This group found mildly oxidised LDL to activate platelets, an effect 
which could not be reproduced with either nLDL or oxLDL. In contrast to work 
presented here, mildly oxidised LDL induced full secondary aggregation. The 
actions of mildly oxidised LDL were attributed to the activation of PLAg and COX,
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since inhibition of these enzymes abolished the effects of the lipoproteins. 
Another recent study by Watson et a/., [1995] suggests that the cellular effects 
of mmLDL are due to oxidised phospholipids. Treatment of mmLDL with PAF 
acetylhydrolase (PAF-AH) eliminated its cellular effects. The data suggest a 
possible role for PAF in the actions of mmLDL. However, Wiedtmann at al., 
[1995], showed that the aggregatory effects of mildly oxidised LDL, which were 
mediated by COX and PLAg, were unaffected by the presence of PAF receptor 
antagonists. PAF-AH has been proposed to be a general scavenger of oxidised 
phospholipids [Strafforini at a/., 1993], and treatment of LDL with PAF-AH 
inhibited the production of a whole range of oxidised phospholipid products. 
These data compare favourably with the present study, as it is postulated here 
that the activatory effects of mmLDL, reside in the oxidised lipid moiety, in 
particular the LPO.
Atherosclerosis is associated with increased levels of plasma lipid peroxide 
levels [Stringer at al., 1989]. In relation to these observations, the antioxidant 
status of the individual preparations may also be of importance, Salonen at al., 
[1991] demonstrated a weak relationship between subjects with low antioxidant 
levels and hyper- responsiveness of platelets. The increased susceptibility of the 
platelet to aggregate was reversed by antioxidant supplementation. The effects 
of mmLDL on platelet aggregation are complemented by two other studies 
[Ardlie at al., 1989, Meraji at al., 1991], both of which showed that oxLDL 
potentiated and induce aggregation. The oxLDL preparations in both of the 
studies possessed relatively low concentrations of oxidation products in 
comparison to other work. The physiological relevance of the actions of mmLDL 
are unclear, but the enhanced aggregation in the presence of plasma suggests
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that mmLDL may potentially increase the formation of thrombi.
The properties of apoB in mmLDL are not significantly different from those 
associated with nLDL. Therefore it is interesting to speculate that mmLDL may 
not be fully recognised by the reticulo-endothelial system and therefore escape 
from the subendothelial compartment and exist in the circulation. Two 
independent studies have shown the presence of a modified LDL in human 
circulation. Avogaro et al., [1987], isolated an LDL subfraction from non- 
lipidaemic subjects, which had an increased electronegativity. The modified LDL 
had a reduced ability to bind to human skin fibroblasts compared to nLDL, but 
was more efficient than acLDL. These modified LDL represented approximately 
5-20% of the total LDL content. These experiments were further characterised 
by a second study [Cazzolato etal., 1991]. Here the modified LDL was found to 
have significantly greater levels of TBARs than nLDL, while the cholesteryl ester 
and phospholipid contents were reduced. In a separate study, Shimano etal., 
[1991] isolated a similar LDL subfraction which comprised approximately 1% of 
the total. This subfraction bound to human fibroblasts with the same affinity as 
nLDL, although they had a greater susceptibility to oxidation, possibly because 
of the presence of preformed peroxides. In all three studies an LDL subfraction 
may have been isolated which may be a closely related species to the mmLDL 
of the present study.
OxLDL underwent both lipid and protein modification, as indicated by the 
concentrations of LPO/TBARs and the increased REM. Fully oxLDL, in contrast 
to mmLDL, did not activate platelets, but inhibited aggregation in both WP and 
PRP. This indicated that further oxidation of LDL again altered the properties of
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the particles. In both platelet models, the inhibition occurred after a 1min 
incubation, suggesting a different mechanism of inhibition to that of nLDL. 
Oxidation of LDL yields high concentrations of lysolecithin [Besterman and 
Gillette 1971] and 4-HNE [Selley et al., 1988], both of which have been shown 
to inhibit platelet function. The relative increase in concentration of these 
products in oxLDL may account for the results obtained. These findings are 
supported by Aviram, [1989], who reported significant inhibition of collagen- 
induced aggregation by oxLDL, but not acLDL, where lysine residues were 
blocked, but no oxidation products were present. This strongly suggests that 
lipid oxidation products, rather than the apoB modification are responsible for 
inhibition of platelet function by oxLDL. Direct interactions between oxLDL and 
platelets are unlikely as oxLDL would be held in the foam cells of the plaque, 
unless the plaque fissures and oxLDL is released. However, one recent study 
has shown oxLDL to bind to platelets with the same affinity as nLDL, although 
the apparent binding site was not identified [Pedreno etal., 1994].
In summary, LDL have previously been shown to activate platelet to varying 
degrees. Many of these studies failed to report the oxidation state of LDL. Here, 
the effects of oxidative modification of LDL on platelet function has been studied 
in a more systematic manner. The extent of oxidation of LDL seems to pe critical in 
determining the nature of their effects on platelet function. It is proposed that 
mmLDL are the most potent form of LDL with regard to platelet activation, a 
supposition which is supported by a recent publication by Wiedtmann et al., 
[1995].
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CHAPTER FOUR: THE INFLUENCE OF EXOGENOUS HYDROGEN 
PEROXIDE ON PLATELET AGGREGATION.
4.1 INTRODUCTION.
Lipid peroxides can influence platelet function by the activation of cyclo- 
oxygenase (COX) [Warso and Lands, 1983]. Plasma lipid peroxide 
concentrations have been shown to be raised in atherosclerosis [Stringer et a!., 
1989], which in turn may relate to the pathophysiology of atherosclerosis and 
thrombosis. Evidence suggets that these LPO are associated, at least in part, 
with plasma lipoproteins [Nishigaki at al., 1981; Bowry at a/., 1992]. In the 
previous chapter, mmLDL was shown to induce activation and aggregation of 
platelets independently of platelet agonists. It was proposed that the pro- 
aggregatory effects of mmLDL are mediated by the low levels of hydroperoxy 
fatty acid oxidation products which are associated with these particles.
Platelets from patients with Type lia hyperlipidaemia are hyper-
aggregable [Carvalho at a/., 1974] and also require more PGIg to inhibit 
aggregation compared to platelets from normal patients [Colli at a/., 1983]. 
However, there were no differences in PGIg stimulation of isolated membrane 
adenylate cyclase between the two groups [Colli at a/., 1983]. These later data 
indicate that there are differences in plasma composition rather than alterations 
of PGIg receptor function and its linked signal transduction systems. LDL were 
subsequently shown to reduce the sensitivity of platelet adenylate cyclase to 
PGIg [Bruckdorfer at a!., 1985, Colli at a/., 1985]. These studies were performed 
before the full implications of LDL oxidation had been appreciated. Thus, 
following the argument laid out in the previous chapter, it is reasonable to
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postulate that the effects of LDL on platelet sensitivity to PGIg were due in part, 
to partially oxidised forms of LDL.
Although interactions between LDL and PGIg, with respect to platelet function 
have been studied by several workers, very little research has addressed the 
effects of LDL on the sensitivity of platelets to NO. The influence of LDL, in 
particular mmLDL, on platelet sensitivity to NO may be relevant to platelet 
function in hyperlipidaemia and vascular disease. Hence, in the following 
chapter the effects of peroxides (viz. mmLDL) on platelet function were 
examined. Initially the simplest model peroxide available, hydrogen peroxide, 
was used. Several studies have demonstrated that HgOg influences platelet 
function: HgOg enhances aggregation of platelet pre-exposed to agonists 
[Canoso et al., 1974; Rodvein ef al., 1976; Del Principe ef al., 1985], but has 
also been shown to inhibit their aggregation [Canoso at a/., 1974; Holmsen and 
Robkin, 1977].
The effects of HgOg on platelet aggregation and platelet sensitivity to NO in vitro 
were investigated. As in the previous chapter, two platelet models were used in 
this study. The plasma environment is rich in antioxidants and free radical 
scavengers, such as ascorbic acid, SOD, catalase and glutathione peroxidase 
(GSM Px), which may have important effects on experiments with exogenous 
NO and HgOg solutions. Using WP, the effects of NO and HgOg could also be 
studied in the absence of these and other plasma constituents. Platelet 
aggregation was induced by either thrombin, collagen or ADP and the inhibitory 
effects of NO and an NO donor, S-nitrosoglutathione (S-NOG), were assessed. 
The influence of HgOg on these platelet inhibitors was investigated in detail.
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4.1.1 Summary of aims.
[1] To assess the effects of HgOg on platelet aggregation in the presence and 
absence of physiological agonists.
[2] To investigate how the aggregatory effects of HgOg influence platelet 
sensitivity to NO and the NO donor s-nitrosoglutathione.
[3] To identify the mechanisms by which HgOg exerts its actions on platelets.
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4.2 THE INFLUENCE OF HYDROGEN PEROXIDE AND NITRIC OXIDE ON 
PLA TELET FUNCTION.
4.2.1 The direct effects of hydrogen peroxide on platelets.
HgOg (1 - i25 ijM) was added as a bolus to WP and aggregation assessed after 
3min. HgOg (10 - 25|jM) induced spontaneous aggregation, but only to a very 
limited extent. The effects were concentration dependent for H2O2, with maximal 
aggregation 9.3 ± 5.4% induced at 25pM [Table 4.1]. Substantial variations in 
the magnitude of responses were observed between the individual platelet 
preparations. In a few preparations H2O2 had no effect at all. The results were 
similar to those observed with mmLDL, although the aggregation traces 
produced by H2O2 did not appear as classical primary responses (see section 
2.6.5).
4.2.2 The effects of hydrogen peroxide on thrombin-stimulated platelets.
The effects of H2O2 (1 - 25pM) were tested in combination with sub-threshold 
concentrations of platelet agonists. WP were 'primed' with thrombin (0.005 - 
0.01 U/ml) which induced an aggregation response of 4 ± 0.7%. Incubation of 
H2O2 for Imin prior to the addition of thrombin had no effect on aggregation. 
However when added Imin after thrombin, H2O2 enhanced total aggregation 
significantly [Table 4.1]. This potentiation of thrombin activity by H2O2 was 
concentration-dependent and was statistically significant at concentrations 
between 10 - 25pM [Table 4.1]. Maximal effects were obtained with 25pM H2O2 
(27.6 ± 6.5%) aggregation (p< 0.05) compared to controls of thrombin alone (4 
± 0.7%).
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4.2.3 The effects of hydrogen peroxide on collagen- and ADP- stimulated 
platelet aggregation.
The effects of HgOg on collagen-stimulated aggregation were studied using the 
same protocol as for thrombin. Collagen (0.1 - 0.2pg/ml) was used to stimulate 
the WP and at these concentrations the aggregation responses were small (3.5 
± 2%). HgOg (1 - 25pM) was added to platelets Imin after the addition of 
collagen and it potentiated aggregation in the concentration range of 5 - 25 pM 
[Table 4.1]. The magnitude of the enhancement was concentration-dependent 
for HgOg: 25pM HgOg induced 16.8 ± 2.2% aggregation (p< 0.05). The effects 
were less variable at lower concentrations of HgOg, with 5pM inducing 12 ± 1.8% 
aggregation [Table 4.1].
HgOg had no effects on aggregation induced by sub-threshold ADP (1 - 2pM).
4.2.4 Investigations Into the mechanism by which hydrogen peroxide
mediated the potentiation of platelet aggregation.
The mechanism by which HgOg potentiated platelet aggregation was investigated 
using aspirin-treated platelets (see section 2.6.4). WP were stimulated with 
thrombin (0.005 - 0.01 U/ml), which induced very low levels of aggregation, 5 ±
2% (not shown). The addition of HgOz (25pM) Imin later enhanced the
aggregation to 31.3 ± 8.2% (p< 0.05) (not shown) [Table 4.1]. Aspirin treatment
of WP did not change significantly the aggregation induced by thrombin alone
(6.3 ± 8%). HgOg added to aspirin-treated platelets, which had been stimulated
with thrombin, failed to significantly enhance aggregation. Total aggregation
induced by thrombin and supplementary HgOg, in aspirin treated platelets, was
8 ± 2.7%, significantly lower than in the absence of aspirin (p:$ 0.05) [Table 4.1].
These data suggest HgOg potentiates platelet aggregation via a cyclo-
oxygenase-dependent mechanism,
thrombin thrombin collagen
H2O2 (pIVI) no agonist (0.005U/ml) (0.005U/ml) + (0.1 pg/ml)
____________________________________ aspirin_________________
_______________ % total aggregation__________________
0 4 ±0.7 6.3 ±1.8 3±2
1 3.5 ±1.5 4 ±0.9 nd 4±1.2
5 4 ±0.7 7.2 ±1.2 nd 12 ± 0.8*
10 4.5 ±0.8 13.6 ± 2.6* nd 16.2 ± 2.8"
15 5.8±1.1 22.6 ± 6.2* nd 15 ±2.4**
25 9.3 ±5.4 27.6 ±6.5** 8 ±2.7 16.8 ± 2.6"
Table 4.1: The effects of hydrogen peroxide on platelet aggregation induced by 
collagen and thrombin.
H2O2 was added directly to WP, from a diluted stock solution, either the the 
absence or presence of platelet agonists. In the experiment using platelet 
agonists, WP were stimulated with either thrombin (0.005U/ml) or collagen 
(0.1 pg/ml) and left for Imin before the addiHoa of H2O2, aggregation was 
measured 3min later. The results are presented as % total aggregation 
compared to thrombin or collagen alone and are expressed as mean ± SEM of 
4 individual experiments. * p< 0.05, **p< 0.01.
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4.3 NITRIC OXIDE iAS AN INHIBITOR OF PLATELET AGGREGATION.
NO solutions have been shown to inhibit platelet function in vitro [Radomski et 
a!., 1987c]. In the following sections the inhibitory effects of NO were tested 
against both thrombin- and collagen-induced aggregation. WP were stimulated 
with sub-maximal concentrations of agonists in the presence of NO solutions. 
When assessing the actions of NO, two parameters were considered: the 
concentration of NO required to induce 50% inhibition (IC50) and the minimal 
concentration required to elicit complete inhibition. The resultant inhibition 
curves were used as a reference guide for the effects, if any, of HgOg.
4.3.1 The measurement of nitric oxide concentrations in solution.
The concentrations of NO solutions were checked by the Griess reaction (see 
section 2.7.2). This measured the nitrite (NO2") ion concentration in any given 
solution. However, the lower limit of detection of the assay is only IpM and 
therefore only NO solutions of higher concentrations could be tested using this 
method.
Solutions of 10 and 20pM NO were prepared, which were diluted ten-fold in the 
volume of the assay. The results demonstrated that in 4 individual solutions of 
each concentration, the expected and actual concentrations were very similar. 
In the case of solutions proposed to be 1 pM the actual concentrations were 0.9 
± 0.05, while the range for the 2pM solutions was 1.9 ± 0.1 pM. The results 
demonstrate that the technique used to prepare NO solutions was reliably 
accurate.
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4.3.2 The effect of nitric oxide solutions on thrombin and coiiagen-induced 
platelet aggregation.
NO (0 - 5|jM) was added as a bolus to WP and incubated for 1 min prior to the 
addition of thrombin (0.02U/ml). NO (1nM) failed to influence 
thrombin-induced aggregation. However above this concentration, NO elicited 
a concentration-dependent inhibition of aggregation. The IC50 for NO against 
thrombin was 95 ± 40nM and complete inhibition achieved at 1.8 ± O.SpM 
[Figure 4.1]. NO also induced a concentration-dependent inhibition of collagen 
(0.5pg/ml)-stimulated aggregation. The IC50 for NO against collagen was 16.8 
± 3.3nM and complete inhibition achieved at 125 ± 50nM [Figure 4.1]. These 
data indicate that inhibition mediated by NO was more effective against platelet 
activity induced by collagen than thrombin, this difference is possibly due to the 
production of endogenous NO by collagen-stimulated platelets.
4.4 THE INFLUENCE OF HYDROGEN PEROXIDE ON PLATELET INHIBITION 
BY NITRIC OXIDE.
4.4.1 Nitric oxide mediated Inhibition of thrombin- and collagen-induced 
aggregation: the Influence of supplementary hydrogen peroxide.
The influence of HgOg on the inhibition of platelet aggregation by NO was 
investigated. NO (0 - lOpM) was incubated for Imin with WP before addition of 
thrombin (0.02U/ml), HgOg was added Imin after the agonist and aggregation 
measured 3min later. The presence of HgOg (0-25pM) antagonised the inhibitory 
actions of NO: the IC50 for NO was elevated and the NO concentration required 
to induce complete inhibition of aggregation was increased [Figure 4.2]. These 
effects of HgOg were concentration-dependent, but only significant at the highest 
concentration of HgOg tested. HgOg (25pM) increased the IC50 to 3.6 ± 0.8pM NO
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Figure 4.1 : Concentration response curves for nitric oxide against both thrombin- 
and collagen-induced aggregation.
WP were incubated with NO solutions (0.001 - lOpM), added as a bolus, Imin 
prior to the addition of thrombin (0.02U/ml) (#) or collagen (0.5pg/ml) (O), and 
total aggregation measured 3min after the addition of the agonist. The results 
represent the percent inhibition of aggregation, compared to controls of inactive 
NO solutions. The data are expressed as mean ± SEM of 4 individual 
experiments.
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Figure 4.2: Concentration response curves for nitric oxide against thrombin- 
induced aggregation: effects of supplementary hydrogen peroxide.
WP were incubated with NO solutions (0.001 - 10pM), added as a bolus, for 
1min prior to the addition of thrombin (0.02U/ml) (•) , after a further Imin H2O2 
(supplementary) was added at a concentration of either 25pM (■) or 5pM (□) 
and the total aggregation measured after a further 3min. The results represent 
the percent inhibition of aggregation, and are expressed as mean ± SEM of 4 
individual experiments. For statistical analysis refer to text {section 4.4.1).
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(p< 0.05) compared to 110.0 ± 30nM NO against thrombin alone [Figure 4.2].
This represented a 30-fold increase in the requirement of NO. Complete 
inhibition was achieved at 3.25 ± I.IpM  NO, significantly greater than the NO 
concentration required in the absence of HgOg (p< 0.05). HgOg was most/effective 
against low concentrations of NO, in some cases completely abolishing any 
inhibitory effects.
The experiments were repeated with collagen (0.5pg/ml)-stimulated WP. HgOg 
again decreased the inhibitory actions of NO [Figure 4.3J. However, NO was 
much more potent against collagen-induced aggregation than was the case with 
thrombin. HgOg (5pM) increased the ICgg for NO to 55 ± lOnM NO from 19 ± 5nM 
(p^ 0.05), a 2.5-fold decease in the effectiveness of NO. Higher'concentrations 
of the peroxide (15 and 25pM) did not significantly change the IC5 0  (data not shown) for NO and 
complete inhibition was not significantly altered at 175 ± 50nM NO (compared 
to 125 ± 20nM) [Figure 4.3]. The reduced actions of HgOg against NO-mediated 
inhibition of collagen-induced aggregation, may reflect an influence of 
endogenously produced NO.
4.5 POSSIBLE DIRECT INTERACTIONS OF NITRIC OXIDE AND HYDROGEN 
PEROXIDE.
In the above sections, it was demonstrated that HgOg antagonised the inhibitory 
actions of NO, when added post-agonist. In these experiments, the intracellular 
concentration of cGMP would be expected to be elevated before the addition of 
the peroxide, since NO and NO-donors increase platelet cGMP within 15sec of 
exposure of the cells to the antagonist [Salvemini et a/., 1990; Nguyen et a!., 
1991]. The question arises as to whether the antagonism of NO by HgOg was
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Figure 4.3: Concentration response curves for nitric oxide against collagen 
induced aggregation: effects of supplementary hydrogen peroxide.
WP were incubated with NO solutions (0.001 - lOpM), added as a bolus, for 
Imin prior to the addition of collagen (0.5 pg/ml) (O), after a further Imin H2O2 
was added at a concentration of 5pM (#) and the total aggregation measured 
after a further 3min. The results represent the percent inhibition of aggregation, 
and are expressed as mean ± SEM of 4 individual experiments. For statistical 
analysis refer to text (section 4.4.2).
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due to an affect of the peroxide on secondary messenger pathways, for 
example, alteration of phosphodiesterase activity, or was a consequence of a 
direct interaction between NO and HgOg. NO and HgOg have been shown to react 
directly to form singlet oxygen [Noronha-Dutra et al., 1992]. Thus, in the 
following experiments NO and HgOg were added simultaneously to isolated 
platelets to investigate their effects on platelet aggregation.
4.5.1 The influence of nitric oxide and hydrogen peroxide added 
simultaneously on agonist-induced platelet aggregation.
HgOg (5 - 25pM) was added simultaneously with NO (0 - IpM) to WP in the 
absence of agonists and left for 3min after which no aggregation response was 
observed. If NO/HgOg were incubated for 1 min with WP prior to the addition of 
thrombin (0.02U/ml), the inhibition of aggregation was to a greater extent than 
with NO alone [Figure 4.4b,c,d]. The effects were concentration-dependent for 
HgOg, with 25pM generating the largest effect. In the presence of HgOg (5pM) the 
IC50 for NO against thrombin-stimulated platelet activity was reduced from 110 
± 35nM to 38.5 ± 6.5nM (p< 0.05) and with HgOg (15pM) the IC50 for NO was 
further reduced to 6.5 ± 2.5 (p< 0.01). When HgOg (25pM) was added with NO 
the peroxide reduced the IC50 for NO to approximately 2 ± 1 nM [Figure 4.5]. This 
is an approximate value as in some cases the inhibitory effects induced by 
NO/H2O2 began at greater than 50% inhibition. In these instances, the IC50 was 
taken as 1 nM NO. Theinhibitory actions of NOwith all concentrations of H2O2 were 
so potent that NO solutions could not be accurately prepared at sufficiently low 
concentrations to abolish the inhibition (lowest final concentration InM NO).
The experiments were repeated using fixed concentrations of NO (1 and lOnM)
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Figure 4.4: Typical aggregation traces demonstrating the effects of nitric oxide and 
hydrogen peroxide on platelet aggregation.
(a) WP were incubated with thrombin (0.02U/ml) for 3min.
(b) NO (10nM) was added to WP 1min before the addition of thrombin.
© NO (lOOnM) was added to WP 1min before the addition of thrombin.
(d) NO (10nM) + HgOg (25pM) were added to WP 1 min before the addition of thrombin.
(e) NO (1nM) + HgOg (25pM) were added to WP 1min before the addition of thrombin.
(f) NO (10nM) + HgOg (25pM) were added to WP 30min before the addition of thrombin.
T: thrombin, N:, nitric oxide, H: hydrogen peroxide
The results are typical of at least 4 independent experiments.
increasing
light
transmission
WH
T "
N(H
i i
f
e
172
co
100
80
60
40
20
0  w — I i # i i |—  
0.001 0.01 100.1 1
NO (|jM)
Figure 4.5: Hydrogen peroxide enhances the inhibition of thrombin-induced 
platelet aggregation by nitric oxide.
A range of concentrations of NO were added simultaneously with HgOg, from 
separate syringes, to WP before the addition of thrombin (0.02U/ml). The data 
are presented as concentration response curves for NO only (• ) , and NO in 
combination with HgOg at either 25pM (O) or 5pM (■). The results represent the 
percent inhibition of aggregation and are expressed as mean ± SEM of 6 
individual experiments. For statistical analysis refer to text (section 4.5.1).
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and variable concentrations of HgOg (0 -25ijM). This was to confirm previous 
findings and, in addition, to explore the concentration range for HgOg at which 
the effects were detectable. NO and HgOg were added simultaneously, and in all 
cases inhibited platelet aggregation to a greater extent than NO alone [Figure 
4.6]. With NO (1nM) the ECgofor HgOg was 4.9 ± 2.3pM and in combination with 
HgOg (1|jM) induced 7.0 ± 3.5% inhibition. These results showed jMgOg to 
influence the action of NO at very low concentrations, within the physiological 
range [Test and Weiss, 1984], and to enhance a normally inactive concentration 
of NO (InM) [Figure 4.4eJ. The inhibitory actions were even greater with NO 
(lOnM), with an EC50 for HgOz of 1.6 ± O.SpM [Figure 4.6/ EC50 (effective 
concentration) was used to describe the effects of HgOg in this instance, as the 
peroxide seemed to play a positive role in the actions of NO.
These results show a potent inhibition of aggregation by NO and HgOg, the 
actions of which are in complete contrast to the observations when HgOg was 
added after NO and thrombin (see section 4.4.1).
4.5.2 The effects of inactive nitric oxide and hydrogen peroxide on plateiet 
aggregation.
To establish whether contaminants of the two solutions could have influenced 
the previous observations, experiments were performed with inactive solutions.
NO solutions left exposed to air for 15min prior to addition to WP, failed to 
induce inhibition of thrombin (0.02U/ml)-stimulated aggregation either alone, or 
in combination with HgOg. Similarly HgOg which had been stirred and exposed to 
air overnight or boiled for 30min, did not potentiate sub-maximal thrombin- 
induced aggregation or enhance the inhibitory actions of NO. This indicates that
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Figure 4.6: Concentration response relationship between nitric oxide and 
hydrogen peroxide on inhibition of thrombin induced platelet aggregation, when 
added simultaneously.
NO and H2O2 were added simultaneously, from separate syringes, to WP 1 min 
before the addition of thrombin (0.02U/ml). Two fixed concentrations of NO, 1nM
(O) and 10nM (•), were used in combination with a range of concentrations of 
HgOg. The results represent the percent inhibition of aggregation and are 
expressed as mean ± SEM of 4 individual experiments. For statistical analysis 
refer to text {section 4.5.1).
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both active NO and H2O2 were required for the powerful inhibitory actions 
observed in previous experiments. In addition, the breakdown products of NO, 
NO2" and NO "^ (see section1.6.4.4), or other possible contaminants were not 
responsible for the protracted effects.
4.5.3 Recovery of platelets from the effects of nitric oxide ornitric oxide 
with hydrogen peroxide.
To ascertain whether the enhanced inhibition of aggregation by NO in the 
presence of H2O2 was not simply a cytotoxic effect, the inhibitory effects 
NO/H2O2 were studied as a function of time.
NO (10nM, lOOnM, 1pM) or NO (10nM)/H2O2 (5, 15, 25pM) were added to WP 
and left stirring for Imin, and incubated at 37°C for up to 1h before
stimulation with thrombin (0.02U/ml). The magnitude and longevity of the NO 
mediated inhibition was concentration dependent. NO (10nM) after Imin 
incubation induced 8.5 ± 3.3% inhibition, which was lost after lOmin. NO (IpM) 
induced the | greatest inhibition, 83.3 ± 6.3%, which persisted until 30min 
(19.8 ± 13.3%), but was not detected at 60min.
Inhibition induced by simultaneous addition of NO/H2O2 was more effective and 
persisted longer than lOnM NO alone [Figure 4.7], After 30min incubation NO 
(lOnM) had no effect on platelet activity. However, in the presence of H2O2 the 
inhibition still persisted. At this time point, NO, in combination with H2O2 (25pM) 
induced 59 ± 7.3% inhibition (p< 0.01). The effects with H2O2 (15 and 25pM) in 
combination with NO (lOnM) were significantly greater than inhibition of 
aggregation by NO (lOOnM) alone (p< 0.05). When H2O2 was tested in the
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Figure 4.7: The recovery of platelets from inhibition induced by nitric oxide in 
combination with hydrogen peroxide.
NO only or, NO in combination with HgOg were added to WP and left for up to 
1 h before stimulation with thrombin (0.02U/ml). A fixed concentration of NO 
(10nM) was added to WP alone (■), or simultaneously with HgOg at 5pM (□), 
'15pM (O) and25pM (•) . Total aggregation was measured 3min after the 
addition of the agonist. The results represent the percent inhibition of 
aggregation and are expressed as the mean ± SEM of 4 individual experiments. 
For statistical analysis refer to text (section 4.5.3).
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absence of NO, it failed to affect aggregation compared to the agonist alone. 
The results are summarised in Figure 4.7.
All WP treated with mixtures of NO/H2O2 fully recovered functional viability after 
60min incubation. No differences in thrombin-induced aggregation responses 
could be detected between WP treated with Tyrode's HEPES buffer (see section 
2.3.2) or NO/H2O2 [Figure 4.4a, e]. This indicates that NO/H2O2 in combination 
are not cytotoxic, and H2O2 acts to both intensify and prolong the effects of NO.
4.5.4 The effects of premixing nitric oxide and hydrogen peroxide before 
their addition to plateiets.
The protracted inhibition of aggregation induced by NO/H2O2 added 
simultaneously, raised the possibility that a new free radical species may be 
formed from a reaction between the two mediators. The new species may 
possess different characteristics to that of authentic NO. This was tested by pre­
mixing NO and H2O2 in stirred Tyrode's HEPES buffer (see section 2.3.2) for up 
to 60sec before aliquots were transferred to WP. Mixing was performed at 37°C 
in a separate aggregation cuvette. WP were then left for 1 min after the addition 
of the mixture before being challenged with thrombin (0.02U/ml). The time for 
transfer between cuvettes was approximately 2 - 3s which was additional to the 
stated pre-mixing times.
NO (1GnM) induced 12.5 ± 3.7% inhibition when added directly to WP. However, 
after 20s premixing addition of NO (lOnM) failed to affect aggregation. In 
contrast, in the presence of H2O2 there was a significant increase in both the 
magnitude and longevity of the inhibitory actions of NO [Figure 4.8]. The effects
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Figure 4.8: The effect of premixing of nitric oxide and hydrogen peroxide on the 
inhibition of platelet aggregation stimulated by thrombin.
NO alone or, NO in combination with HgOg were premixed in Tyrodes HEPES 
buffer for up to Imin before their addition to WP. NO was used at a fixed 
concentration of lOnM (□), or in combination with HgOg at concentrations of 5pM 
(• ) , 15pM (O) and 25pM (■). An aliquot of the mixture was added to WP and 
left stirring for Imin before the addition of thrombin (0.02U/ml), total aggregation 
was measured 3min after addition of the agonist. The time scale excludes the 
transfer time (2-3s) of the aliquots from the mixing cuvette to the platelets. The 
results represent the percent inhibition of aggregation and are expressed as the 
mean ± SEM of 4 individual experiments. For statistical analysis refer to text 
{section 4.5.4).
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were concentration-dependent for HgOg with 25pM exerting the greatest 
influence. NO(10nM) pre-mixed with HgOg (25pM) for 20s induced | 87.5 ± 9% 
inhibition (p< 0.005, compared to NO alone) and was still active after 60s 
premixing (13.9 ± 4.3%). H2O2 (5 and 15pM) in combination with NO also 
exerted significant inhibitory effects after 20s pre-mixing, 11.8 ± 3.9% (p< 0.01, 
compared to NO alone) and| 63.5 ± 8% (p< 0.05, compared to NO alone) 
respectively, compared to NO alone [Figure 4.8]. All combinations of NO and 
HgOg still had slight inhibitory actions after 60s pre-mixing compared to controls, 
where NO was added with Tyrode’s HEPES buffer. This suggested that a new 
free radical species may have been formed, but further investigations were 
required to substantiate this.
4.6 THE INFLUENCE OF PEROXYNITRITE ON PLATELET AGGREGATION.
The interaction of NO and HgOg in solution may produce peroxynitrite, via 
formation of nitrous acid, although this has not been reported to occur at neutral 
pH [Beckman, 1990] (see below). Peroxynitrite is produced in vivo by a reaction 
between NO and O2" (see section 1.6.6.4)
H2O2 + HNO2 -  ONOO" +H2O + H+
Peroxynitrite solutions were prepared (see section 2.8) and their effects on 
platelet aggregation were tested. Peroxynitrite (0.01 - lOOpM) was added to WP 
and no aggregation observed after 3min incubation. Incubation of peroxynitrite 
for Imin prior to addition of thrombin (0.02U/ml) resulted in a concentration- 
dependent inhibition of platelet aggregation [Figure 4.9]. The IC50 for 
peroxynitrite against thrombin-stimulated platelets was 3.1 ± I.IpM, which was
180
co
100
80
60
40
20
0
0.01 0.10 1 10 100
Peroxynitrite (jjM)
Figure 4.9: The effect of peroxynitrite solutions on platelet aggregation 
stimulated by thrombin.
Peroxynitrite, diluted from a stock solution immediately before use, was added 
to WP over a range of concentrations 1min before the addition of thrombin 
(0.02U/ml). Total aggregation was measured 3min after the addition of the 
agonist. The results represent the percent inhibition of aggregation, and are 
expressed as mean ± SEM of 4 individual experiments. For statistical analysis 
refer to text {section 4.6).
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approximately 30 times less effective than NO (IC50 110 ± 35nM) and 3000 
times less effective than NO (lOnM) in combination with HgOg (25pM) [Figure 
4.9]. Controls of decomposed peroxynitrite (see section 2.8) had no effect on 
platelet function. This suggested the inhibitory actions of NO/HgOg were not due 
to formation of peroxynitrite.
Peroxynitrite, once prepared, was stored in its anionic form at alkaline pH. To 
check for the influence of pH on platelet function, aliquots of known 
concentrations of peroxynitrite were added to stirred Tyrode's HEPES buffer 
(see section 2.3.2) and the pH was monitored continuously. No significant 
change in pH was observed at concentrations below lOOpM peroxynitrite, which 
suggested the inhibitory action of peroxynitrite was not mediated by an increase 
in pH {not shown).
4.7 THE INFLUENCE OF FREE RADICAL SCAVENGERS, ENZYMES, METAL 
CHELATORS AND NITRIC OXIDE QUENCHERS ON NITRIC OXIDE AND 
HYDROGEN PEROXIDE MEDIATED INHIBITION.
Results from previous sections suggested inhibition of platelet activity induced 
by simultaneous addition of NO and H2O2 may be due to a new radical species 
with different properties than NO or peroxynitrite. This was further investigated 
by addition of free radical scavengers. Specific radical scavengers were 
incubated with WP for Imin at 37°C before the addition of either NO(IOnM), 
NO/HgOg (10nM/25pM) or peroxynitrite (5pM). WP were stimulated with thrombin 
(0.02U/ml) and aggregation measured after 3min. Addition of Tyrode's HEPES 
buffer (see section 2.3.2) instead of a scavenger was used as a control.
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(I) Sodium urate: a hydroxy! radical scavenger.
Sodium urate (0.5mM) when added directly to WP did not induce aggregation 
and had no effect on aggregation stimulated by thrombin (0.02U/ml). However, 
the presence of sodium urate (0.5mM) significantly decreased the inhibition of 
aggregation induced by both NO/HgOg (89 ± 5.4%) and peroxynitrite (73.3 ± 
6.2%), but had no effect on inhibition by NO alone [Table 4.2]. The levels of 
inhibition elecited by NO/HgOg and peroxynitrite in the presence of urate were 
65.6 ± 7.9% (p< 0.01) and 43.0 ± 5.1% (p< 0.005) respectively, significantly less 
than in the absence of urate [Table 4.2]. Sodium urate was more effective 
against peroxynitrite than NO/HgOg.
(II) Mannltol: a hydroxyl radical scavenger
Thrombin- (0.02U/ml) induced aggregation was not affected by the presence of 
mannitol (50mM). Mannitol pre-incubated with WP reduced the inhibition of 
platelet aggregation elicited by both NO/H2O2 and peroxynitrite, but as in the 
case of sodium urate it was more effective against peroxynitrite. Inhibition by 
NO/H2O2 and peroxynitrite were 60.5 ± 5 % (p< 0.01) and 50.5 ± 4.6% (p< 
0.005) respectively, a significant reduction of inhibition compared to controls 
[Table 4.2]. Mannitol had no effects on NO-mediated inhibition.
(III) Ascorbate.
Ascorbate had no effect on inhibition of aggregation induced by either NO, 
NO/H2O2 or peroxynitrite [Table 4.2].
(Iv) Catalase and superoxide dismutase.
WP were incubated with catalase for Imin prior to addition of NO/H2O2. The
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Addition
1% inhibition of aggregation
NO(10nM)+ peroxynitrite NO
H2O2 (25mM) (5|jM)_______ (200nM)
buffer 89 ± 5.4 73.3 ±6.2 42
Na urate (O.SmM) 65.6 ± 7.9 43 ±5.1 38
mannitol (50mM) 60.5 ± 6 50.5 ±4.6 45
ascorbate (0.2mM) 84.3 ± 7.8 50.5 ±4.6 30
800(100 U/ml) 89.5 ±4.4 74.9 ± 5.3 32
catalase (100 U/ml) 57.5
DTPA(IOpM) 86
Table 4.2: The influence of reagents which suppress radical oxygen species on 
the effects of nitric oxide and hydrogen peroxide on platelet aggregation.
NO was added simultaneously with HgOg, from separate syringes, to WP before the 
addition of thrombin (0.02U/ml). WP were preincubated with the individual radical 
scavengers for 1min prior to testing the effects of NO and HgOg The results represent 
the percent inhibition of aggregation and are expressed as mean ± SEM of 5 individual 
experiments and in some cases only two individual experiments. For statistical analysis 
refer to text (see secton 4.7).
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presence of catalase (lOOunits) reduced the inhibition of thrombin-mediated 
aggregation from 100% to 57.5%, but had no effect on the actions of 
peroxynitrite. SOD (lOOunits) had no effect on inhibition of aggregation induced 
by either NO, Isfo/HgOg or peroxynitrite [Table 4.2].
(v) Diethenetriaminepentaacetic acid: a metal ion chelator.
DTPA was shown not to influence agonist-induced aggregation of platelets (see 
section 3.6). Incubation of DTPA with WP for Imin prior to addition of NO or 
NO/HgOg did not affect inhibition of thrombin-stimulated aggregation. This 
indicates that the effects of NO and HgOg were not catalysed by metal ions 
[Table 4.2].
(vi) Carboxy-PTiO: an NO séquestrant
Carboxy-PTIO reacts with NO stoichiometrically (carboxy-PTIO/NO = 1.0) in 
neutral solution, antagonising the biological effects of NO [Akaike et al., 1993].
Carboxy-PTIO (1 pM) was incubated with WP for 30s prior to the addition of NO. 
The presence of carboxy-PTIO significantly decreased the inhibitory actions of 
NO on thrombin-induced aggregation compared to controls (WP without 
carboxy-PTIO) [Figure 4.10]. NO (lOOnM) induced 52.5 ± 6.4% inhibition which 
was reduced to 2.5 ± 2.2% in the presence carboxy-PTIO. At higher 
concentrations of NO, the carboxy-PTIO was less effective. For example, NO 
(IpM) induced 93.1± 4.6% inhibition which was reduced to 35.7 ± 7.4% (p< 
0.01). Although the carboxy-PTIO significantly reduced the actions of NO, it 
seemed in the present system that carboxy-PTIO did not work in a completely 
stoichiometrical manner and only induced complete abolition of NO as a ten-fold
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Figure 4.10: The effects of the nitric oxide quencher, carboxy-PTIO, on the 
inhibition of thrombin-induced platelet aggreagtion by nitric oxide.
A range of concentrations of NO were added to WP, in the presence (O) or 
absence (#) of carboxy-PTIO (1pM), Imin before stimulation by thrombin 
(0.02U/ml). Total aggregation was measured 3min after the addition of the 
agonist. The data are presented as the percent inhibition of aggregation and 
represent the mean ± SEM 3 independent experiments. For statistical analysis 
refer to text (section 4.7).
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excess [Figure 4.10].
Carboxy-PTIO (lOOnM), preincubated with platelets before the addition of 
NO(10nM)/H2O2(25pM), antagonised the inhibition of platelet activity. NO/H2O2 
induced 89.5 ± 1.4% inhibition, which was significantly reduced to 12.0 ± 9.3% 
(p< 0.001) in the presence of carboxy-PTIO. In addition, when NO and H2O2 
were premixed for 10s and carboxy-PTIO was added to the platelets 
simultaneously with the inhibitors, the inhibition was reduced from 94 ± 7 to 24 
± 4%. These results indicate that although other free radicals may be involved 
in the mechanism of inhibition by NO/H2O2, NO was still of major importance and 
suggested that H2O2 interacts synergistically with NO rather than reacting to form 
a free radical species other than NO.
4.8 THE INFLUENCE OF NITRiC OXIDE AND HYDROGEN PEROXIDE ON 
PLATELET GUANYLATE CYCLASE ACTIVITY.
NO exerts its cellular effects by the stimulation of soluble guanylate cyclase and 
a subsequent increase in cGMP [Mellion eta!., 1983, Radomski ef a/., 1990a, b]. 
Therefore, the possibility that the protracted inhibition of aggregation by 
NO/H2O2 is mediated by enhanced formation of cGMP was investigated.
4.8.1 Does inhibition of platelets by nitric oxide and hydrogen peroxide 
involve enhanced cGMP formation?
NO, NO/H2O2 and H2O2 were added to WP under the same conditions as the 
aggregation experiments, and the cGMP concentrations measured by RIA (see 
section 2.9). The platelets were pre-incubated with IBMX for 30min prior to 
experimentation. cGMP concentrations in platelets incubated with buffer alone
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were |o.39 ± 0.07 pmol cGMP/1 x 10® platelets, and this was taken as the basal 
concentration of cGMP [Table 4.3]. NO (0.01 - IpM) induced a significant 
concentration-dependent increase in cGMP basal levels. The concentrations of 
cGMP induced by NO (IpM) was| 3.66 ±0.5pmol/1 x 10® platelets (p< 0.01) 
[Table 4.3].
Simultaneous addition of NO(IOnM) with HgOg (1 - 25pM) increased the 
concentrations of cGMP, and significantly increased the concentration of the 
cyclic nucleotide levels induced by NO(IOnM) alone. The effects of HgOg were 
concentration-dependent and were significant at all concentrations except the 
lowest, 1 pM. cGMP concentrations in platelets treated with NO/HgOg (25pM) was 
1.45 ± 0.21(p< 0.01) compared to 0.64 ± 0.06pmol for platelets treated with NO 
only. H2O2 (15 and 25pM) |elicited a 2-fold increase in intraplatelet cGMP levels 
The addition of HgOg alone appeared to cause only a slight increase in cGMP, 
but the effects were not significant [Table 4.3].
4.8.2 The influence of hydrogen peroxide on platelet Inhibition by dlbutryl- 
cGMP.
Dibuytryl cGMP (dB-cGMP) is a non-hydrolysable analogue of cGMP, which can 
enter cells. Once inside, the buytryl groups are cleaved and the cGMP becomes 
metabolically active. WP were incubated with dB-cGMP (0.001 - 5.0pM) for 
Imin prior to the addition of thrombin (0.02U/ml). Db-cGMP caused a 
concentration-dependent inhibition of the normal agonist induced response. The 
IC50 for dB-cGMP inhibition of thrombin-stimulated aggregation was 200 ± 50pM 
[Figure 4.11]. To replicate the conditions of the previous experiments examining 
the influence of HgOg on the inhibitory actions of NO, HgOg was added to WP
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NO or H2O2 cGMP
addition__________(mM)____________(pmols/ 1x10^ platelets)
control (buffer) 0.39 ± 0.07
NO 0.01 0.64 ± 0.06#
0.1 1.36 ±0.22#
1 3.66 ± 0.5#
H2O2 25 0.66 ±0.19
NO (0.01 pM)
/ H2O2 (pIVI) 1 0.69 ±0.11
5 0.79 ± 0.09
15 1.38 ±0.36
25 1.45 ±0.21**
Table 4.3; The effect of simultaneous addition of nitric oxide and hydrogen 
peroxide on guanylate cyclase activity in platelets.
NO alone, HgOg alone or NO in combination with HgOg were added to platelets, 
preincubated with IBMX (lOOpM), and left stirring for Imin before addition of 
cold perchloric acid (200pl, 0.5M). The samples were vortexed and stored at -70°C. On 
the day of the assay the samples were thawed and the acid neutralised using 
K2HPO4 (200pl, 1M). cGMP levels were measured by radioimmunoassay (see 
section 2.9). The data are representativeof 4 individual experiments and expressed 
as the mean ± SEM pmol cGMP/ 1x10® platelets. # p< 0.05, ** p< 0.01.
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Figure 4.11: The influence of hydrogen peroxide on platelet inhibition by 
dibutrylcGMP.
WP were preincubated with a range of concentrations of dBcGMP for 1 min 
before the addition of thrombin (0.02U/ml). The experiment were performed in 
the absence of HgOg (□), or with HgOg (20pM) added simultaneously with 
dBcGMP (■), or with HgOg added Imin after the thrombin (#). Total aggregation 
was measured 3min after the addition of the agonist. The data are presented as 
the percent inhibition of aggregation and are expressed as mean ± SEM of 3 
independent experiments. For statistical analysis refer to text {section 4.8.2).
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either simultaneously with dB-cGMP or 1 min after the addition of thrombin (2min 
after db-cGMP). Simultaneous application of dB-cGMP and HgOg resulted in a 
small, but significant increase in the effectiveness of db-cGMP [Figure 4.12]. The 
IC50 for dB-cGMP against thrombin-induced aggregation was reduced to 80 ± 
40pM (p< 0.05) in the presence of HgOg. Conversely, addition of the peroxide 
after db-cGMP resulted in a decrease in the effects of the platelet inibitor. These 
latter actions of HgOg were much more powerful than when it acted 
synergistically with db-cGMP, increasing the IC50 to 830 ± 130pM dB-cGMP (p< 
0.001) [Figure 4.11].
The enhancement of dB-cGMP mediated inhibition by HgOg was relatively small 
compared to the effects of the peroxide on the actions of NO. This suggests that 
the effects of H2O2 are not exerted downstream of the formation of cGMP. In 
contrast, addition of H2O2 after the platelet inhibitor, resulted in the antagonism 
of cGMP-mediated effects. These data corroborate the previous results which 
showed that H2O2 reduced the effectiveness of NO when added after the main 
agonist (see section 4.4.1).
4.9 INVESTIGATION OF POSSIBLE ARTIFACTS WHICH MAY AFFECT THE 
SYNERGISM BETWEEN OF NITRIC OXIDE AND HYDROGEN PEROXIDE.
In this section platelets were prepared by different methods than in previous 
sections to assess whether artifacts inherent in the methods were responsible 
for the novel effects observed with H2O2.
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(I) Comparison between platelets Isolated using prostacyclin and low pH.
Platelets isolated by the method of Vargas et s i, [1981], as used in this study, 
relied on a transient increase in intracellular cAMP, evoked by PGIg, to facilitate 
the isolation procedure. It is therefore possible that the effects of NO/HgOg 
reported in this chapter may have involved residual levels of PGIg-induced 
cAMP. This was investigated by direct comparison of the inhibitory actions of 
both NO and NO/H2O2 on autologous PGIg isolated platelets (WP-PGIg) and pH 
isolated platelets (WP-pH) {see section 2.6.3). In both preparations NO (0.001 - 
lOpM) induced concentration dependent inhibition of thrombin (0.02U/ml)- 
induced aggregation with little difference in the IC50. For WP-PGIg and WP-pH 
the IC50S were BOnM and 90nM NO respectively. Similarly inhibition of platelet 
activity induced by NO(10nM)/H2O2(25pM) were almost identical with both 
preparations, 80 and 84% inhibition for WP-PGIg and WP-pH respectively. This 
indicated that residual cAMP did not significantly influence the inhibition by 
NO/H2O2.
(II) Comparison of different platelet buffers.
WP used in this study were normally resuspended in a HEPES based buffer 
(see section 2.6.3). To investigate whether HEPES influenced inhibition of 
aggregation by NO or NO/H2O2, autologous platelets were resuspended in either 
Tyrode's HEPES based buffer or Tyrode's phosphate buffer (see section 2.3.2) 
and the inhibition by NO and NO/H2O2 were compared. NO induced a 
concentration-dependent inhibition of thrombin-stimulated aggregation in both 
WP preparations with little difference in their IC50. The IC50 for NO were 120 and 
130nM respectively. In addition, little difference was observed with inhibition of 
platelet aggregation induced by N0(1QnM)/H20g(25pM), 93 and 100%
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respectively.
(i) Oxyhaemoglobin as a possible contaminant of the platelet preparations.
NO is known to bind to OxyHb which leads to the inactivation of the inhibitor 
(see section 1.6.4.4). OxyHb is found in plasma and was thus a possible 
important contaminant of the WP preparations which could influence the 
inhibitory actions of NO and NO/HgOg. If oxyHb were present in the WP 
preparation, HgOg added with NO could oxidise OxyHb to MetHb, and thus 
prevent the inactivation of NO. The overall effect would suggest an apparent 
synergism.
In order to determine whether oxyHb influences the action of NO on platelet 
activity, WP were pre-washed with HgOg (15pM) (see section 2.6.3) and the 
effects of NO and NO/HgOg compared to WP prepared normally. No significant 
difference in IC50 for NO against thrombin (0.02U/ml)-induced aggregation was 
observed between WP (109 ± 16nM) and HgOg-washed WP (122 ± 13nM). 
Inhibition of platelet aggregation by NO(IOnM) /H202(25pM) was also unaffected 
by pre-washing with H2O2, 89.7 ± 6.4% and 86.0 ± 5.8%, for WP and H2O2- 
washed WP respectively. This demonstrates that oxyHb had little or no effect on 
the observed synergy.
4.10 THE INFLUENCE OF NITRIC OXIDE AND HYDROGEN PEROXIDE ON 
PLATELET AGGREGATION IN THE PRESENCE OF PLASMA.
4.10.1 Nitric oxide-mediated inhibition of collagen-induced platelet 
aggregation in PRP.
The efficiency of NO as an inhibitor of platelet aggregation was tested in the
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presence of plasma. NO solutions (0.01 - 20pM final concentrations) were added 
directly to PRP and incubated for Imin prior to addition of collagen (0.5pg/ml). 
At concentrations greater than lOnM, NO induced a concentration-dependent 
inhibition of platelet aggregation. The IC50 for NO was 826.7nM ± 291.4nM (p< 
0.005), and complete inhibition achieved with 16.7 ± 5.8pM NO (p< 0.01) 
[Figure 4.12]. Both the IC50 for NO and the concentration of NO required to 
completely inhibit collagen-induced platelet aggregation were significantly 
greater than those required to inhibit the aggregation of WP. The data 
demonstrate that increased concentrations of NO are required to inhibit platelet 
aggregation in the presence of plasma and suggests the plasma environment 
enhances the breakdown or sequestration of NO.
4.10.2 The effects of nitric oxide and hydrogen peroxide added 
simuitaneously on coilagen-induced platelet aggregation in PRP.
In a previous section of this chapter (section 4.5.1) HgOg was shown to enhance 
the inhibition of collagen-induced aggregation of WP. Here the effect of HgOg 
on inhibition of collagen-induced platelet aggregation by NO in the presence of 
plasma was examined. Simultaneous addition of NO (0 -1 pM) with HgOg (25pM) 
significantly increased the effectiveness of NO. The IC50 for NO against 
collagen-induced agrégation in the presence of HgOg was reduced to 149.3 ± 
66.5nM (p < 0.05). This concentration of NO was still much greater than the IC50 
found in similar experiments with WP (p< 0.001) [Figure 4.12]. These data 
suggest that the previously found synergy between NO and HgOg can occur in 
the presence of plasma.
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Figure 4.12: Inhibition of platelet aggregation by nitric oxide in the presence of 
plasma: the influence of hydrogen peroxide.
Platelet rich plasma were incubated with a range of concentrations of NO in the 
presence (#) or absence (O ) of HgOg (20pM,) for 1 minute before the addition 
collagen (0.5pg/ml). Total aggregation measured after 3min. In all cases the 
HgOg was added simultaneously with NO. The results are expressed as the 
percent inhibition of aggregation compared to collagen alone and represent 
means ± SEM of 3 independent experiments.
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4.11 S-NITROSOGLUTATHIONE AS AN INHIBITOR OF PLATELET 
AGGREGATION.
S-nitrosoglutathione (S-NOG) is a stable S-nitrosothioi which releases NO 
intracellularly, and inhibits agonist induced platelet aggregation by increases in 
intracellular cGMP concentration [Radomski et ai, 1992]. NO solutions may be 
come partially oxidised to nitrite (NO2") in the aggregation cuvette during the 
duration of the experiment, which would reduce efficiency of its biological 
effects. Release of NO from dissolved S-NOG is low, but enhanced by platelet 
lysate suggesting the release of NO may be mediated by an enzyme present in 
the platelet membrane [Radomski at ai, 1992]. The S-nitrosothiol was employed 
to investigate whether the antagonistic effects of HgOg were specific to the 
effects on exogenous NO solutions or a more general effect against cGMP- 
mediated inhibition. Evidence suggests that S-NOG was a more potent inhibitor 
of platelet aggregation in vitro than NO [Radomski at ai, 1987c], and this may 
relate to the enhanced release of NO by a factor associated with the platelet 
membrane. If NO is released from S-NOG close to the platelet membrane the 
possiblity of NO becoming oxidised before entry to the cell is reduced. Thus S- 
NOG provided a tool to investigate whether synergism between NO and HgOg 
occurred intra or extracellularly .
4.11.1 The effects of S-nitrosoglutathione on sub-maximal thrombin and 
collagen-induced aggregation.
S-NOG was incubated with WP for 1 min prior to addition of thrombin (0.02U/ml), 
which resulted in a concentration dependent inhibition of aggregation. The IC50 
for S-NOG was 19.3 ± 2.4nM and complete inhibition aginst thrombin-stimulated 
aggregation was achieved at 133.3 ± 47.1nM: both values were significantly (p<
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0.05) less than for NO solutions [Figure 4.13a, b]. When S-NOG was tested 
against collagen it was found to be more effective than against thrombin with an 
IC50 of 2.1 ± 0.8nM (p< 0.001). Reduced glutathione (0 - lOOnM) was used as 
a control for S-NOG, and had no effects on platelet aggregation.
4.11.2 S-nitrosoglutathione-induced inhibition of piateiet aggregation: 
effects of carboxy-PTIO.
In order to investigate whether S-NOG released appreciable amounts of NO 
extracellularly, its effects on platelet aggregation were assessed in the presence 
and absence of carboxy-PTIO (IpM). WP were incubated with carboxy-PTIO 
(1 pM) or Tyrode’s HEPES buffer (see section 2.3) for 1 min prior to the addition 
of SNOG (0 -1 pM). The presence of carboxy-PTIO had no significant effect on 
SNOG mediated inhibition of thrombin (0.02U/ml)-induced aggregation. The IC50 
for WP and carboxy-PTIO incubated WP were 24 and 26nM respectively. The 
experiments were performed twice with similar results obtained. These results 
are in contrast to those obtained when carboxy-PTIO was tested against 
authentic NO solutions, where substantial antagonism of NO-mediated inhibition 
was observed. These results indicated that S-NOG released NO intracellularly 
or close to the membrane where carboxy-PTIO had little access to NO. These 
results may indicate that the synergistic phenomenon observed between NO and 
H2O2 occurs intracellularly.
4.11.3 The effects of simuitaneous addition of S-nitrosoglutathione and 
hydrogen peroxide on piateiet aggregation.
S-NOG and h202were added simultaneously to WP in order to examine whether 
the synergism observed with NO/H2O2 could be reproduced with S-NOG.
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Simultaneous application of S-NOG (0 - 10nM) and HgOg (25pM) to platelets 
1min prior to the addition of thrombin (0.02U/ml), resulted in a concentration- 
dependent inhibition of aggregation. The IC50 for S-NOG added with HgOg was 
0.71 ± 0.21 nM, significantly lower than that for S-NOG alone (p< 0.001). This 
represented a 25-fold increase in the effectiveness of S-NOG as an inhibitor. 
Complete inhibition of thrombin-stimulated aggregation was achieved with S- 
NOG 16.7 ± 4.7nM (p< 0.05), significantly less than with S-NOG alone [Figure 
4.13a, b]. When glutathione (0 - lOOnM), used as a control for S-NOG, was 
added in combination with HgOg the aggregation response was unaltered. The 
results indicated that the proposed synergistic actions may occur intracellularly.
When the experiments were repeated with a fixed concentration of S-NOG 
(lOnM) and HgOg (0 -20pMI) produced an inhibition which was concentration 
dependent for HgOg. S-NOG/HgOg (20pM) induced 95.2 ± 2.1% inhibition. The 
ICsofor H2O2 was 2.7 ± 0.3pM, significantly (p< 0.01 ) greater than the EC50 with 
NO (1.6 ± 0.5pM) [Figure 4.14].
4.11.4 The effects of S-nitrosoglutathione on coiiagen-induced 
aggregation in PRP.
Incubation of S-NOG (0 - 5pM) with PRP for 1 min prior to addition of collagen 
(0.5pg/ml) produced a concentration-dependent inhibition of the normal 
aggregation response. The IC50 for S-NOG was 476 ± 162nM and complete 
inhibition was achieved with 2.5 ± 1.5pM S-NOG [Figure 4.15].
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Figure 4.13a: Hydrogen peroxide enhances the inhibition of platelet aggregation 
by s-nitrosoglutathione.
WP were incubated with thrombin (0.02U/ml) alone or, pre-incubated with S- 
NOG (1 OnM) prior to addition of thrombin. In the third trace S-NOG as added 
simultaneously with H2O2 (20pM) and incubated for 1 minute before the addition 
of thrombin. T represents the addition of thrombin, while H and S represent the 
addition of HgOg and/or S-NOG. The results are typical traces of at least 5 
independent experiments.
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Figure 4.13b: Hydrogen peroxide enhances the inhibition of platelet aggregation 
by S-nitrosoglutathione.
The effect of HgOg on platelet inhibition by S-NOG was invetsigated. WP were 
princubated with S-NOG (0 - IpM) before the addition of thrombin (0.02U/ml), 
either in the presence (O) or absence ( • )  of HgOg, and aggregation measured 
after 3min. The data are presented as the percent inhibition of aggregation and 
are expressed as mean ± SEM of 5 independent experiments. For statistical 
analysis refer to text {section 4.11.1).
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Figure 4.14: Concentration response relationship between hydrogen peroxide 
and S-nitrosoglutathione on platelet aggregation stimulated by thrombin.
S-NOG and H2O2 were added to WP 1min before the addition of thrombin 
(0.02U/ml) and aggregation was measured 3min later. A single concentration of 
S-NOG (1QnM) was used in combination with a range of concentrations of HgOg 
(□). In control experiments HgOg which had previously been exposed to air for 
24h were used (■). The results are expressed as the percent inhibition of 
aggregation and represent the mean ± SEM of 4 independent experiments, 
using inactive HgOg the experiment was performed twice For statistical analysis 
refer to text (see section 4.11.3).
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S-NOG (0 - 5|jM) and HgOg (25|jM) were applied simultaneously to platelets to 
determine whether the synergism between the two inhibitors also occurred in 
plasma. The presence of H2O2 significantly enhanced the inhibitory effect of S- 
NOG on platelet activity. The ICgofor S-NOG was reduced to 32 ± 9nM from 476 
± 162nM (p< 0.05). Complete inhibition was also significantly reduced, 0.33 ± 
0.18nM (p< 0.05) [Figure 4.15]. The synergism between S-NOG and HgOg to 
inhibit platelet aggregation may imply that similar phenomenon could occur with 
other nitrosothiols. This could have wider biological implications, as nitrosothiols 
such as S-nitrosoalbumin are known to occur in plasma [Stamler at a/., 1992].
4.11.5 The influence of radical scavengers on S-nltrosoglutathione and, S- 
nitrosoglutathione and hydrogen peroxide induced inhibition of plateiets.
The influence of sodium urate (0.5mM) and mannitol (50mM) on the actions of 
S-NOG and S-NOG/HgOg was assessed to examine the possible influence of 
other radicals. Pre-incubation of the free radical scavengers with WP for Imin 
had no effect on the inhibition of platelet aggregation by S-NOG or S-NOG/HgOg. 
However, if urate or mannitol were incubated with platelets for 30min prior to 
addition S-NOG/HgOg the subsequent inhibition of thrombin-induced aggregation 
was attenuated slightly. The level of inhibition was reduced from 94 ± 6% in the 
presence of the scavengers to 75.9 ± 4.0 % and 80 ± 3.3%, for urate and 
mannitol respectively.
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Figure 4.15: Inhibition of piateiet aggregation by S-nitrosoglutathione in the 
presence of plasma: the influence of hydrogen peroxide.
Platelet rich plasma was incubated with a range of concentrations of S-NOG in 
the presence (■) or absence (□) of H2O2 (20pM,) for 1 minute before the 
addition collagen (0.5pg/ml). Total aggregation was measured after 3min. In all 
cases the H2O2 was added simultaneously with S-NOG. The results are 
expressed as the percent inhibition of aggregation compared to collagen alone 
and represent means ± SEM of 4 independent experiments. For statistical 
analysis refer to text (see section 4.11.4)
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4.12 THE IMPORTANCE OF TIME INTERVALS SEPARATING THE ADDITION 
OF S-NITROSOGLUTATHIONE OR NITRIC OXIDE AND HYDROGEN 
PEROXIDE ON THE INHIBITION OF PLATELET AGGREGATION.
In order to establish whether simultaneous addition of NO or S-NOG and HgOg 
was essential for the synergistic inhibition of platelet activity to occur, HgOg was 
added upto 1min after or 1min before S-NOG/NO. In all cases the time interval 
between S-NOG/NO and thrombin (0.02U/ml) was 1min, so that in some 
experiments HgOg was added immediately before the agonist. Simultaneous 
addition of S-NOG/HgOg induced 92.2 ± 2.1% inhibition of aggregation. 
However, if HgOg was added before S-NOG a reduction in the level of inhibition 
was observed [Figure 4.16a]. Incubation of HgOg with WP for Imin prior to S- 
NOG induced 61.1± 6% (p<0.01) inhibition, while at 30s before the inhibition 
was 72.2 ± 1.1% (p<0.01), both significantly less than when added 
simultaneously. If HgOg was added after S-NOG for up to one minute, no 
significant change in the level of inhibition was observed [Figure 4.16aJ. When 
these experiments were repeated with NO, the effect of separation of addition 
of NO and HgOg was greater, with a clear optimal synergism when the two were 
added simultaneously. However, the enhanced inhibitions were still observable 
at all the time intervals studied. This indicates that the key manipulation is the 
addition of NO and HgOg before the agonist and that the effects are not totally 
dependent on the simultaneous addition of these agents.
Cyclic GMP concentrations were measured in platelets where NO and HgOg had 
been added simultaneously or at intervals up to 1 minute apart.
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Figure 4.16: The effect of separating the addition of s-nitrosoglutathione or nitric 
oxide and hydrogen peroxide on the inhibition of platelet aggregation.
a) HgOg (20pM) was added WP up to 1 minute before or 1 minute after S-NOG or 
NO (10nM). In all cases WP were stimulated with thrombin (0.02U/ml) 1 minute 
after the addition of S-NOG (O) or NO (#), so in some cases HgOg was added 
immediately before the agonist and aggregation measured after 3 minutes. The 
results are expressed as % inhibition of aggregation compared to thrombin alone 
and are representative of at least 3 individual experiments.
b) The experiments were performed as in a., except that an excess of cold HCI 
was added instead of thrombin and platelet cGMP measured by 
radioimmunoassay.
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In all cases the presence of HgOg significantly increased the rate of cGMP 
formation compared to that with NO alone. A greater variation in the inhibition 
of aggregation had been found with NO than if S-NOG was used (see above). 
The extent of the inhibition of aggregation was parallelled to a significant degree 
by variations in the concentrations of cyclic GMP [Figure 4.16b], in that the 
relative increase in the rate of cGMP formation was greater at reduced time 
intervals, indicating the importance of the role of this nucleotide in the 
interactions of HgOg and NO.
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4.13 DISCUSSION.
In chapter three of this thesis mmLDL were shown to activate platelets, an action 
which was proposed to be mediated by the presence of low concentrations of 
LPO. The effects of peroxides on platelet aggregation and platelet inhibition by 
NO, were first investigated by assessing the influence of H2O2 This simple 
peroxide induced opposing effects on platelet function which were dependent 
on the order in which it was presented to the platelets relative to the main 
agonist.
4.13.1 The pro-aggregatory effects of hydrogen peroxide.
H2O2 was added directly to platelets and found to induce small amounts of 
primary aggregation. This contrasted with previous studies where aggregation 
in the absence of agonists was not observed [Canoso et a/., 1974; Pratico at a/., 
1992; luliano at a/., 1992]. The aggregation traces were not conventional in 
appearance, and may be due to fusion of platelets in the presence of H2O2, as 
observed by Rodvein at a/., [1976]. When tested in combination with sub­
threshold concentrations of thrombin or collagen, H2O2 enhanced the 
aggregation response to initiate secondary aggregation. However this was only 
observed if the peroxide was added after the agonist. This phenomenon was 
also reported by other workers [Canoso at a/., 1974; Rodvein at al., 1976; 
Pratico at al., 1992; luliano at al., 1992]. The potentiation of aggregation was 
cyclo-oxygenase mediated, since pre-incubation of platelets with aspirin, 
abolished the action of the peroxide. Previous work has also implicated the 
involvement of cyclo-oxygenase in the actions of H2O2 [Del Principe at al., 1985, 
Pratico at a/., 1992, luliano at a/., 1992], although the effects seemed to be 
dependent on which agonist was used. Pratico at a/., [1992] found H2O2 to
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potentiate aggregation by collagen and AA, but not thrombin, whereas in the 
present study enhancement of aggregation was demonstrated with both collagen 
and thrombin, but not ADP. One possible explanation for this apparent anomaly 
is the concentration of peroxide used. The optimal HgOg concentrations for 
potentiation of collagen and thrombin-induced aggregation were 5 and 25pM 
respectively. In the previous study by Pratico et a/., [1992] the maximum 
concentration of peroxide used was 7.5pM, indicating that potentiation of 
thrombin-induced aggregation may have not occurred, because the amount of 
peroxide provided was not sufficient to induce the effect. Nanomolar quantities 
of HgOg are generated by resting platelets, which is significantly increased after 
stimulation with either thrombin or AA [Maresca at al., 1992]. HgOg has been 
shown to increase entry in both platelets [Del Principe at a/., 1985, Pratico 
ate!., 1992] and endothelial cells [Kimura at a!., 1992]. In platelets the increase 
in [Ca^ "^ ]j may activatePLAg, inducing the release of AA and its subsequent 
metabolism by cyclo-oxygenase. The increase in [Ca^ ""]; associated with these 
agonists was further enhanced by inhibition of GSH Px, but not catalase, 
suggesting that GSH Px is the dominant enzyme for HgOg degradation in 
platelets [Maresca at a!., 1992]. The peroxide has also been proposed to be an 
intermediate in the platelet activation cascade. HgOg is produced after 
stimulation with collagen, but not thrombin [Del Principe at al., 1985]. However, 
in a separate study HgOg was shown to be a poor activator of cyclo-oxygenase 
compared to other longer chain peroxides found in the platelet [Hemler at al., 
1979].,
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4.13.2. The influence of hydrogen peroxide on nitric oxide-mediated 
inhibition of piateiet aggregation.
NO inhibited both thrombin and collagen-induced aggregation in a concentration 
dependent manner: | the IC5 0  values for NO against both agonists were at 
concentrations found physiologically [Gross and Wolin, 1995]. NO was more 
potent against collagen than thrombin, but this may be an additive effect due to 
the production of endogenous NO. Platelet aggregation by collagen, but not 
thrombin, has been associated with the endogenous production of NO 
[Radomski et al., 1990]. NO was also shown to inhibit collagen induced 
aggregation in PRP although greater concentrations were required, probably 
because of increased breakdown or complexing of NO by factors such as oxyHb.
The activatory effects of HgOg on platelets were tested against the inhibitory 
actions of NO. HgOg antagonised the effects of NO, when it was added after the 
agonist. This suggested that the combined effects of the peroxide and thrombin 
were sufficiently potent to override the effects of NO which include, 
sequestration of Ca^ "", decreased p47 phosphorylation and 5-HT secretion 
[Nguyen at al., 1991]. This latter study also demonstrated NO was unable to 
inhibit aggregation induced by Ca^ "" ionophore A23187 and in some cases even 
enhanced the aggregatory response. Recently Okamoto et al., [1995], showed 
Ca^ "" influx induced by thrombin to have partial resistance to the inhibitory 
actions of NO. Thus, it is possible to speculate that an increased Ca^ '" influx, 
associated with HgOg [Del Principe at al., 1985, Pratico at al., 1992] may not 
only enhance thrombin-induced aggregation, but also alter the actions of NO. 
The results were very similar when collagen was used to stimulate platelets, 
although HgOg was less effective, probably because of the additional formation
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of endogenous NO by platelets activated by collagen. HgOg is produced by the 
endothelium and activated PMNs [Test and Wiess, 1984], both of which are 
involved in the pathogenesis of atherosclerosis and are in close contact with 
platelets throughout the circulation. The data presented here suggest, at first 
sight, that the metabolic production of HgOg seems to be a potentially important 
pro-thrombotic factor. In these particular experiments HgOg was added to the 
platelets 2min after NO. Since the rate of formation of cGMP occurs very rapidly 
after addition of NO in vitro [ Salvemini et al., 1990; Nguyen at al., 1991], the 
peroxide was added to platelets with elevated intracellular cGMP 
concentrations. Thus, it was unclear whether the antagonism of NO by HgOg was 
due to (in influence on cGMP breakdown or a consequence of a direct 
interaction between NO and H202,This required further investigation.
4.13.3 The effects of nitric oxide and hydrogen peroxide on piateiet 
aggregation when added simultaneously.
In complete contrast to previous experiments, simultaneous addition of NO and 
H2O2, added before the agonist, led to a protracted inhibition of aggregation, 
which reduced the IC50 for NO by almost two orders of magnitude. Potent 
inhibitory actions for NO in the presence of H2O2 were found with concentrations 
as low as InM. In addition, the effect of H2O2 was half maximal at 1.6pM, well 
within the concentration ranges found physiologically [Test and Wiess, 1984]. 
This appears to contradict the idea that H2O2 as a ROS is pro-thrombotic. Three 
possibilities existed for these unexpected observations, a) the effects of 
NO/H2O2 were cytotoxic, b) the effects were due to formation of a new radical 
species possibly peroxynitrite, or c) an authentic synergism occurred between 
the two species.
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In order to investigate the cytotoxicity, the actions of NO/HgOg were assessed 
as a function of time. The presence of HgOg significantly enhanced and 
prolonged the effects of NO, but importantly 1h after the addition of NO/H2O2 the 
platelets completely recovered their response to thrombin. This indicated that 
the reactants had no effect on the functional viability of the cells. In addition, 
inactive solutions of both NO and HgOg failed to induce inhibition, indicating that 
possible contaminants of the solutions were not responsible for the observed 
effects.
Inhibition was not due to the formation of peroxynitrite, the IC50 for this oxidant 
was approximately 5000 times greater than NO/HgOg. In fact peroxynitrite was 
a less effective platelet inhibitor than authentic NO. Moro et a/., [1994] showed 
that peroxynitrite activated washed platelets, however the effects were modest 
even at 200pM, a concentration of peroxynitrite which platelets are unlikely to 
encounter in vivo. The authors also showed the oxidant to be inhibitory to 
platelets in the presence of plasma, but the IC50 was 30 times greater than 
observed here. Methodological differences may account for these disparities. In 
the present study, peroxynitrite was only tested in isolated platelets, whereas 
plasma would accelerate its decomposition. In addition, Moro at a!., [1994] used 
greater concentrations of agonist than the present study.
The inhibition by NO/HgOg could be due to formation of a new molecular species 
different from that of NO. This concept was strengthened when it was found that 
premixing NO/HgOg prior to addition to platelets, led to the mixtures being 
effective 3 times longer than NO alone. NO and HgOg were believed to form 
singlet oxygen (Og), as measured by chemiluminescence [Noronha-Dutra at a/..
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1992] However, the half-life was less than Isec, while the half-life of the 
inhibition in this study was over 30s, much greater than the half-life of most free 
radicals. To investigate whether the formation of a new species was important 
, an NO séquestrant was used. Carboxy-PTIO reacts stoichiometrically with NO 
(NO/C-PTIO = 1), antagonising the biological actions of NO [Akaike et al., 1994]. 
In the present study carboxy -PTIO did not react 1:1, but had to be used in 10- 
fold excess, where it induced complete inhibition of the effects of NO. 
Importantly, when carboxy-PTIO was added simultaneously with NO/HgOg, which 
had been premixed for 10s, there was an attenuation of their inhibitory actions. 
In the presence of carboxy-PTIO, inhibition was reduced to 24% from a control 
value of 94%, indicating that NO was of key importance to the effects. However, 
the remaining inhibition left a possibility of other radicals still being involved. The 
results suggest that the protracted effects are probably due to a synergism and 
an increased sensitivity of platelets to residual NO in the presence of HgOg.
The loss of NO by auto-oxidation is represented by the following equation:-
2N0 + 02-^  2N0z
The reaction involves 2 molecules of NO and 1 molecule of Og, and thus the 
reaction rate falls exponentially as the NO concentration falls linearly [Gross and 
Wolin, 1995]. This would suggest that NO at low concentrations in buffer would 
be fairly stable and not disappear within seconds. The rate constant for this 
reaction is 1000 times greater in aqueous solution than in air [Kharitonov at a/., 
1994]. With solutions of NO (lOOnM) and Og (230pM; approximate concentration 
found in buffer), the half life of NO by auto-oxidation would be approximately two
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hours [Kharitonov et al., 1994]. From these studies, one could predict that 
concentration of NO would fall relatively slowly, although it may be accelerated 
by the continual stirring and incubation at 37°C. Hence, inhibition still occurring 
after 30s would probably be due to HgOg, which may increase the sensitivity of 
platelets to the residual concentrations of NO, which alone would not normally 
affect platelet aggregation. It is proposed that the increased levels of inhibition 
observed with mixtures of NO and HgOg are due to an authentic synergism.
4.13.3. The possible mechanism of the proposed synergy between nitric 
oxide and hydrogen peroxide.
In order to establish a mechanism by which the synergy occurred, the effects of 
various radical scavengers, enzymes and NO quenchers were tested on the 
action of NO/HgOg. Carboxy-PTIO, an NO séquestrant, inhibited the actions of 
NO/HgOg but not completely, which indicated that other radicals may play a role. 
The attenuation of the inhibition by hydroxyl radical scavengers, mannitol and 
urate, indicated that another radical species may be involved. However, the 
inhibition was not influenced by DTPA, a transitional metal chelator. This 
demonstrated that "OH radicals, produced by the Fenton reaction and requiring 
Fe^  ^ions, were not responsible for the protracted inhibition. This is particularly 
important as "OH is a proposed activator of guanylate cyclase [Schmidt, 1992]. 
SOD and ascorbate, both free radical scavengers had no effect, however 
catalase did reduce the inhibition, presumably by decreasing the concentration 
of HgOg. None of the above affected the inhibition of platelet aggregation by NO 
alone and therefore the effects of the scavengers only occurred on the synergy 
between NO and HgOg.
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To investigate the location of the apparent synergism, the stable S-nitrosothiol, 
S-NOG, was used. Nitrosothiols are becoming increasingly important not only 
as tools for NO research, but also as possible carriers for NO in vivo. S- 
nitrosothiols were thought to occur via a direct interaction between NO and free 
sulphydryl groups [Stamler eta!., 1992]. However, it has been suggested that 
peroxynitrite is a more potent nitrosating agent [Beckman eta!., 1992]. Platelet 
inhibition by peroxynitrite was proposed to occur by nitration of GSH and 
subsequent release of NO [Moro et a/., 1994]. If nitrosylation by peroxynitrite 
does occur physiologically, it may serve two functions. Firstly, it may protect 
against possible oxidative damage by peroxynitrite, and secondly, to act as a 
mechanism to recycle NO and thereby preventing wastage. The addition of S- 
NOG to platelets induced inhibition of both thrombin and collagen-induced 
aggregation, in all cases it was found to be a more potent platelet antagonist 
than NO, a phenomenon already recognised by Radomski at a/., [1987c]. The 
increased potency of S-NOG may be due to its intracellular release of NO. 
Radomski at a/., [1992] demonstrated that release of NO from S-NOG was 
enhanced by platelet lysate, but not whole platelets suggesting enzymatic 
release at membrane level. Recently Freedman at al., [1995], showed that GSH 
Px could enhance the release of NO from S-NOG, implicating GSH Px as a 
possible mediator of S-NOG induced actions. In the present studies, when the 
inhibitory actions of S-NOG were tested in the presence of carboxy-PTIO, no 
attenuation of inhibition was observed. This is in complete contrast to NO, and 
strongly suggests that NO is released from S-NOG intracellularly or close to the 
platelet membrane where the quencher would have limited access, thus 
providing a tool to assess the location of the apparent synergism.
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The intracellular release of NO. may account for the increased potency of S- 
NOG in comparison to NO. Authentic NO if added exogenously, may undergo 
partial oxidation before entering the platelet. Radomski et al., [1992], found an 
increase in cAMP associated with platelet inhibition by S-NOG. However cAMP 
did not significantly increase until concentrations of at least SOOnM S-NOG were 
used, and therefore, this would have little bearing on the results presented here 
where a much lower concentration was used. When S-NOG was tested in 
combination with HgOg, the inhibitory actions were significantly increased, but 
to a slightly lesser extent than with authentic NO. However, inhibition was 
observed at less than InM S-NOG, one order of magnitude lower than the 
concentration of nitrosothiols quoted to be found in plasma [Stamler at a/., 1992]. 
Mannitol and urate, as with NO/HgOg, were shown to attenuate inhibition by S- 
NOG and HgOg, however a 30min incubation of the scavengers with platelets 
was required before they had an effect. Platelets are strongly pinocytotic and 
over this time period they may accumulate mannitol/urate in intracellular 
vacuoles, where they may have partial access to S-NOG/HgOg. This is in 
contrast to NO/HgOg where the effects of the scavengers occurred more rapidly. 
When the effects of both NO and S-NOG were tested in the presence of plasma 
both of them inhibited aggregation, but greater concentrations of these 
antagonists were required. This is probably due to their increased breakdown 
in the presence of plasma factors. In the case of NO one such inhibitor would be 
maybe oxyHb, while a study by Freedman at a/., [1995] suggested that the 
concentration of S-NOG would be affected by plasma glutathione peroxidase 
(GSH Px). GSH Px was reported to increase the inhibitory actions of S-NOG on 
platelet aggregation. The authors suggested that GSH Px increased the 
availability of NO from S-NOG or converted it into a from that could more readily
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interact with platelets. In the presence of HgOg, the concentrations of NO and S- 
NOG required to induce inhibition were reduced. The results produced using S- 
NOG suggest that the synergy may occur intracellularly and importantly the 
occurrence of the synergy in the presence of plasma suggests the phenomena 
may be of physiological importance. It also indicates that synergism may occur 
between HgOg and other nitrosothiols such and S-nitrosoalbumin and S- 
nitrosocysteine.
4.13.3.1 Does the order of addition of hydrogen peroxide relative to the 
agonist affect platelet function?
The effects of HgOg on platelet function have been studied many times with 
contradictory results: presumably many of these discrepancies are due to 
methodological differences. HgOg has been shown to activate platelets 
[Patscheke, 1977; Del Principe et ai, 1985; Pratico et ai, 1992; luliano et ai,
1992], in all these studies washed or gel filtered platelets were used. When HgOg 
was tested in PRP it failed to activate platelets [Salvemini et ai, 1991 ; Ambrosia 
et ai, 1994], which suggested that the activatory effects of HgOg may not be that 
important physiologically. Other investigators have shown H2O2 to inhibit platelet 
aggregation [Canoso et ai, 1974; Rod vein et ai, 1976; Holmsen and Robkin, 
1977; Ambrosia et ai, 1994]. The study by Holmsen and Robkin, [1976], 
proposed that exposure of platelets to HgO 2 leads to changes in energy 
metabolism. H2O2 induced a rapid depletion of platelet ATP levels, albeit at 
concentrations greater than used here, which had little effect on aggregation 
until the energy charge was reduced. However minor changes did occur at 
concentrations of H2O2 relevant to this work, and may be interesting to speculate 
that NO could enhance these action of H2O2 Obvious differences such as H2O2
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concentrations and whether HgOg was added as a bolus or via a generating 
system would account for some of these inconsistencies. However, what seems 
to be the most important factor is the order in which the peroxide is presented 
to the platelets relative to the agonist. Generally it seems that addition of H2O2 
before the agonist leads to platelet inhibition, while addition of H2O2 after the 
agonist results in the activation of platelets. This] phenomenon was recognised by 
Canoso et al., [1974] and largely ignored, but was confirmed by the data 
presented here.
4.13.3.2 The effects of nitric oxide and hydrogen peroxide on cGMP.
NO exerts its biological actions by entering platelet and stimulating the formation 
of cGMP, this leads to a number of intracellular events the most important of 
which is the increased sequestration of Ca^ '" [Haynes, 1993]. In the present 
study NO induced a concentration dependent increase in cGMP formation, 
which in the presence of H2O2 was significantly enhanced, even though 4  Q 
alone did not increase cGMP. This suggested the potent inhibition by NO/H2O2 
was a cGMP mediated effect. However, an anomaly within the data became 
apparent. The presence of H2O2 increased the effects of NO (lOnM) so that it 
produced cGMP concentrations equivalent to that produced by lOOnM NO 
alone. This concentration of NO however, only produced approximately 50-60% 
inhibition, while the NO/H2O2 mixture almost completely inhibited the platelets. 
This indicated that an additional mechanism to the increased cGMP formation 
may be responsible for the potent inhibitory actions of the mixtures. The 
peroxide was tested in combination with dBcGMP, which also inhibits platelets. 
Here, H2O2 enhanced the inhibition induced by dBcGMP, but the effect was 
modest in comparison to the enhancement of NO/S-NOG mediated inhibition by
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HgOg. The results suggest that HgOg may have the ability to enhance the actions 
of the cyclic nucleotide, but its major action is prior to cGMP formation. 
Interestingly, when HgOg was added after the agonist it antagonised the action 
of dBcGMP, the magnitude of this effect was far greater than the complementary 
effects on cGMP and fits well with the earlier data showing the diminution of NO 
mediated effects by H2O2 when added after the agonist.
When the addition of NO and HgOg was separated by up to 1 min, the level of 
inhibition was altered. The data showed substantial, but reduced, inhibition if the 
additions were separated. In all cases when NO and HgOg were added before 
the agonist the inhibitions were greater than those of NO alone. The 
inhibition was greatest when the two reagents were added simultaneously. The 
results were slightly different with S-NOG, in that inhibition was reduced if HgOg 
was added first: but remained constant if S-NOG was added first, with NO all 
inhibitions were reduced if the two reagents were not added simultaneously. 
These inconsistencies probably represent difference in how the NO is presented 
to the platelets. In the case of S-NOG, not all the NO is probably released 
immediately, allowing longer exposure of the cell to NO. This may account for 
the increased longevity of the synergy. The reduced inhibition observed if HgOg 
is added prior to NO/S-NOG possibly relates to loss of active HgOg by 
evaporation or enzymatic decomposition,
cGMP concentrations rise very rapidly after addition of NO and are maintained 
for several minutes [Salvemini et a/., 1990; Nguyen at a/., 1991]. When the 
addition of NO and HgOg were separated there were variations in the level of 
cGMP formation. The presence of HgOg again increased the cGMP levels
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induced by NO compared to NO alone, but the greater the time interval between 
NO and HgOg the lower the concentration of cGMP formed. MO/H^Oz added 
simultaneously induced almost complete inhibition, without reaching maximal 
cGMP concentrations (those levels produced by concentrations of NO which 
induce complete inhibition alone). This again gives credence to the possibility 
of that there may be another mechanism operating alongside the increased 
formation of cGMP. In these studies it is clear that HgOg has no direct effects on 
guanylate cyclase, since alone it did not raise cGMP concentrations. In addition 
the peroxide has no effect on the activity of purified soluble guanylate cyclase 
[Mayer, personal communication]. Schmidt, [1992] showed that HgOg had no 
direct effect on soluble guanylate cyclase, which is in agreement with data 
presented here. However, a recent study by Ambrosio et a/., [1994], suggests 
that HgOg may be an activator of guanylate cyclase. These workers presented 
evidence showing that HgOg induced inhibition of platelet aggregation which was 
associated with a 10-fold increase in cGMP above basal levels. The inhibition 
was totally cGMP dependent, as the inhibition was prevented if methylene blue, 
a guanylate cyclase inhibitor, was added. The action of HgOg on cGMP mediated 
inhibition seem surprising initially, however other studies have also recognised 
a similar phenomenoruHgOz was shown to elicit the relaxation of isolated 
pulmonary arteries by a mechanism which was associated with increases in 
cGMP [Burke-Wolin et a/., 1987]. The mechanism of these effects seems very 
complex, but it is thought to involve catalase and higher oxidation state of Fe. 
Wolin and Burke, [1987] demonstrated that activation of purified guanylate 
cyclase by HgOg was dependent on the presence of catalase, and that cGMP 
formation was intimately related to the production of catalase-compound I. 
Compound I intermediates are thought to be formed during the interaction of
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peroxides with Fe (III). Here the redox reaction involves Fe(lll) derivatives which 
are formally Fe(V). The general equation is given as:
Fe(lll) + HOOH -> Fe(V) + HgO
Therefore, the compound I intermediates store the oxidising potential of the 
peroxide [Jones, 1989]. It is possible that compound I intermediates act as a 
radical species, allowing it to interact with the haem centre of guanylate cyclase. 
Whether HgOg can activate guanylate cyclase is open to debate, in this study 
HgOg did cause a slight increase in cGMP, but this was not significant.
It is likely that the mechanism of the inhibitory effects of HgOg observed by 
Ambrosio et al., [1994] and other workers may be very closely linked to the 
results presented in this study. Neither Ambrosio et a!., [1994], Canoso at a!., 
[1974] nor Rodvein at a!., [1976], tested the effects of HgOg against thrombin 
stimulated platelets, which could be of fundamental importance of the 
interpretation of their results. Thrombin-induced platelet aggregation occurs 
without a significant increase in the action of endogenous NOS and production 
of NO [Radomski at a!., 1990a, b]. The previously cited studies used collagen 
and/or ADP, both of which induce the production of NO during aggregation. It 
is possible that the inhibitory actions are due to synergy between endogenously 
produced NO and exogenously added/generated HgOg in the fashion previously 
described. The levels of inhibition cited in previous studies are lower than 
described here, but separation of their presentation to the platelets may account 
for this. The inhibitions were in the order of 40 - 50%, which is similar to the level 
of inhibition found in section 4.12, when the addition of NO and HgOg were
220
separated by 1min. A related mechanism has also been shown to occur in 
arterial relaxation. Zembowicz et al., [1993], showed HgOg to induce a 
concentration dependent increase in relaxation of rabbit aorta: the effect was 2-3 
fold greater if the endothelium was still present and was inhibited by the 
presence of NOS inhibitors. This strongly suggested that H2O2 induced the 
activation of NOS. It is possible that HgOg increases NOS activity in platelets, but 
it is unlikely that this accounts for the results in the present study. Mai inski et a/., 
[1993], demonstrated that platelets could produce 10-20nM NO during collagen- 
induced aggregation. However, this concentration of NO could not account for 
the almost complete inhibition of aggregation: NO alone is unable to achieve this 
in vitro at concentrations less than 1 pM. Although 50% inhibition was achievable 
at 80nM, and in the presence of HgOg this concentration of NO (10-20nM) may 
be adequate to induce inhibition.
In conclusion, HgOg has been shown both to enhance and to diminish the actions 
of NO. The most interesting aspect is the possible synergy leading to the 
potentiation of the inhibition of aggregation by NO. This may to occur 
intracellularly and is associated, at least in part, by increased cGMP formation. 
Implicitly, this would suggest that formation of HgOg from Q i" by SOD on 
endothelial cells, may not only be a mechanism for preventing the formation of 
peroxynitrite, but could have a positive role in prolonging and intensifying the 
anti-aggregatory actions of NO. A recent study has shown that NO can 
reversibly inhibit the activity of both purified and intracellular GSM Px, leading 
to an increase in intracellular peroxide concentration [Asahi et a!., 1995]. It is 
interesting to speculate that NO itself may be able to regulate the intracellular 
levels of H2O2, and thus favour a potential synergism. In relation to the previous
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observation, Leoncini, [1994], found that inhibition platelet GSH Px with N- 
ethylmaleimide, led to an increase in intracellular HgOg concentration and a 
concomitant decrease in platelet aggregation, suggesting an inhibitory role for 
the peroxide.The concept of a ROS acting as |a positive secondary messenger, 
is idiosyncratic, as ROS have been generally viewed as toxic and potentially 
damaging to normal homeostasis. However, brain NOS has been reported to 
produce HgOg at low L-arg concentrations [Heizel et al., 1993], which may be a 
compensatory mechanism to enhance the effect of reduced NO formation. In 
addition, the endogenously produced NO and HgOg may synergise to control 
platelet function.
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CHAPTER FIVE: THE INFLUENCE OF LOW DENSITY LIPOPROTEINS AND 
LIPID PEROXIDES ON PLATELET SENSITIVITY TO NITRIC OXIDE
5.1 INTRODUCTION.
Lipid hydroperoxides are formed by the peroxidation of unsaturated fatty acid 
side chains of both phospholipids and cholesteryl esters (see section 1.3.1). In 
recent years, evidence has accumulated linking increased plasma 
concentrations of lipid hydroperoxides (LPO) to various disease states. Plasma 
or serum LPO levels have been found to be increased in diabetes [Sato at a/., 
1979], hyperlipidaemia [Loeber ef a/., 1983], hypertension [Uysal etal., 1986] 
and atherosclerosis [Stringer at a!., 1989]. The involvement of LPO in 
atherosclerosis was first demonstrated by Glavind at a/., [1952], who showed 
the presence of LPO in human atherosclerotic plaques. A subsequent study by 
Harland at a/., [1973] demonstrated that the severity of aortic atherosclerosis 
was strongly correlated with the concentration of LPO in the arterial wall. The 
possible importance of LPO in the atherosclerotic process has become more 
topical since it was postulated that LDL undergo post-secretory oxidative 
modification, which contributes heavily to the pathogenesis of the disease 
[Steinberg at a/., 1989]. Nishigaki at a/., [1981] analysed the LPO content of 
serum lipoproteins and found VLDL, LDL and HDL were all vehicles for LPO, but 
the most prominent was LDL.
The direct effects of LPO on the development of atherosclerosis was 
investigated by Yagi at a/., [1982]. Linoleic hydroperoxide was injected into 
rabbit ears and the serum LPO levels measured. After injection, the serum LPO 
levels were raised, but more importantly scanning electron microscopy revealed 
that the aortic endothelium had undergone morphological changes which were
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similar to those observed in the early stages of atherosclerosis. The half life of 
the injection was approximately 50min, indicating that only short term exposure 
of the vasculature to LPO may induce physiological alteration of the 
endothelium.
Elevated LPO levels have been proposed to be causative factors for the 
induction of atherosclerosis. Three possible mechanisms by which LPO exert 
these effects have been suggested. In the first instance, high peroxides levels, 
may increase platelet aggregation. Injection of a large amount of 
polyunsaturated fatty acid, particularly arachidonate, has been shown to cause 
formation of microthrombi leading to death in rabbits [Goto, 1982]. Aggregation 
and adhesion of platelets may initiate atherosclerosis, by release of PDGF with 
subsequent SMC proliferation [Ross and Glomset, 1976]. Secondly, LPO may 
exert a direct effect on endothelial cells leading to altered functionality. Exposure 
of the endothelium to LPO could lead to reactions between membrane proteins 
and the peroxides altering enzyme function and possibly membrane fluidity. In 
the third instance high lipid peroxides concentrations may cause an imbalance 
in the production of vasoactive mediators. High levels of LPO attenuate the 
activity of cyclo-oxygenase [Gryglewski etal., 1979]. The increased retention of 
oxLDL in the sub-endothelial space may provide the local high peroxide 
concentration which accounts for the diminished production of PGIg in the area 
of atherosclerotic plaques [Sinzinger ef a/., 1977; De' Angelo, 1978]. A reduction 
in the levels of PGIg would favour platelet aggregation and increase thrombotic 
potential.
The influence of lipid peroxides, and their breakdown products, on endothelial
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cell function have been studied previously. However, less research has been 
devoted to how exogenous LPO affect platelet function. Lipid peroxides have 
been shown to be of importance in the functioning of platelet COX, where their 
presence is required as an activator of the enzyme [Warso and Lands, 1983]. 
In chapter three of this thesis, mmLDL were shown to activate platelets after only 
a Imin incubation. It was proposed that these effects were mediated by the low 
levels of LPO present, since this was the only compositional difference between 
mmLDL and nLDL which could account for their contrasting actions on platelet 
function. The short duration of these experiments would limit the amount of lipid 
exchange between LDL and platelets, suggesting that exogenous LPO may 
have a direct effect of platelet activity.
Elevated plasma lipoprotein levels are thought to cause a increase in PGIg 
production by EC [Spector et al., 1988], but reduce PGIg sensitivity in platelets 
[Beitzefa/., 1983; Bruckdorfer ef a/., 1985; Colli etal., 1985]. Isolated LDL has 
also been shown to reduce the effects of the other EC-derived vasodilator, NO. 
Jacobs et al., [1990] demonstrated that both native and oxidised LDL reduced 
the bioactivity of NO on aortic rings. Intense research has shown the 
effectiveness of NO as a biological mediator is reduced in atherosclerotic and 
hyperlipidaemic models [review: Flavahan, 1992]. However the question which 
has not been addressed is how LDL, and in particular modified forms of LDL, 
affect platelets as target cells for NO. In the following sections, preliminary 
investigations into how specific peroxides affect platelet aggregation and platelet 
sensitivity to NO, were performed. A water soluble peroxide, cumene 
hydroperoxide, and an authentic lipid hydroperoxide, 15(S)- 
hydroperoxyeicosatetraenoic acid (15 (S)-HpETE), were used to investigate
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further the proposal that the pro-aggregatory actions of mmLDL were mediated 
by the presence of LPO. In doing so, the effects of lipid hydroperoxides with 
those of H2O2 were compared.
In the second part of the study, the influence of LDL at different stages of 
oxidation, on platelet sensitivity to NO was investigated. The activation of 
platelets was inhibited with a range of NO or S-NOG concentrations to 
determine the IC50 in the presence of the lipoproteins.
5.1.1 Summary of aims.
[1] To examine the effects of short term exposure of platelets to cumene 
hydroperoxide and 15 (S)-hydroperoxyeicosatetraenoic acid on platelet 
aggregation.
[2] To determine the influence of these peroxides on platelet sensitivity to NO.
[3] To investigate the influence of oxidative modification of LDL on the sensitivity 
of platelets to NO.
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5.2 THE INFLUENCE OF PEROXIDES ON PLATELET AGGREGATION.
mmLDL were shown to induce and potentiate the aggregation of platelets (see 
section 3.4.1), whereas both nLDL and oxLDL were inhibitory. The activatory 
properties of mmLDL may have been mediated by the associated lipid 
peroxides, present in low concentrations. Higher concentrations of peroxides 
may be associated with inhibition of platelet activation, as was the case with 
oxLDL. In sections 4.2.1 and 4.2.2, HgOg induced small amounts of aggregation 
alone and potentiated aggregation induced by sub-threshold concentrations of 
thrombin and collagen. In the following section the effects of more complex 
peroxides on platelet aggregation were examined. The peroxides used were 
cumene hydroperoxide (cum-OOH), a water soluble aromatic peroxide, and 
15(S) -hydroperoxyeicosatetraenoic acid (15-HpETE), an oxygenated metabolite 
of AA, known to be present in oxLDL [Esterbauer, 1993]. The peroxides were 
presented to the platelets either Imin before or Imin after thrombin and the 
aggregation measured 3min later.
5.2.1 The effects of cumene hydroperoxide on thrombin-induced platelet 
aggregation.
The addition of cum-OOH (0 - lOOpM) alone to WP did not induce aggregation. 
Pre-incubation of cum-OOH (0 - 50|jM) with WP for Imin prior to addition of 
thrombin (0.02U/ml) also failed to influence aggregation: at lOOpM, cum-OOH 
caused a significant inhibition of aggregation (11.2 ± 3.5%, p< 0.05).
Pre-incubation of cum-OOH (0 - lOOpM) with WP prior to addition of a 
subthreshold concentration of thrombin (0.005U/ml) also failed to affect 
aggregation, except at lOOpM when it was slightly inhibitory. However, addition
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of cum-OOH to platelets 1 min after the agonist, led to a significant enhancement 
of thrombin-induced aggregation [Figure 5.1]. The potentiation of platelet activity 
reached statistical significance at 10, 30 and 50pM cum-OOH. Thrombin alone 
induced 7.7 ± 1.8% aggregation this was increased to 15.7 ± 3.8 (p< 0.05), 28.7 
± 4.9 (p< 0.01 ) and 27.3 ± 5.1 (p< 0.05) respectively for the three concentrations 
of peroxide. The enhancement of aggregation was maximal at 30pM cum-OOH 
and at 10OpM was able to exert only a slight effect (9.3 ± 1.8%) [Figure 5.1J. The 
potentiation effects are comparable to those observed with supplementary HgOg, 
as it also enhanced aggregation when added post-agonist.
5.2.2. The effects of 15 (S)-hydroperoxyeicosatetraenoic acid on thrombin- 
induced piateiet aggregation.
The incubation of 15 (S)-HpETE (0.01 -lOpM) with WP did not induce 
aggregation. Furthermore, 15 (S)-HpETE (0.01 - lOpM) was shown not to 
influence thrombin-induced aggregation, regardless of whether the peroxide was 
added to the platelets before or after the agonist. Stimulation of platelets with 
thrombin (0.005U/ml) resulted in aggregation of only 6.3 ± 1.9%. The addition 
of 15 (S)-HpETE either before or after thrombin had little effect (6 + 1 and 7.7 
± 1.2% aggregation respectively).
5.3 THE INFLUENCE OF PEROXIDES ON THE SENSITIVITY OF PLATELETS 
TO NITRIC OXIDE.
Previously, HgOg was shown to both diminish and enhance the effectiveness of 
NO as a platelet inhibitor (see sections 4.4.1 and 4.6.1). In the following section, 
the effects of the more complex peroxides on platelet sensitivity to NO were 
examined. The peroxides were added to platelets either 1min before NO, as in
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Figure 5.1: The effects of cumene hydroperoxide on sub-threshold platelet 
aggregation induced by thrombin.
WP were stimulated with thrombin (0.005U/ml) and left stirring for Imin before 
the addition of cum-OOH (0 -lOOpM), total aggregation was measured 3min 
later. The data represent the percent total aggregation and are expressed as 
mean ± SEM of 4 independent experiments.
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[a], or 1min after thrombin, as in [b].
[a] peroxide -  NO -  thrombin [b] NO -  thrombin -  peroxide
A 1min gap between the addition of NO and thrombin was maintained 
throughout the experiments.
5.3.1 The influence of cumene hydroperoxide on the sensitivity of platelets 
to nitric oxide.
The influence of cum-OOH (30pM) on the inhibition of platelet aggregation by 
NO was determined. Cum-OOH added to WP, pre-incubated with NO 1min after 
thrombin, reduced the inhibitory actions of the platelet inhibitor ([b]). Cum-OOH 
(30pM) increased the IC50 for NO against thrombin-induced aggregation from 
133 ± 30nM to 706 ± ISOnM (p< 0.05) [Figure 5.2]. These results are very similar 
to those observed when HgOg was added after the agonist (see section 4.4.1). 
If cum-OOH was incubated with the platelets for 1 min before the addition of NO, 
as in [a], no change in the IC50 for NO was observed. This contrasted with 
actions of HgOg which enhanced the inhibitory actions of NO when it was added 
before the agonist.
5.3.2. The effect of simultaneous addition of cumene hydroperoxide and 
nitric oxide on piateiet aggregation.
The simultaneous addition of NO and HgOg resulted in a potent enhancement of 
the inhibitory actions of NO (see section 4.6.1). When cum-OOH (20pM) was 
added to WP simultaneously with NO (10nM), before thrombin (0.02U/ml), it did 
not modify the inhibitory actions of the antagonist. NO alone induced 5.8 ± 1.2% 
inhibition of platelet aggregation which remained unaltered at 6.7 ± 3.5%, when
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Figure 5.2: Concentration response curves for nitric oxide against thrombin- 
induced aggregation: effects of supplementary cumene hydroperoxide.
WP were incubated with NO solutions (0.001 - lOpM), added as a bolus, for 
1 min prior to the addition of thrombin (0.02U/ml) (#), after a further 1 min cum- 
OOH was added at a concentration of 30pM (O) and the total aggregation 
measured after 3min. The results represent the percent inhibition of aggregation, 
and are expressed as mean ± SEM of 4 individual experiments.
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cum-OOH was added simultaneously with NO. These data indicate that the 
enhancement of NO mediated inhibition was a specific effect of HgOg.
5.3.3 The influence of 15(S)~hydroperoxyeicosatetraenoic acid on piateiet 
sensitivity to nitric oxide.
Pre-incubation of 15(S)-HpETE with WP for 1min before the addition of NO 
caused a modest reduction in the effectiveness of the platelet inhibitor. In the 
presence of 15 (S)-HpETE (lOpM) the IC50 for NO against thrombin (0.02U/ml)- 
stimulated aggregation was increased significantly from 122 ± 14nM to 367 ± 
50nM (p< 0.01) [Figure 5.3]. In contrast, the addition of the LPO Imin after 
thrombin (2min after NO) failed to affect platelet inhibition by NO (IC50 106 ± 
5.8nM).
These data show 15(S)-HpETE to differ from both HgOg and cum-OOH, with 
regard to their effects on platelet sensitivity to NO. The presence of 15 (S)- 
HpETE with platelets before the addition of NO led to a reduction in the effects 
of the inhibitor, while HgOg intensified platelet inhibition by NO and cum-OOH 
had no effect. Conversely, the addition of 15 (S)-HpETE to platelets after 
thrombin had no effect on platelet inhibition by NO, while both HgOg and cum- 
OOH antagonised the inhibition when added at this point.
5.4 NiTRiC OXiDE-MEDiATED iNHiBITiON OF PLATELET AGO REGATiON: 
EFFECTS OF LOW DENSITY LiPOPROTEiNS.
LDL may cause a reduction in the bioactivity of NO in atherosclerosis [Flavahan,
1993]. Hence, the influence of LDL on platelets as target cells for NO was 
investigated. LDL were incubated with WP for Imin either before ([a]) or after
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Figure 5.3: The influence of 15 (S)-hydroperoxyeicosatetraenoic acid on platelet 
sensitivity to inhibition by nitric oxide.
WP were incubated with NO (0 - lOpM) for 1 min prior to the addition of thrombin 
(0.02U/ml), either in the presence ( • )  or absence(O) of 15 (S)-HpETE (lOpM), 
and total aggregation measured 3min later. The results are expressed as the 
percent inhibition of aggregation compared to thrombin alone and represent 
means ± SEM of 4 independent experiments.
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([b]) addition of NO, but prior to stimulation of platelets by thrombin, collagen or 
ADP.
[a] LDL -  NO -  thrombin [b] NO -  LDL + thrombin
A 1 min gap between the addition of NO and thrombin was maintained, and thus 
in experiments ([b]), the LDL were added immediately before the thrombin. The 
results in each section represent 3 independent experiments.
5.4.1 The influence of native low density lipoproteins on nitric oxide- 
mediated inhibition of platelet aggregation.
In section 3.3.1, nLDL were shown to inhibit thrombin-induced aggregation of 
WP in a concentration dependent manner. In order to assess the effects of nLDL 
on the inhibition of platelet activity by NO and to account for the independent 
effects of nLDL on aggregation, thrombin was used at a higher concentration 
(0.1U/ml) than in previous experiments (0.02U/ml).
Pre-incubation of WP for 1min with nLDL (1mg protein/ml) inhibited thrombin- 
induced platelet aggregation by 12.4 ± 6%. NO (0 - lOpM) induced a 
concentration-dependent inhibition of thrombin-stimulated aggregation (ICgo 1.3 
± 0.1 pM). nLDL did not significantly affect platelet sensitivity to NO. In the 
presence of nLDL the ICgg for NO was increased slightly to 1.9 ± 0.4pM. When
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the lipoproteins were added after NO the IC50 remained unaltered at 1.2 ± 
0.3pM. Collagen (1pg/ml) activated platelets were inhibited by nLDL (Img 
protein/ml) by 10.3 ± 5.2%. Again nLDL did not significantly affect inhibition of 
aggregation mediated by NO. The IC50 for NO was 0.42 ± 0.01 pM, compared to 
0.57 ± 0.09pM when nLDL was added before NO, and 0.28 ± O.OZpM when 
added after NO.
5.4.2 The influence of minimally modified low density lipoproteins on nitric 
oxide-mediated inhibition of platelet aggregation.
mmLDL (Img protein/ml) incubated with WP Imin prior to addition of thrombin 
(O.IU/ml) failed to affect aggregation compared to that induced by thrombin 
alone. This is similar to results obtained in section 3.4.1, where mmLDL 
potentiation of ADR-induced aggregation was not detectable if the agonist alone 
induced secondary aggregation. NO (0 - lOpM) induced a concentration- 
dependent inhibition of thrombin stimulated aggregation of WP (IC50 1.3 ± 
0.1 pM). The presence of mmLDL seemed to antagonise slightly the inhibitory 
actions of NO. Pre-incubation of mmLDL with WP prior to NO, as in [a] (see 
above), increased the IC50 for NO against thrombin-induced aggregation to 2.4 
± 0.3pM (p< 0.05) [Figure 5.4]. If the mmLDL were added after NO, as in [b], 
they had little effect on platelet inhibition by NO (IC50 1.7 ± 0.3pM). Similar 
results were obtained when platelets were stimulated with collagen. The IC50 for 
NO against collagen-stimulated aggregation was 0.57 ± 0.06pM, which 
increased to 0.86 ± 0.2pM (p< 0.05) in the presence of mmLDL. However 
addition of mmLDL after NO failed to affect the IC50 for the inhibitor (0.54 ± 
0.12pM). These data suggested that the presence of mmLDL may decrease the 
sensitivity of platelets to NO. However, this is a cautious interpretation of the
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Figure 5.4: The influence of minimally modified low density lipoproteins on the 
inhibition of platelet aggregation by nitric oxide.
mmLDL prepared by the ultracentrifugation of human plasma followed by air 
oxidation (see section 2.5.3). Concentration response curves for NO (0 -lOpM) 
against thrombin (0.02U/ml)-induced aggregation of WP were performed in the 
presence ( • )  and absence (O) of mmLDL (Img protein/ml). Total aggregation 
measured 3min after the addition of thrombin. The results represent the percent 
inhibition of aggregation and are expressed as the mean ± SEM of 3 
independent experiments
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results and greater numbers of experiments are required to establish their true 
nature.
5.4.3 The influence of oxidised iow density iipoproteins on nitric oxide- 
mediated inhibition of aggregation.
Thrombin-induced aggregation of WP was inhibited by 12.2 ± 7% in the 
presence of oxLDL (1mg protein/ml). oxLDL did not affect platelet sensitivity to 
NO, regardless of when they were presented to thrombin-stimulated platelets. 
However, the oxidised lipoproteins did enhance the inhibition of collagen- 
induced aggregation by NO. oxLDL alone inhibited the normal aggregation 
response to collagen by 11.4 ± 4.5%. The presence of oxLDL (1 mg protein/ml) 
enhanced inhibition of collagen-induced aggregation by NO. OxLDL were most 
effective when added before NO, reducing the IC50 for the platelet inhibitor from 
0.51 ± 0.06pM to 0.28 ± 0.05pM (p< 0.01), but when added after NO, the IC50 
was also lowered to 0.32 ± O.OBpM (p< 0.05). The data represent three 
independent experiments. These results indicated that oxLDL may increase 
platelet sensitivity to NO, although it is likely that these are additive effects of 
oxLDL.
5.5 PLATELET INHiBITiON BYS-NITROSOGLUTATHIONE: INFLUENCE OF 
LOW DENSITY LIPOPROTEINS.
Since NO is released from S-NOG intracellularly or close to the membrane (see 
section 4.11.2), it is possible to demonstrate that the effects of LDL on 
platelet sensitivity to NO, are independent of direct interactions between 
lipoproteins and NO. LDL were added to WP either Imin before or Imin after 
SNOG. In each case, a Imin gap was maintained between the addition of S-
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NOG and collagen, and, in some cases, the lipoproteins were added 
immediately before the agonist (see section 5.4). Collagen (1pg/ml) was used 
to stimulate WP, because the effects of mmLDL and oxLDL on platelet sensitivity 
to NO were more potent against collagen-induced aggregation (see sections
5.4.2 and 5.4.3).
5.5.1. Native low density lipoproteins and S-nitrosogiutathione-mediated 
inhibition of platelet aggregation.
nLDL (1mg protein/ml) inhibited collagen-induced platelet aggregation by 18.2 
± 6.3% (p< 0.05). S-NOG added to platelets Imin before collagen inhibited 
aggregation in a concentration dependent manner (IC50 0.072 ± 0.022pM). The 
incubation of nLDL with WP for 1min before addition of S-NOG, increased 
significantly the inhibition of platelet activity by the nitrosothiol [Figure 5.5]. 
Here, the IC50 for S-NOG was reduced to 0.020 ± 0.004pM (p< 0.05). This was 
also the case when nLDL was added 1 min after S-NOG (IC50 0.044 ± 0.015pM; 
p< 0.05) [Figure 5.5].
5.5.2 Minimally modified low density lipoproteins and inhibition of platelet 
aggregation by S-nitrosoglutathione.
Collagen-induced platelet aggregation was not affected by the presence mmLDL 
(Img protein/ml), as compared to controls. This phenomenon was also found in 
section 3.4.1, where mmLDL did not potentiate ADP-induced aggregation if the 
agonist alone induced a secondary response. S-NOG (0 - lOpM) produced a 
concentration dependent inhibition of aggregation of WP (IC50 of 0.091 ± 
O.OSSpM). mmLDL, added to the platelets before or after S-NOG, failed to alter 
the IC50 for the inhibitor (0.081 ± 0.039pM and 0.084 ± 0.034pM) against
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Figure 5.5: The influence of native low density lipoproteins on the inhibition of 
platelet aggregation by s-nitrosoglutathione.
nLDL (Img protein/ml) prepared by the ultracentrifugation of human plasma 
(see section 2.5.1). Concentration response curves for NO (0 -lOpM) against 
collagen (0.02U/ml)-induced aggregation of WP were performed in the presence 
( • )  and absence (O) of nLDL (Img protein/ml). Total aggregation measured 
3min after the addition of thrombin. The results represent the percent inhibition 
of aggregation and are expressed as the mean ± SEM of 3 independent 
experiments
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collagen-induced aggregation. This suggested that mmLDL has no significant 
effect on the sensitivity of platelets to the secondary messenger actions of NO 
once inside the cell.
5.5.3 The influence of oxidised low density iipoproteins on S- 
nitrosoglutathione-mediated inhibition of piateiet aggregation.
In these experiments, oxLDL (1mg protein/ml) incubated with WP for 1min 
before the addition of collagen induced 21.9 ± 6.4% (p< 0.05) inhibition. S-NOG 
alone inhibited collagen-induced platelet aggregation in a concentration- 
dependent manner with an IC50 of 0.073 ± 0.022pM. The IC50 for the nitrosothiol 
was reduced to 0.035 ± O.OOSpM in the presence of oxLDL and to 0.029 ± 
0.007pM when oxLDL was added after the S-NOG. However, neither of these 
effects were statistically significant.
5.5.4. Résumé.
The native lipoproteins slightly enhanced the actions of cGMP-mediated 
inhibition of platelet aggregation by NO and S-NOG. These observations may 
be related to the independent inhibitory actions of the LDL preparations and 
suggests that a direct interaction between these lipoproteins and NO does not 
occur. In contrast, mmLDL seemed to attenuate slightly the inhibition of platelet 
activity by NO, but had a minimal effect on the actions of S-NOG. This 
suggested that the activatory effects of mmLDL may be potent enough to 
attenuate the actions of NO, but not S-NOG. The entry of NO into platelets may 
be impeded by mmLDL, although thejeffects are likely to have been small.
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5.6 THE SUPPLEMENTATION OF NATIVE LOW DENSITY LIPOPROTEINS 
WITH 15 (S)-HYDROPEROXYEICOSATETRAENOIC ACID, AND THEIR 
EFFECTS ON PLATELET FUNCTION.
In chapter three of this thesis mmLDL were shown to induce the activation and 
aggregation of WP (see section 3.4). The mediator of these pro-activatory 
effects is proposed to be the low levels of lipid peroxides associated with the 
particles. Consequently, the direct effects of an authentic lipid peroxide, 15 (S)- 
HpETE, which is an oxygenated metabolite of arachidonic acid, on platelet 
aggregation was investigated (see section 5.2.2). 15 (S)-HpETE was of 
particular importance, since the phospholipid surface monolayers of LDL are 
known to be rich in arachidonate [Esterbauer et ai., 1990], and thus the peroxide 
represents a key LDL oxidation product. The effects of both the LPO and LDL 
on platelet aggregation and platelet sensitivity to NO have been examined 
individually. In the following experiments, both factors are combined. nLDL were 
utilised as a carrier particle to test the effects of 15 (S)-HpETE on WP (see 
section 2.5.4). Autologous nLDL were used as controls within each experiment. 
Supplementation of LDL with LPO, allowed assessment of the effects of LPO on 
platelet function in a more realistic model: peroxides have been demonstrated 
to be associated with lipoproteins in vivo [Nishigaki et a/., 1981; Bo wry et a/., 
1992].
5.6.1 The measurement of total lipid hydroperoxide of native low density 
lipoproteins suppiemented with 15 (S)-hydroperoxyeicosatetraenoic acid.
Native LDL (5mg protein/ml) were incubated with SOOnmol of 15 (S)-HpETE 
which equated to 60nmol 15 (S)-HpETE/mg protein. Measurements of LPO 
content (see section 2.5.6) for both nLDL and the corresponding 15 (S)-HpETE-
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LDL were performed to assess the efficiency of the incubation procedure for the 
uptake of 15 (S)-HpETE.
nLDL incubated with buffer under the same conditions as nLDL and 15 (S)- 
HpETE showed no significant change in total LPO. Freshly isolated nLDL 
possessed 14.0 ± 3.5 nmol LPO/mg protein which only increased to 15.7 ± 3.4 
nmol/mg LDL protein after further incubation and dialysis. In contrast, total LPO 
of nLDL was increased significantly from 14.0 ± 3.5nmol/mgLDL protein to 48.7 
± 7.3nmol/mg LDL protein (p< 0.005) after incubation with 15 (S)-HpETE.
5.6.2 The effects of 15 (S)-hydroperoxyeicosatetraenoic acid suppiemented 
iow density iipoproteins on platelet aggregation.
The influence of 15 (S)-HpETE-LDL on platelet aggregation was tested in the 
same manner as mmLDL (see section 3.4.1), assessing their actions in the 
presence and absence of platelet agonists. WP were activated with a sub­
threshold concentration of ADP (1 pM), which induced 11.3 ± 1.3% aggregation. 
The presence of 15 (S)-HpETE-LDL (0.25, 0.5 and Img protein/ml) for Imin 
before addition of ADP significantly enhanced platelet aggregation, at all 
concentrations used (p< 0.05) [Figure 5.6]. The actions of 15 (S)-HpETE-LDL 
were not concentration-dependent within the physiological range of 
concentrations for LDL, with 0.5mg protein/ml inducing the greatest effect (23.3 
± 1.5%) [Figure 5.6/. In control experiments, WP were incubated with autologous 
nLDL (Img protein/ml) preparations. In the presence of nLDL, ADP-induced 
aggregation was reduced to 4.7 ± 0.9% (p< 0.05). When experiments were 
repeated with sub-threshold concentrations of thrombin (0.005U/ml) or collagen 
(0.1 pg/ml), no potentiation of aggregation with 15 (S)-HpETE-LDL was
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Figure 5.6: The influence of 15 (S)-hydroperoxyeicosatetraenoic acid on platelet 
aggregation stimulated by ADP.
15 (S)-HpETE was presented to WP as a complex with LDL to form 15 (S)- 
HpETE-LDL (see section 2.5.4). The 15 (S)-HpETE-LDL (0-1 mg protein/ml) were 
incubated with WP for Imin prior to the addition of ADP (IpM). Total 
aggregation was measured 3min after the addition of ADP. The data represent 
the percent total aggregation and are expressed as mean ± SEM of 3 
independent experiments.
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observed. These experiments were not pursued. Incubation of 15 (S)-HpETE- 
LDL with WP in the absence of agonists failed to induce platelet aggregation. 
These data provide clear evidence that the presence of LPO associated with the 
particles alter their normal properties, allowing them to activate platelets.
5.6.3 The influence of low density lipoproteins supplemented with 15(S)~ 
hydroperoxyelcosatetraenolc acid on nitric oxide mediated Inhibition of 
platelet aggregation.
Following the same line of investigation as for H2O2, cumene-OOH and 15 (S)- 
HpETE alone, the effects of 15 (S)-HpETE-LDL on inhibition of aggregation by 
NO were investigated. WP were stimulated with ADP, but not thrombin or 
collagen, as the aggregatory actions of 15 (S)-HpETE-LDL were limited to ADP. 
NO (0 - lOpM) pre-incubated with WP (Imin) induced a concentration 
dependent inhibition of ADP (lOpM)-induced aggregation (IC50 63.7 ± 8.4nM). 
Incubation of 15 (S)-HpETE-LDL (Img protein/ml) with WP for Imin before the 
addition of NO, caused a very small, but statistically significant reduction in the 
actions of the antagonist. Here, the IC50 for NO was increased to 76.0 ± 7.7nM, 
(p< 0.0^) [Figure 5.7]. This phenomenon was also observed with 15 (S)-HpETE 
and mmLDL. 15 (S)-HpETE-LDL added Imin after NO, and immediately before 
ADP failed to affect inhibition by NO.
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Figure 5.7; Concentration response curves for nitric oxide against ADP-induced 
aggregation: the influence of 15(S) Hydroperoxyeicosatetraenoic acid.
15(S)HpETE was presented to WP as a complex with LDL to form 15(S)HpETE- 
LDL (see section 2.5.4). IP were incubated with a range of concentrations of NO 
in the presence (#) or absence (O ) of 15(S)HpETE-LDL (1 mg protein/ml) for 
Imin before stimulation with ADP (lOpM), and total aggregation measured after 
3min. In all cases the 15(S)HpETE-LDL was incubated with IP for 1min before 
the addition of NO. The results are expressed as the percent inhibition of 
aggregation compared to ADP alone and represent means ± SEM of 3 
independent experiments.
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5.7. DISCUSSION
5.7.1 Organic peroxides and platelet function.
The possible actions of peroxides on platelet function and platelet sensitivity to 
NO were investigated further using cum-OOH and 15(S)-HpETE. Cum-OOH was 
selected as it was water soluble and to complement previous work suggesting 
that NO reacts with organic peroxides leading to its inactivation [Padmaja and 
Huie, 1993]. Cum-OOH potentiated aggregation induced by sub-threshold 
concentrations of thrombin, but failed to induce aggregation. This peroxide only 
enhanced platelet aggregation when added to the platelets after the main 
agonist, as was the case with HgOg. Pre-incubation of cum-OOH with platelets 
prior to the agonist failed to influence aggregation, except at lOOpM where a 
slight inhibition was observed. 15(S)-HpETE, in contrast to cum-OOH, had no 
significant effects on platelet aggregation at any of the concentrations tested. 
The effects of the different peroxides on platelet aggregation are summarised 
in Table 5.1.
The results suggest that peroxides such as cum-OOH and HgOg behave 
differently from a lipid soluble peroxide, such as 15(S)-HpETE, with respect to 
platelet function [Table 5.1]. Both cum-OOH and HgOg were able to potentiate 
aggregation, while 15(S)-HpETE had little effect. These differences may be due, 
at least in part, to differences in cellular permeabilities between the individual 
peroxides. HgOg has been shown to increase platelet [Ca^T when added after 
the agonist [Del Principe et al., 1985, Pratico et ai, 1992] leading to an increase 
in PLAg activation [Pratico et ai, 1992]. However, HgOg has also been proposed 
to be an activator of cyclo-oxygenase [Del Principe et ai, 1985]. In section 4.2.4 
evidence was presented demonstrating the pro-aggregatory effects of HgOg were
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no
peroxide agonist
before
agonist
after
agonist
H2O2
cum-OOH
primary
aggregation
no effect
15 (S)-HpETE no effect
no effect
no effect
no effect
enhanced
aggregation
enhanced
aggregation
no effect
15 (S)-HpETE/LDL no effect enhanced no effect
aggregation
Table 5.1 : Summary of the effects of different peroxides on platelet aggregation
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totally reliant on COX. No evidence is presented here to indicate that cum-OOH 
enhances aggregation by the same mechanism. However, water soluble 
properties of cum-OOH may allow it to enter the cell. If this is the case, it may 
be speculated that cum-OOH also enhances aggregation by activation of COX. 
The more complex structure of 15(S)-HpETE would negate rapid entry of the 
peroxide into the platelet, and thus any effects would probably be mediated 
extracellularly.
A mechanism by which the peroxides may enhance aggregation could involve 
both COX and PLAg. The addition of peroxides after an agonist may increase the 
[Ca^ i^ to a greater extent than the agonist alone, as observed by Del Principe 
et al., [1991].The elevated [Ca^^j may activate PLAg, which is known to be 
calcium-dependent [Rittenhouse, 1984] and release AA from the membrane, 
which would then be metabolised by COX. These processes may enhance TXAg 
production and subsequent aggregation of the platelets [summarised in Figure 
5.8]. This concept fits well with the present observations that peroxides only 
enhance activation of platelets when added after the agonist. The peroxides 
alone are unable to mobilize AA from the membrane to induce functioning of 
COX. However, if the agonist is added first, the additive effect of peroxides on 
platelet [Ca^ j^, may be sufficient to induce PLAg activation: HgOg alone does not 
increase [Ca^^j in platelets [Del Principe et ai., 1991]. A study by
Hashizume et ai., [1991], demonstrated that tert-butyl hydroperoxide enhanced 
collagen-induced aggregation and AA release. These effects were inhibited by 
the presence of mepacrine and indomethacin, PLAg and COX inhibitors 
respectively. Alternatively, it is possible that early addition of peroxides to the 
platelet leads to their enzymatic removal before the agonist is added. The
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Figure 5.8: The proposed mechanism by which hydrogen peroxide and cumene 
hydroperoxide may influence platelet aggregation induced by submaximal 
concentrations of agonists.
In this scheme the peroxide increases [Ca^^j induced by the agonist, which 
causes activation of PLAg and release of AA. The peroxide also enhances 
activation COX, leading to the conversion of AA to TXAg and a subsequent 
increase in platelet aggregation.
Ca '^': calcium ions, COX: cyclooxygenase, PLAg: phospholipase Ag, TXAg ; 
thromboxane Ag.
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reduced peroxide concentration may not be sufficient to exert a pro-aggregatory 
effect. Platelets possess two enzymes, GSH Px and catalase, which reduce 
peroxides to their hydroxy derivatives. HgOg and cum-OOH induced different 
levels of aggregation which to some extent jweredependent on the agonist, they 
were all optimally effective at similar concentrations (20 - 30pM).
The actions of peroxides may be related to the structure of the individual 
peroxide being investigated. Hemler et al., [1979] demonstrated that the 
efficiency of lipid hydroperoxide activation of cyclo-oxygenase was dependent 
upon chain length, position of double bonds and location of the peroxide group. 
It is possible that the activation of platelets by LDL associated peroxides may be 
governed by such structural determinants. Indeed, in the present study 15(S)- 
HpETE had no significant effect on platelet activation, while Aharony at a!., 
[1982] demonstrated that 12(S)-HpETE inhibited platelet aggregation (IC50 2- 
3pM).
5.7.2 The effects of peroxides on the sensitivity of piateiets to nitric oxide
The pattern observed when cum-OOH enhanced aggregation, with respect to 
the order of addition to the platelets, also emerged when the effects of cum-OOH 
were tested against NO. Addition of the peroxide to WP after the thrombin, 
decreased the inhibition by NO. In contrast, addition of cum-OOH prior to NO, 
had no effect on the actions of the antagonist. This suggested that cum-OOH did 
not influence the entry of NO into the platelets, and that the reduced inhibition 
by NO, when the peroxide was added after thrombin, was due exclusively to its 
pro-aggregatory influence on platelet function. In this respect, cum-OOH 
behaved similarly to HgOg: both peroxides increased platelet activation and
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decreased platelet sensitivity to NO when added after the main agonist and were 
maximally effective at similar concentration (20 - 30pM). In contrast to H2O2, 
when cum-OOH was added simultaneously with NO before the agonist, no 
change in the level of inhibition was observed. It has been proposed that NO 
can react with organic peroxides, leading to the inactivation of the inhibitor. In 
the present study there is no direct evidence to substantiate this previous study 
[Padmaja and Huie, 1993], as addition of NO to platelets pre-incubated with 
cum-OOH did not alter the efficiency of the platelet antagonist. The mechanism 
of action of these peroxides seem to differ from that of 15(S)-HpETE. The lipid 
hydroperoxide did reduce slightly the inhibition of platelet aggregation by NO, 
but only if present before the NO. As 15(S)-HpETE showed no pro-aggregatory 
effects, this would suggest that the peroxide reduced the entry of NO into the 
platelet. Recently, it has been shown that NO can undergo direct reactions with 
LOO* and LO* radicals of linoleic acid [Rubbo et al., 1994]. It is possible that the 
formation of reaction products between 15(S)-HpETE and NO may prevent its 
entry into the platelet. However, this requires further investigation.
In conclusion, cum-OOH and 15(S)-HpETE, unlike HgOg, can only reduce the 
inhibition of platelets by NO. Both 15(S)-HpETE and cum-OOH, increased the 
IC50 for NO, although the mechanisms by which the effects were induced 
seemed to be different. Since, cum-OOH was only effective against NO when 
added before the agonist, whilst 15(S)-HpETE was antagonistic when present 
before NO. The effects of the different peroxides on platelet sensitivity to NO are 
summarised in Table 5.2.
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peroxide
before
NO
simultaneously after
with NO NO
H2O2 enhanced
inhibition
enhanced
inhibition
reduced
inhibition
cum-OOH no effects no effects reduced
inhibition
15(S)-HpETE reduced
inhibition
nd no effects
15 (S)-HpETE/LDL no effects no effects no effects
Table 2: Summary of the effects of different peroxides on platelet sensitivity to 
nitric oxide.
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5.7.3 Low density lipoprotein and platelet sensitivity to nitric oxide.
NO is an extremely lipophilic molecule, which allows it to freely enter platelets 
and exert its biological effects. The hydrophobic characteristics of the molecule 
indicate it may be possible that NO is attracted to the hydrophobic cores of 
lipoproteins, and this may represent a process of NO deactivation. This could 
be particularly relevant in small localised areas of high lipoprotein concentration 
such as an atherosclerotic plaque [Smith, 1974; Hoff et a/., 1977]. Incubation of 
nLDL with platelets prior to the addition of NO, decreased slightly the IC50 for 
NO. This is not unexpected as nLDL itself has been shown to inhibit agonist 
induced aggregation of WP and, more importantly, suggests that there is no 
direct interaction between the lipoproteins and NO. Oxidised LDL gave 
essentially similar results, although the reduction in the IC50 was greater than 
observed with nLDL. This probably reflects the fact that oxLDL is a more potent 
inhibitor of platelets than nLDL (see sections 5.4 and 5.5).
NLDL was shown to have little effect on inhibition by NO, but to synergise with 
S-NOG, which again contradicts the earlier concepts implicating these 
lipoproteins as pro-thrombotic. This effect was lost even when the lipoproteins 
became only partially oxidised. The presence of mmLDL, led to an increase in 
the IC50 for NO against thrombin-stimulated platelets. However the lipoproteins 
had little effect on platelet inhibition when added after the NO. This indicated 
that the pro-aggregatory effects of mmLDL were not sufficiently potent to 
antagonise the intracellular actions of NO. When mmLDL is added before NO, 
the pro-aggregatory effects of the lipoproteins may reduce the inhibition, but it 
is also possible that there is a direct interaction between the lipoproteins (or 
their constituents) and NO. This implies that the reduced effectiveness of NO in
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the presence of mmLDL may be due to a direct interaction between NO and LPO 
present in the lipoproteins, thereby reducing the amount of NO available to enter 
the platelet. It has been demonstrated that NO can react with organic peroxyl 
radicals [Padmaja and Huie, 1993] and lipid peroxyl radicals [Rubbo et al.,
1994]. A reaction between NO and LPO would be detrimental to haemostasis as 
it could lead to the loss of NO. The presence of GSH Px and GSH which act to 
reduce LPO [Maddipati at a!., 1987], may protect against this. Conversely, a 
reaction between NO and peroxyl radicals, could protect cells and lipoproteins 
against free radical mediated damage, and in this respect NO may be viewed as 
an antioxidant.
In contrast to the experiments with authentic NO, mmLDL did not affect inhibition 
by S-NOG, regardless of when mmLDL was presented to the platelets. There 
are two possibilities for the different results obtained with NO and S-NOG in the 
presence of mmLDL. S-NOG has been shown to be a more effective platelet 
inhibitor than NO [Radomski at a/., 1987], and this increased potency may be 
sufficient to attenuate the activatory effects of mmLDL. Alternatively, the LPO 
associated with mmLDL may interact directly with free NO, reducing its entry into 
the platelet (as discussed above). However, stabilisation of NO by a thiol group, 
such as that found on GSH, could reduce the possibility of a reaction. The 
effects of LDL and more specifically mmLDL on both platelet activation and 
platelet sensitivity to NO, may tip the balance in favour of aggregation. At 
present the mechanism of these actions are unknown, but it indicates a possible 
important role for mmLDL in thrombosis.
If mmLDL causes the inactivation of NO, in addition to activating platelets, it may
254
have important implications for the maintenance of vascular tone, in addition to 
haemostasis.
5.5.5 The supplementation of low density lipoproteins with the lipid 
peroxide 15(S) -hydroperoxyeicosatetraenoic acid
15(S)-HpETE was used to examine how LPO affected the influence of plasma 
lipoproteins on platelet function. Supplementation of nLDL with 15(S)-HpETE 
changed the properties of the particles from being inhibitory to activatory. 15(8)- 
HpETE alone did not induce aggregation, but enhanced aggregation induced by 
ADP. This provided strong evidence that LPO are at least partly responsible for 
the effects of mmLDL on platelets. The full pro-aggregatory effects associated 
with mmLDL may be a cumulative effect of different peroxides, of which 15(8)- 
HpETE may be one of many. It is possible that other modified components of 
mmLDL are also involved in their pro-aggregatory actions. A number of reports 
have shown that lipoproteins bind to platelets, but this does not result in 
endocytosis [Mazurov et al., 1982; Curtiss and Plow, 1984; 8hmulewitz at a!., 
1984]. This would suggest that the actions of 15(8)-HpETE, and possibly other 
peroxides associated with mmLDL, are probably exerted at or near the cell 
surface.
Essentially, the 15(8)-HpETE/LDL behaves similarly to mmLDL: both species 
enhance aggregation when pre-incubated with platelets before the addition of 
the agonist. This again suggests that LPO interact with platelets differently from 
the simpler water soluble peroxides, which only activated platelets when added 
after the agonist [Table 5.1]. However, a very recent study by Wiedtmann et al., 
[1995] showed that mildly oxidised LDL-induced aggregation of platelets was
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inhibited by mepacrine and indomethicin, inhibitors of PLAg and COX 
respectively. This is the same activation pathway proposed for the potentiation 
of aggregation by HgOg and cum-OOH (see section 5.5.1). This may indicate a 
common pathway for the enhancement of platelet function by peroxides, 
although the mechanism by which the enzymes involved in signal transduction 
are activated may be different in the two cases.
15(S)-HpETE/LDL attenuated the inhibition of aggregation by NO, although the 
effects were very small. This reduction in NO sensitivity was only observed if 
15(S)-HpETE/LDL was pre-incubated with platelet before the addition of NO. In 
this respect 15(S)-HpETE/LDL behaved like 15(S)-HpETE alone and mmLDL, 
both of which antagonised NO in this manner. Interestingly 15(S)-HpETE/LDL 
had little effect on NO-mediated inhibition when added after the agonist, which 
may correspond to its inability to enhance aggregation when added at this point. 
Since 15(S)-HpETE/LDL, 15(S)-HpETE alone and mmLDL attenuated inhibition 
by NO when present before the antagonist, this may suggest that the 
lipoproteins reduce the entry of NO into the platelets. However, this proposal 
needs to be investigated further before a conclusive answer can be given.
Peroxides, therefore, have a varied action on blood platelets which may have 
significant consequences in the modulation of their activity in the normal and 
diseased state.
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CHAPTER SIX : GENERAL DISCUSSION.
6.1 Plaque development and platelet aggregation.
Atherosclerosis is characterised by the presence of lipid-laden plaques in the 
intima of the arterial wall [Hoff and Gavbatz, 1982]. The plaques are prone to 
rupture which expose their contents to flowing blood, increasing the risk of 
platelet aggregation and formation of a thrombus. It is widely accepted that 
plaque fissure leads to thrombosis [Constantinides, 1966; Friedman and van den 
Bovencamp, 1966], and these two events are the precursors to acute coronary 
syndromes [Davies and Thomas, 1985; Falk, 1989]. Fibromuscular plaques have 
an increased size compared to the lipid-laden plaques, because of the 
incorporation of mural thrombi. Evidence suggests that plaque size increases 
by recurrent minor fissures of soft plaques, with subsequent mural thrombi and 
fibrin meshwork formation [Fuster et a/., 1990]. Morphologically, plaques are 
composed of healed fissures with overlying mural thrombi, suggesting that most 
fissures of the plaque reseal and incorporate the thrombus, without producing 
acute clinical complications.
Platelet activation and aggregation are major events during the formation of 
thrombi, suggesting a close relationship between platelet aggregation and 
vascular disease [Rubenfire at a/., 1986]. Several studies have shown an 
alteration in platelet function after coronary complications. The Caerphilly 
Collaborative Heart Disease Study, involving a cohort of over 200, demonstrated 
a strong positive relationship between previous myocardial infarction (M l.) and 
ADP-induced platelet aggregation [Elwood at al., 1990]. In a separate study of 
patients with past M l., the subjects with platelets which more readily underwent 
spontaneous aggregation had a significantly greater mortality rate than those
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with unresponsive platelets [Trip etal., 1990]. These studies strongly implicated 
platelet aggregation as an integral part in the development of atherosclerotic 
plaques and their clinical sequelae. However, the most convincing evidence of 
the role of platelets, is the reduction of coronary events by treatment with aspirin 
[Anti-platelet trialists collaboration, 1988].
6.2 Platelet function is modulated by plasma low density lipoproteins.
Early observations in hyperlipidaemic patients suggested a causal relationship 
between plasma LDL concentrations and increased susceptibility of platelets to 
aggregate [Carvalho et al., 1974, Joist at al., 1979, Zahavi at al., 1981]. 
Subsequently, LDL was shown to have direct effects on platelet aggregation and 
secondary messenger levels (see saction 1.7.2). The discovery that LDL may 
undergo a post-secretory oxidative modification and that this process alters the 
properties of lipoproteins, rendering them more atherogenic, put a question mark 
over the findings of previous studies. It is reasonable to speculate that slight 
oxidation of the isolated LDL preparations may account for some of the 
observations. Subsequently, oxLDL were shown to have a greater effect on 
platelet activation than nLDL [Ardlie at al., 1989, Meraji at al., 1992]. In the 
present study, attention was paid to the extent of which the degree of oxidative 
modification of LDL may affect their influence on platelet function.
Stringent oxidation procedures were used in the isolation of LDL, before their 
oxidation. In contrast to previous studies, nLDL did not activate platelets, but 
inhibited aggregation in a plasma free environment, and early activation in the 
presence of plasma. It is proposed that these observations are attributed to 
nLDL interfering with the normal binding of FGN to the GPIIb-llla receptor.
258
Several studies have shown LDL to bind to the platelet surface [Mazurov et al., 
1982; Curtiss and Plow, 1984; Shmulewitz et a!., 1984; Katzman et a!., 1991; 
Pedreno eta!., 1994], although no direct evidence has been presented to show 
this binding site is GPIIb-llla. Whether the binding of LDL to platelets is specific 
or non-specific, or to GPIIb-llla or an alternative site remains to be resolved. 
More importantly, the present study demonstrates that LDL in their native form 
do not activate platelets, but have a small inhibitory effect. A recent finding 
demonstrating that nLDL and isolated apoB inhibited thromboplastin (tissue 
factor) activity [Ettelaie et a/., 1995] raises an interesting question. As nLDL 
seems to inhibit both platelet activation and thromboplastin activity, does this 
point to a role for apoB in haemostasis ? These preliminary data may suggest 
that apoB at physiological concentrations, could have a functional role in the 
regulation of some haemostatic functions.
Modified LDL modulate platelet activity, although the nature of the effect is 
dependent on the extent of oxidation. OxLDL inhibited platelet activation and 
aggregation. The potency of these effects were greater than observed with 
nLDL, and seemed to occur via a different mechanism. Since oxLDL inhibited 
aggregation after a Imin incubation both in the presence and absence of 
plasma. OxLDL has been shown been to be cytotoxic to various cell types [Morel 
et a/., 1984; Cathcart et a!., 1985; Zhao et a!., 1994], and it is plausible that it 
exerts similar effects of platelets. In addition two oxidation products of LDL, 
lysolecithin [Besterman and Gillette, 1971] and 4-HNE [Selley etal., 1988], both 
inhibit platelet aggregation independently. mmLDL induced and enhanced early 
activation, aggregation and increased the expression of markers for 
degranulation. The effects occur in the presence of plasma and implicate
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mmLDL as potentially important pro-thrombotic factors, in addition to their 
documented pro-atherosclerotic effects (see section 1.4.3). The results indicated 
that the activatory effects of mmLDL are due to the formation of oxidised lipids, 
since the protein moiety of the particles was not significantly modified (see 
section 3.2.3). The actions of oxidised and minimally modified LDL taken 
together suggested that the products of lipid oxidation may have a diphasic 
effect on platelet function. MmLDL, characterised by small increases in both 
LPO and TBARs concentrations, activated platelets, while increased 
concentrations of these products seemed to induce a potent inhibition of 
aggregation, as was the case with oxLDL. This phenomenon has already been 
recognised for 4-HNE, an LDL oxidation product. Selley et a/., [1988] 
demonstrated that 4-HNE could activate platelets at low concentrations, but at 
concentrations in excess of lOOpM it inhibited aggregation. The initial results of 
the study suggested both LPO and their breakdown products exert a strong 
influence on platelet activation. Consequently, the effects of peroxides on 
platelet aggregation were investigated in greater detail.
6.3 The influence of peroxides and platelet function.
Warso and Lands, [1985] found plasma LPO concentrations of approximately 
O.SpM in healthy subjects. However, plasma LPO concentrations have been 
shown to be raised in patients with atherosclerosis [Stringer et al., 1989]. These 
studies found an upper limit of 5 - 7pM peroxides in the plasma of patients with 
IHD. Platelet samples from subjects with various complications associated with 
atherosclerosis were shown to be hyper-responsive to physiological agonists 
[Cavarlho et al., 1974; Joist et al., 1979, Zahavi etal., 1981; Trip et al., 1990; 
Elwood etal., 1990; Buczyhski etal., 1993]. In the present study mmLDL were
260
found to activate platelets. It is possible to speculate that the actions of mmLDL 
may link the above observations. The increased levels of plasma LPO may be 
in part due to the presence of mmLDL, since it is feasible that they may exist in 
circulation (see section 3.7.3). Increased plasma concentrations of mmLDL may 
increase the sensitivity of platelets to physiological agonists. This may be 
particularly relevant to the previously cited studies (see above), since their 
experimental analysis of platelet function were performed in PRP.
The actions of peroxides on platelet function were tested by addition of both 
water soluble and LPO directly to platelets. All the peroxides tested were shown 
to increase platelet activation in response to agonists, although some 
differences in the mechanism of these effects were found (see section 5.1). HgOg 
and cum-OOH activated platelets when added post-agonist, which was not the 
case with 15 (S)-HpETE. The LPO (15 (S)-HpETE) only activated platelets when 
it was complexed with LDL and only if present before the agonist. It is proposed 
that HgOg and cum-OOH may enter the platelets where they activate PLAg and 
COX {discussedin section 5.5.1). The more complex structure of 15 (S)-HpETE 
would preclude rapid entry into the platelet. However, if the LPO is complexed 
with LDL, the lipoprotein may bind to the platelets and thus expose the cells to 
a high local concentration of the peroxide. This may facilitate platelet activation 
in the same manner as proposed for mmLDL (see section 3.7.4). The results 
indicated that LPO are partially responsible for the actions of mmLDL.
The prevention of LPO induced effects are mediated by the activity of anti­
oxidant enzymes such as SOD, catalase and GSH Px. In a recent study by 
Buczyhski et a/., [1993], it was found that increased platelet activity in patients
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with CHD was associated with reduced activities of these enzymes. Of particular 
importance was GSH Px, the major hydroperoxide reducing enzyme in platelets 
[Merasca et al., 1992]. The activity of platelet GSH PX was reduced by 38% in 
these patients. The authors did not speculate as to how these decreased 
activities occurred. However, it may be related to the increased circulating 
peroxides associated with the disease. Exposure of endothelial cells to linoleic 
hydroperoxide led to the peroxidation of cellular phospholipids [Pacific! at a!., 
1994a] and produced a rapid release of fatty acids, particularly arachidonic acid, 
into the culture media [Pacific! at a!., 1994b]. If a similar effect occurred in 
platelets it would lead to enhanced platelet aggregation. This concept is 
supported by a clinical study of patients at risk from cardiovascular disease. A 
sub-group of people with low plasma antioxidant status was selected and 
various platelet parameters measured [Salonen at al., 1991]. These subjects 
exhibited enhanced platelet activation compared to controls, which was 
positively correlated with higher plasma LPO. The activation markers were 
reduced after oral administration of antioxidants. Interestingly, LPO may also 
increase thrombogenicity by a mechanism different to that of platelet activation. 
They have been shown to increase the pro-coagulant activity of the blood by 
inhibiting anti-thrombin III [Grey and Barrowcliffe, 1985].
6.4 Influence of lipoproteins and peroxides on platelet sensitivity to nitric 
oxide.
The endothelium releases PGIg and NO, two factors which protect the blood 
vessel against pathological platelet deposition (see saction 1.6). PGIg has been 
shown to mainly inhibit aggregation [Higgs at al., 1978], while NO inhibits both 
aggregation and adhesion [Radomski atal., 1987a, b]. PGIg and NO have been
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shown to synergise in the inhibition of platelet aggregation [Moncada et al., 
1990]. Reduced formation or reduced cellular sensitivity to NO or PGIg would 
favour both activation and adhesion of platelets. Platelet sensitivity to PGIg has 
been shown to be reduced in the presence of LDL, a process associated with 
reduced production of cAMP [Bruckdorfer etal., 1985; Beitz etal., 1985].
In the present, study evidence is presented to suggest that mmLDL, water 
soluble and lipid peroxides, all reduce platelet sensitivity to NO. The most 
effective peroxide was HgOg, although the pathophysiological relevance of these 
actions is not clear. HgOg may be produced locally in high concentrations by 
activated neutrophils [Test and Wiess, 1984], and thus could be an important 
mediator of platelet function in local inflammatory events. However, it is unlikely 
that this peroxide is raised in the circulation, and evidence presented earlier in 
this thesis suggests it may play a contrasting role to other peroxides with respect 
to platelets {discussed in section 6.5). The actions of LPO associated with 
lipoproteins seem to be slightly different to those of other organic peroxides. The 
reduced effectiveness of NO induced by HgOg and cum-OOH seem dependent 
on their pro-aggregatory actions, since they were only effective when added 
after the agonist. Pre-incubation of mmLDL, 15(S)HpETE alone or LDL- 
15(S)HpETE, but not nLDL with platelets before the addition of NO, attenuated 
the inhibitory effects of the platelet antagonist. This suggests that LPO 
associated with LDL may impede the entry of NO into the platelet or operate by 
some other mechanism. In a recent publication it was demonstrated that NO has 
the ability to terminate radical induced peroxidation of linoleic acid. This involves 
a direct interaction between NO and LOO* or LO radicals, leading to the 
formation of nitrogen containing lipid products [Rubbo et al., 1994]. The authors
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speculate that NO could prevent the oxidation of LDL by terminating lipid radical 
chain propagation reactions, and thus possess antioxidant properties. 
Conversely, these antioxidant properties may lead to a reduction the vascular 
actions of NO, favouring SMC contraction and luminal platelet adhesion and 
aggregation.
The mechanism of how peroxides, in particular those associated with LDL, could 
reduce the effectiveness of NO is undefined. A direct reaction between NO and 
peroxides would reduce NO entry to the platelets and hence decrease cGMP 
production. However, it is possible that the pro-aggregatory effects of the 
peroxides could impair or oppose the actions of cGMP, without a direct 
interaction. The full mechanism of these observations remains to be elucidated.
6.5 The potential anti-thrombotic actions of hydrogen peroxide.
In contrast to the proposed vascular effects of peroxides and ROS, evidence is 
presented here which suggests that HgOg may be an important secondary 
messenger which increases the activity of NO. The influence of HgOgOn platelet 
function has been tested many times with contradictory results produced (see 
section 4.13.3.1). Similarly, HgOg increased cGMP formation in rabbit aortas 
[Zembowics at a!., 1993], while HgOg induced oxidative stress can reduce the 
effectiveness of NO production and cGMP formation in cocultures of calf 
pulmonary EC and SMC [Marczin at al., 1991]. Many of these studies used 
unrealistically high concentrations of HgOg (0.5 - 2mM). In the present study 
using physiologically relevant concentrations, HgOg acted positively to increase 
the effectiveness of NO, both in the presence and absence of plasma. The 
mechanism of these effects is poorly understood, as increased formation of
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cGMP does not completely account for the protracted inhibition of aggregation. 
It is possible that NO and H2O2 synergise to reduce energy charge in the cell. 
H2O2 has been shown to decrease platelet ATP levels [Holmsen and Robkin, 
1977], while NO inhibits several enzymes involved in mitochondrial respiration 
in rat hepatocytes [Stradler et al., 1991]. NO also inhibits the action of 
glyceraldehyde-3-phosphate dehydrogenase [Molina at a!., 1992]. In fact, 
inhibition of mitochondrial respiration was one of the initial processes 
investigated to explain the action of nitrovasodilator drugs [Gross and Wolin,
1995]. The combined inhibition of glycolysis and aerobic mitochondrial 
respiration would profoundly impair ATP synthesis. However it is unclear 
whether the two antagonists exert such an effect in the time span used at these 
low concentrations.
The data presented here shows that H2O2 may have opposing effects on 
platelets which are dependent upon the point when it is applied to the cells. If 
H2O2 formation by the action of SOD outstrips the GSH Px activity, it would result 
in oxidative stress. Buczyhski at a!., [1993] showed that GSH PX activity in 
platelets with CHD was reduced. Since this is the major enzyme for H2O2 
degradation in platelets [Maresca at a!., 1992], excess H2O2 production in this 
instance may well lead to cellular damage. The work in this thesis supports the 
concept that H2O2 is more likely to play an inhibitory role in platelet function. 
H2O2 formation is a continual process in vivo [Ramasarma, 1982], produced both 
by platelets and the endothelium. Local concentrations of H2O2 may be 
significantly increased in inflammatory events, as neutrophils are known to 
produce large quantities of H2O2 [Test and Wiess, 1984]. Thus H2O2 would be 
present both intra- and extracellularly, with respect to the platelet. This may
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imply that the synergy between NO and H2O2 to inhibit platelet aggregation, 
could occur between NO and HgOg from different cellular sources. It may be 
important to confirm whether NO and HgOg produced endogenously by the 
platelet can limit their activation, or that their presence is required from sources 
external to the platelet.
The results from chapter four of this thesis indicate that the potent inhibitory 
actions of NO/HgOg are not due to the formation of peroxynitrite. However, this 
does not exclude the possibility of other free radicals or products of free radicals 
being involved in the inhibition of platelet aggregation. Indeed, the hydroxyl 
radical scavengers, mannitol and sodium urate, antagonised the inhibition of 
platelet activity by both NO/HgOg and peroxynitrite, implying the inhibition may 
have a common factor.
Peroxynitrite has been implicated in the formation of nitrosothiols, by a reaction 
between the oxidant and free sulphydryl groups on proteins and other peptides 
[Beckman etal., 1992]. The presence of nitrosothiols have been demonstrated 
in human plasma [Stamler et a/., 1992]. In this thesis HgOg was shown to 
enhance the inhibition of platelet aggregation by S-NOG, both in the presence 
and absence of plasma. Several workers have shown HgOg alone can inhibit 
platelet activity in PRP. It is reasonable to speculate that these inhibitory effects 
of HgO 2 in PRP, could be due to a synergism with naturally occurring 
nitrosothiols present in the plasma, for example S-nitrosoalbumin [Stamler at a/., 
1992]. The full implications of the synergy between H2O2 and NO remain to be 
fully defined, but the actions of H2O2 may be pro- or anti-thrombotic depending 
on the conditions at the time.
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6.6 Conclusions.
From the data presented in this thesis, it is postulated that organic peroxides are 
critical determinants of platelet function. Many studies have shown patients 
suffering from various manifestations of heart disease have increased plasma 
peroxide concentrations and platelet which are hyper-responsive. It is possible 
that the peroxides are associated with LDL, which have undergone a post- 
secretory modification. Thus rendering the particles with similar characteristics 
to the mmLDL used here. These mildly oxidised forms of LDL may be 
responsible for the increased potential for platelet aggregation. Recently, it has 
been demonstrated that platelets involved in the formation of occlusive thrombi 
in vitro produce free radicals which can oxidise LDL [Gorog and Ko vacs, 1995]. 
Hence, platelet themselves may initiate an increase in the formation of 
atherogenic factors such as mmLDL and thus enhance chances of thrombosis.
NO produced by the endothelium may act to regulate platelet activity in vivo. 
Here data is presented which show that LDL in their native state, may reduce 
platelet activity and increase the inhibitory properties of NO. Mild oxidation of 
LDL leads to the loss of these actions, mmLDL increase platelet aggregation 
and seem to oppose the actions of NO. The actions of mmLDL were proposed 
to be mediated by the low levels of peroxides associated with the particles. The 
effects of organic peroxides were on platelet aggregation and platelet sensitivity 
to NO were investigated. HgOg, cum-OOH and 15(S)-HpETE all antagonised the 
inhibitory actions of NO. Conversely, HgOg also enhanced the actions of NO, 
leading to a prolongation and intensification of NO-mediated inhibition of platelet 
activity. This effect seemed specific for HgOg, and give a new insight into cellular 
regulation by NO.
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APPENDIX ONE 
The measurement of nitric oxide solutions using a sensor probe.
In this thesis, NO solutions are quoted as concentrations. Thus, it was 
important to verify the actual concentration of NO in each solution. This was 
achieved by the use of a specific sensor probe for NO(ISO-NOP: World 
Precision Instruments, USA).
Principle.
NO diffuses through a selective membrane and is oxidised at the working 
electrode resulting in an electrical current. The redox current is proportional 
to the concentration of NO in solution.
Calibration of the probe.
The sensor probe is calibrated using a finite amount of nitrite (NOg ) which is 
converted to NO, according to the following equation:-
2KNO2 + 2KI + 2H2SO4 - ,  2N0 + I2 + 2H2O + 2K2SO4
The reaction goes to completion, an therefore KNO2 is the rate limiting 
reagent. The ratio between KNO2 and NO is 1:1, and therefore the amount of 
NO generated in solution will be equal to the amount of KNO2 added.
For calibration of the probe, KNO2 solutions were added to a 10ml reservoir 
to give final concentrations between 5 and lOOnM. The response in picoamps 
(pA) is then used to generate a standard curve (see accompanying figure).
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Procedure and results.
Two solutions of NO ( 20|jM) were prepared (see section 2.7.1). The tip of the 
probe was placed in a 10ml reservoir of Tyrode's HEPES buffer (see section 
2.3.2) and left for 30min to equibrilate. Aliquots (lOOpI) of the NO solutions 
were added the reservoir to give a final concentration of 20nM NO and the 
maximal change in pA measured. The pA could then be used to measure the 
concentration of the solutions from the standard curve. Each solution was 
measured three times and the results presented below.
___________ concentration of NO (nM)________ mean
solution 1 16 19 20 18.3 ±2.1
solution 2 17 18 19 18 ±1
results are expressed as mean ± sd
The results suggest that the method employed to prepare solutions of NO are 
reliably accurate.
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standard curve used for the measurements of NO solutions.
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APPENDIX TWO 
Future work.
There are several possible avenues of study which could be followed up from 
the results presented in this thesis.
(1) Characterisation of the interactions between LDL and platelet GPIIb-llla.
It may be important to investigate the mechanism of this interaction under 
various conditions to assess whether the inhibition of platelet fibrinogen binding 
by nLDL could be of physiological relevance.
(2) Investigation into the mechanism by which HgOg enhances the inhibitory 
action of NO on platelet activity.
The possible synergism between NO and HgOg to inhibit platelet aggregation 
may have wider biological implications. It is important to investigate the 
contribution of endogenously produced NO and HgOg on platelet aggregation. 
It is possible that a new radical species may be formed between NO and HgOg 
which is more potent than NO with respect to platelet inhibition: this possibility 
should be examined. Finally the effects of HgOg on NO-mediated functions in 
other cell types should be assessed.
(3) Further investigations into the effects of LPO on NO-mediated cellular 
function.
Preliminary evidence is presented in this thesis to suggest that LPO may 
antagonise the action of NO. This observation needs to be examined since LPO 
are known to be raised in several pathological states, and this may contribute 
to the disease.
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